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           ABSTRACT: 
Title: Evaluation of Berlin-Frankfurt-Munster (BFM) protocols in acute lymphoblastic 
leukemia and the role of flow cytometry in minimal residual disease monitoring: A single 
tertiary centre analysis from India.  
Department: Clinical Hematology, Christian Medical College, Vellore.  
Name of candidate: Dr. Jain Punit Lalchand.  
Degree and subject: D.M. Clinical Hematology   
Name of the guide: Dr. Vikram Mathews, Professor, Department. of Clinical 
Hematology. 
Aims and Objectives of the study: (1) To study the clinical profile of children and 
adults diagnosed with acute lymphoblastic leukemia in our institute and their treatment 
outcome, when treated with different BFM protocols (2) To evaluate the clinical outcome 
in adolescent patients with acute lymphoblastic leukemia between 15 - 20 years of age, 
by using pediatric treatment regimens instead of adult regimens as currently used. (3) To 
assess the role of minimal residual disease status monitoring by flow cytometry at time of 
documenting remission, post induction phase of chemotherapy.  
Methodology: For retrospective analysis of adult patients, we included all newly 
diagnosed patients with acute lymphoblastic leukemia from January 2004 to February 
2014. For adolescent patients, we compared adolescents treated by adult regimens from 
January 2004 to June 2012 with those adolescents treated with pediatric regimens from 
July 2012 to February 2014. We also compared standard and intermediate risk pediatric 
patients treated with the non BFM 95 regimens from January 2004 to those receiving 
BFM 95 based regimens from 2008. Lastly, since July 2012 we prospectively analyzed 
the role of flow cytometry in assessing the minimal residual status at the end of induction 
chemotherapy and compared the outcomes of those who tested positive with those tested 
negative. 
Results:  Among 455 adults analyzed, there were 331(72.7 %) standard risk and 124 
(27.2 %) high risk adults. Median follow up duration was 65 months. There were 132 
(29 %) relapses and 179 (39.3 %) deaths. The 5 year EFS was 50.1 ± 2.9 % and the 5-
year OS was 51.6 ± 2.9 %.  
Among children with standard risk ALL, with an actuarial median follow up period of 
25(1.5 - 65) months and 17(1- 64) months for those treated with the BFM 95 protocol and 
those with the Non MTx/Non RT based study protocol; the three year event free survival 
was 95 ± 4.9 % and 86.5 ± 6.5 % respectively. (P value= 0.391). Among children with 
intermediate risk ALL, with an actuarial median follow up period of 27 (1 - 47) months 
and 18 (1-116) months for those treated with the BFM 95 protocol and those with the 
radiation (RT) based protocol; the two year overall survival was 96.9 ± 3.1 % and 85.6 ± 
2.4 % respectively. (P value = 0.103)  With an actuarial median follow up period of 7.7 
(1 - 19) months and 18(1-118) months those treated with intermediate risk pediatric 
protocol and the modified adult GMALL protocol; the one year event free survival was 
82.3 ± 7.3 % and 75.9 ± 3.6 % respectively.(P value = 0.752) Among patients tested for 
the minimal residual disease, with an actuarial median follow up of 7.7 (1-19) months, 
the 6 months and 1 year EFS in MRD (-) cohort (n = 53) is 97.4 ± 2.6 %. With an 
actuarial median follow up of 7.7 (1-13) months, the 6 months and 1 year EFS in MRD 
(+) cohort (n = 16) is 75 ± 21.7 %. With a median follow up of 6 months, the 6 months 
OS in MRD strongly (+) cohort (n = 6) is 20 ± 17.9 %.  (P = 0.000) 
 
Conclusions:  I] Using the current modified GMALL and BFM 95 regimens in adults (≥ 
15 years) and children (>1<15 years), treatment outcomes were comparable to those 
reported in the international literature. There was no significant difference as yet in the 
BFM 95 and the non BFM 95 regimens. II] Using pediatric regimens in adolescent age 
group (≥15 ≤ 20 years) did not reveal any significant difference in overall outcome as 
compared to adult regimens. Though the follow up is short, pediatric regimens are 
feasible in adolescents with minimal toxicity and there appears to be a trend towards 
improvement in their outcomes with pediatric regimens. III] Using flow cytometry in 
detecting minimal residual disease can significantly identify high risk patients and 
improve their outcome by timely intensification. 
 




 Acute lymphoblastic leukemia (ALL) is a malignant disease of immature lymphoid cells 
proliferating at an uncontrolled rate with a block in its early stage of differentiation.(1) It has 
been reported as one of the most common malignancy of the childhood, accounting for almost 
25% of all pediatric tumours and about 80% of pediatric leukemia.(1,2) Its incidence shows a 
bimodal peak, with the initial and the highest peak seen between 2 to 5 years of age and then a 
continues decline in the incidence with increasing age till the age of 50 years, following which it 
again shows a second peak.(3)  
 Among adults with ALL, although the complete remission rates (CR) have approached 
74% to 93 %, the overall survival rates has only approached 27% to 54%.(4) These response 
rates are much lower than the response rates achieved in children, which is close to 80 %. (5,6) 
There are multiple reasons for these differences, though they have been mainly attributed to the 
higher occurrence of poor risk cytogenetics, along with a reduction in incidence of the 
favourable cytogenetics and a poor tolerability to chemotherapy with increasing age. Also, the 
adult leukemic blasts have been shown to be more resistant to chemotherapy. (7) 
 Among younger adults with ALL, there have been significant changes in the overall 
survival in comparison to the older adults. An improvement in the relative survival rates in 
the age group of 15-19 years from 41.0% to 61.1% at 5 years, and from 33.0% to 60.4% at 10 
years has been reported.(8) 
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  The response rates in adults ≥ 15 years from our institute, treated using a modified 
GMALL protocol between 1994 to 2003 have also been published, showing a CR rate, a 5 
year Kaplan Meier estimate of OS, EFS and a DFS of 38%, 36% and 44% respectively.(9)  
 Among children (<15 years), the annual incidence of ALL varies between 
approximately 1 - 4 new cases per 100,000 children (< 15 years of age). (10–12)  India has a 
population of more than a billion people, including 340 million children (33%) (<15 years) 
and it can be estimated that 8,160 newly diagnosed cases of childhood ALL will require 
treatment every year. (13) 
 With improvised risk stratification, judicious chemotherapy and adequate supportive 
care, western world has successfully achieved a cure rate of about 80% in pediatric patients with 
acute lymphoblastic leukemia. (5, 6, 14) 
 In contrast, the cure rates in the children reported from the developing countries have 
struggled to meet such numbers and have only approached 60 %.(15, 16) In our institute, 
treatment of children < 15 years of age has traditionally been on the lines of pediatric BFM 
regimens. The success of the treatment of pediatric patients with acute lymphoblastic leukemia 
from our institute using BFM based protocols is reflected in the achievement of a 5 year Kaplan 
Meier estimate of overall survival (OS) of 59.8%, event free survival (EFS) of 56%, and disease 
free survival (DFS) of 53.9%.(16)  
 The challenges faced in achieving better response rates in the developing countries 
include limited government funding considering its other urgent health priorities and more 
importantly the poor family resources and its associated high dropout rates.(17–19)  
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 Since mid 2008, there have been major modifications in the treatment protocols of the 
pediatric population in our institute. From mid 2008, the BFM protocols for the pediatric 
population < 15 years of age have been changed from the 76/79-based regimens to the BFM 95 
based regimens for children of the same age group.   
 These changes were implemented in an effort to improve the clinical outcomes and 
achieve results on par with those achieved in developed countries. Since the introduction of 
these changes, no systematic analysis has not been done to assess if the anticipated improved 
clinical outcomes were achieved. The present study will analyze the response rates of the 
children treated between 2008 to February 2014 by the BFM 95 protocol and compare its 





















                                                         Review of literature:  
 The earliest classification of ALL was the French American British (FAB) classification, 
which traditionally described three classes of ALL (L1, L2, and L3) (20–22). This classification 
did not describe the genetic behavior, the Immunophenotype or the clinical behavior of the 
disease, thus was deficient in adequately prognosticating the disease.  
 Subsequently, a classification of ALL based on type of cell lineage (B or T), using 
monoclonal antibodies in the form of immunophenotyping was proposed. ALL blasts were 
traditionally classified into precursor–B-cell types, mature–B-cell ALL, and T-lineage ALL on 
the basis of immunophenotyping, each having its individual prognostic significance. (23) About 
85% of pediatric ALL are reported to be of B-lineage phenotype, while the rest are of the T- 
lineage.(24) 
 At present, ALL classification has evolved from the traditional FAB to the present WHO 
2008, which has incorporated morphology, immunophenotyping as well as cytogenetics, to 
determine the lineage and stratify the disease. (25) According to the WHO 2008, ≥ 20% blasts in 








 [I] Adult ALL:  
 Based on published literature worldwide, although the complete remission rates in the 
adults diagnosed with acute lymphoblastic leukemia have approached 74% to 93 %, the overall 
survival rates has only approached 27 % to 54 %.(26) The results of adult ALL (15 years and 
above) treated with a modified GMALL protocol earlier from our institute from a period 
between 1994 to 2003 has been published, with the estimated 5 year overall survival, event free 
survival and disease free survival being 38%, 36% and 44% respectively.(9) There are 
significant changes in the biology of the disease with an increasing age. Listed below in table 1 
are the relevant prognostic factors in adult acute lymphoblastic leukemia.(26) 
Prognostic factors: 
(i) Age – It shows a perpetual decline in survival with an advancing age. The OS for adults < 30 
years has been shown to be between 34% to 57% v 15% to 17% for > 50 to 60 years of age. 
(27–31) 
(ii) Elevated WBC at presentation has been considered as a poor prognostic factor.(32) A WBC 
> 30,000 in B cell ALL has been shown to have an OS between 19 to 29 %. (28, 33) 
(iii) Comparatively, T-lineage ALL shows a better outcome when compared to B-lineage ALL. 
The leukemia free survivals also differs according to the subtypes in T cell ALL Early T-ALL - 
25%, Thymic (cortical T-ALL) - 63% and mature T-ALL— 28%.(28, 34)  
(iv) Other significant factors include: 
(a) Sensitivity of ALL cells to corticosteroids and the chemotherapy in vitro. (35, 36). 
ALL cells in adults are less sensitive to prednisone, vincristine, and L-asparaginase 
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unlike in children. (7) 
(b) Deteriorating organ function with age, thereby affecting the metabolism of the drugs.  
(c) Higher incidence of infections, organ dysfunctions, treatment delays and omissions 
in chemotherapy medications. (37) 
  
Table 1: Relevant prognostic factors in adult ALL (26)  
 FAVOURABLE               ADVERSE FACTORS 
Age <25 yr., <35 yr. >35 yr., >55 yr., >70 yr. 
At Diagnosis  B Lineage T Lineage 
WBC Count 
at diagnosis 
< 30,000/ L > 30,000/ L > 100,000/ L 
Immuno- 
Phenotype 































Low Hypo diploid/ 
Near tetraploid (?) 
Others 
1. Prednisone 
    response 
2. MRD after 
    Induction 


















The overall outcomes reported in various trials are shown in table 2 below: 
Table 2: Major adult ALL trials: (26) 
Study Year   N 
Median age,  





CALGB9 111, USA 1998 198 35 (16-83) 85% 40% (3 yr) 
LALA 87, France 2000 572 33 (15-60) 76% 27% (10 yr) 
GMALL 05/93, Germany 2001 1,163 35 (15-65) 83% 35% (5 yr) 
MD Anderson, USA 2004 288 40 (15-92) 92% 38% (5 yr) 
MRC XII/ ECOG E 2993, 
UK-USA 
2005 1,521 15-59 91% 38% (5 yr) 
GIMEMA 0496, Italy, 2005 450 16-60 80% 33% (5 yr) 
Pethema ALL-93, Spain 2005 222 27 (15-50) 82% 34% (5 yr) 
GMALL 07/03 2007 713 34 (15-55) 89% 54% (5yr) 
Abbreviations: CALGB, Cancer and Leukemia Group B; LALA, leucémie Aiguë 
Lymphoblastique de l'Adulte; MRC, Medical Research Council; NOPHO, Nordic Society of 
Pediatric Hematology and Oncology; GIMEMA, Gruppo Italiano Malattie EMatologiche 
dell'Adulto; GMALL, German Multicentre study group for Adult ALL; PETHEMA, 








[II] Adolescent ALL: 
 About 5,000 to 6,000 cases of ALL occur in the United States every year, with about 
50% of them being < 20 years old. Lately, there is improvement in the overall survival rates for 
ALL in all ages except for those > 60 years. The outcome in the adolescent and young adults 
has improved, but still lags behind the survival and outcome rates in the children. (8, 38)  
The treatment response rates in adolescent ALL using a modified GMALL protocol from our 
institute have already been published.(9) Age has had a significant impact on survival with 5 
year EFS of 46.7% for patients between 15 to 20 years, 33.38% for patients between 20 - 30 
years and 14% for patients > 40 years of age (P =. 005).  
 Adolescents with ALL show features similar to both pediatric and adults (Table 3). (39)  
Table 3: Correlation of age with immunophenotype and cytogenetics in ALL. (40–42) 
Subgroup  1-9              10-14         15-19           20-39           40+ 
B Cell   86   68   70   60   75 






  39 
  5 
  37 
 
  44 
  8 
  20 
 
  30  
  7 
  29 
 
  37 
  6 
  16 
 
  34 
  7 
  15 
Cytogenetics: 
t (12; 21) 
t (1; 19) 
t (4; 11)  
t (9; 22) 
 
  24 
  2 
  1 
  1 
 
  18 
  3 
  2 
  3 
 
  5 
  2 
  2 







  - 
  4 
  9 
  19 
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Treatment: 
 Several comparative studies have shown better outcomes for adolescents (15–21 years) 
with ALL who were treated with pediatric regimens rather than adult regimens.(43) 
 
A) Retrospective study results: As shown in table 4. 
B) Prospective Study results:  
 As shown in the table 5 below, several prospective studies had also evaluated the 
outcome of pediatric protocols in adolescent age group.(51)  
 
[III] Pediatric ALL: (2) 
 The first serious attempt for categorizing ALL was proposed from the Rome Workshop 
in 1985. (52) Later, US National Cancer Institute (NCI) in 1993 classified ALL based on age 
and total count at presentation, as newer prognostic variables like cytogenetics and 
immunoglobulin gene rearrangement were not universally available at that time.(53)  
 Similarly, several other factors have been found to have important prognostic 
implications in the pediatric ALL.(54, 55) The commonly used risk factors for prognosticating 






Table 4: Comparison of retrospective studies in adolescents and young adults with 
               acute lymphoblastic leukemia:(44–51)  
Country Protocol Age N CR (%) EFS (%) 5 yr OS (%) 
USA 
(1988–2001) 













































































Abbreviations: A, adult based; P, pediatric-based. CALGB, Cancer and Leukemia Group 
B; CCG, Children's Cancer Group; DCOG, Dutch Children's Oncology Group; FRALLE, 
French Acute Lymphoblastic Leukemia Group; HOVON, Hemato-Oncologie Voor 
Volwassenen Nederland; LALA, leucémie Aiguë Lymphoblastique de l'Adulte; MRC, 
Medical Research Council; NOPHO, Nordic Society of Pediatric Hematology and 
Oncology; AIEOP, Associazione Italiana Ematologia Oncologia Pediatrica; GIMEMA 
Gruppo Italiano Malattie EMatologiche dell'Adulto. 
  
Note: p value was significant for the EFS and the OS showing a significant difference between 




Table 5: Comparative pediatric-based prospective studies in the adolescent 
and young adults 
Country Protocol Age Number CR (%) EFS (%) 
USA DFCI 91-01, 95-01 15–18a 51a 94 78 









France GRAALL-2003 15-45 172 95 58 
USA DFCI 18-50 74 82 72b 
Canada Modified DFCI 17-71 68 85 65c 
 
a. Results restricted to adolescents.     b. Estimated at 2 years.    c. Overall survival. 
Abbreviations:  
DFCI: Dana Farber Cancer Institute; PETHEMA: Programa Para el Tratamiento   











Table 6: (2) Risk factors in pediatric ALL 
    Variables Favorable (Incidence in %) Unfavorable (Incidence in %) 
Age at diagnosis 1 - 10 years (77%) 1 year (3%) or ≥ 10 years (20%) 
WBC at Diagnosis ≤ 50, 000/UL (80%) ≥ 50,000/UL (20%) 
Immunophenotype CD10 
+
 precursor  
B-cell ALL (83%) 
CD10 
_
 precursor B-cell  
ALL (4%), T-ALL (13%) 
CNS disease¶  CNS 1 (80%) CNS 3 (3%), TLP
**
 + (7%) 
Cytogenetics  Hyperdiploidy (20%), 
TEL/AML1 positivity 
 (20%) 
Hypodiploidy (1%), t(9;22) or  
BCR/ABL positivity and t (4;11) or 
MLL/AF4positivity (2%) 
Day 8 Prednisone  
response (PR) 
1000/UL blood blasts 
 (90%) in peripheral blood 
≥ 1000/UL blood blasts (10%)  
in peripheral blood 
Early bone marrow  
response during  
induction phase 
 5% blasts (M1) on  
Day 15 (60%) 
≥ 25% blasts (M3) on day 15 
 (15%) 
Remission status 
after Induction  
therapy  
(Morphologically) 
 5% blasts (M1) in bone 
marrow after 4 to 5 Weeks  
of Induction treatment  
(98%) 
≥ 5% blasts (M2 or M3) after 4  
to 5 weeks of induction therapy 
 (2%) 
Minimal residual  






 blasts after 5  
Weeks of Induction 
 Treatment  (40%) 
10 
3
 blasts after 12 weeks  
Of Treatment  (Induction and 
 Consolidation) (10%) 
 
¶ Central Nervous System (CNS) disease criteria:(56,57)
 
CNS 1: Puncture nontraumatic, no leukemic blasts in cerebrospinal fluid (CSF) after        
             cytocentrifugation.  
CNS 2: Puncture nontraumatic,  5 leukocytes/L CSF with Identifiable blasts.  
CNS 3: Puncture nontraumatic  5 leukocytes/ L CSF with identifiable blasts.  
 
** 
Traumatic LP (TLP): 
(i) TLP traumatic lumbar puncture with identifiable leukemic blasts.   
(ii) A TLP with no identifiable blasts is not an adverse factor.   
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Differences in outcome in favourable and the unfavorable group are as listed below in Table 7. 
Table 7: Event free survival among the favourable and unfavorable factors (58–66) 
Risk Factors       Favourable  Unfavorable 
Poor Prednisolone Response  (PPR)          74 – 80 %          26 - 42 % 
Cytogenetics          86 - 89 %           28 – 50 %  
Minimal Residual Disease    (MRD)          88 - 95 %          33 - 59 %  
 
Based on risk stratification criteria of BFM 95 group, ALL is stratified into 3 groups (table 8) 
Table 8:(57) Risk stratification in pediatric ALL 
 High    Risk (HR)  Poor Prednisolone Response (PPR) 
 No Complete Remission (CR) on day 33 
  t (9; 22) ; t (4; 11) . 
Medium Risk (MR) 
 
    No HR criteria 
    Initial ≥ 20 x 109/L  
    Age at diagnosis  < 1 or > 6 years  
    T -Acute Lymphoblastic Leukemia 
Standard Risk (SR)  No HR criteria, and 
 Initial WBC ≤ 20 x 109/L, and  













Treatment of pediatric ALL (≥1 < 15 years) 
 
 The basic BFM structure involves: 1) an induction regime consisting of  oral 
corticosteroids, intravenous vincristine along with daunorubicin, intramuscular L-asparaginase, 
and intrathecal cytarabine with methotrexate; 2) a consolidation regime with 6-mercaptopurine 
and intravenous and intrathecal methotrexate; 3) a re-intensification regime with dexamethasone, 
vincristine, doxorubicin, and L-asparaginase followed by cyclophosphamide, cytarabine, 6-
thioguanine, and intrathecal methotrexate; and 4) maintenance therapy with oral methotrexate 
and 6-mercaptopurine for a maximum  time of 24 to 36 months .(67, 68) 
 Later, as stated by Smith et al.,(69) treatment modifications tested in inter group trials 
identified several key points: the inclusion of an interim maintenance phase, augmentation of 
BFM-type delayed intensification, and minimizing the use of cranial irradiation for CNS 
prophylaxis in children. These approaches, which are focused on prolonged and intensive use of 
the ―pivotal‖ drugs glucocorticoids, vincristine, l-asparaginase (and lately, use of an extended 
release PEG-asparaginase,(70) methotrexate, and anti- metabolites), have improved the cure 
rates in a large number of children with ALL. 
 Thus, the BFM protocol has evolved through multiple sequential trials with an aim of 
maintaining high remission rates along with minimizing the long-term toxicity. The present cure 
rates in children with the BFM 95 protocols have approached 80 % from the initial 50 % with a 
reduction in the long term toxicity.(5) 
 Data from the developing countries on the use of the pediatric BFM ALL protocols is 
scarce, though the results of the BFM 76/79 ALL protocol over the years from 1985 to 2003 in 
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the Indian population < 15 years have been published. The estimated Kaplan Meier estimate 5 
year OS, EFS and DFS was 59.8%, 56%, and 53.9%, respectively.(16)  
 
 
[IV] Evaluation of MRD (Minimal Residual Disease):  
 A significant cause of treatment failure in ALL has traditionally been due to relapse of 
the disease.(1) in any treatment regimen it is vital to identify early those patients who do not 
achieve remission in order to achieve a better cure. Among the primary prognostic factors, an 
early response to the therapy has traditionally been considered as a significant factor for 
survival.(1, 71) Establishing the role of the minimal residual disease in delivering a risk based 
approach to the therapy has been one of the major challenges in the last decade or so. 
 Patients with acute leukemia may have a total of approximately 10
12
 malignant cells at the 
time of their diagnosis.(72,73) Though, a state of complete remission is considered to be when 
fewer than 5% of the cells in bone marrow (BM) sample are morphologically identifiable blasts, 
a significant tumor cells close to 10
11
 may not be detected on morphology alone.(74) These 
persistent tumor cells, not detected by morphology, defines a state of minimal residual 
disease.(75) 
 These blast cells can be recognized either by either  
(i)     Clonal rearrangement of immunoglobulin and T-cell receptor genes, 
(ii)    Expression of gene fusions, and /or  
(iii)  Leukemia-associated specific Immunophenotype.  
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 ALL cells express immunophenotypic features that can be used to distinguish them from 
normal hematopoietic cells, including hematogones and activated lymphocytes. (76) During the 
last decade, levels of minimal residual disease measured either quantitatively by the use of PCR 
based techniques or by flow cytometry, have been successfully used to predict the prognosis, 
irrespective of the historically proven risk factors, like age and WBC count at presentation.(77–
79) Majority of cells in approximately 95% of cases express immunophenotype, which are quite 
dissimilar from those of normal cells thereby allowing a sensitivity of detection of 0.01%. 
(80,81) MRD based risk stratification and the subsequent risk directed therapy will be the new 
standard of care in the coming years.(82, 83) 
 Molecular detection of MRD has established.(84) Flow cytometry (FCM), although less 
standardized, is quicker, generally cost effective and more informative (64,85,86). In a study by 
Helene Cave et al, it was shown that the relative risk of relapse at end of induction was found to 
be higher in patients with persistent disease than those without any disease. On comparison, 
chances of developing a relapse was significantly higher in patients with detectable disease than 
without detectable disease (87) Thus, it’s important to identify prognostic factors signifying 
relapse early in any protocol, in order to justify a therapeutic change. MRD as a significant 
prognostic marker has already been incorporated in the newer BFM protocols like the BFM 
2000 and the IC BFM 2002.  Recently,  flow cytometry to identify MRD for B cell ALL has 
been standardized and reported from our institute.(88) In present study, we will validate  same 




Aims and Objectives 
 
1. To study the clinical profile of children and adults diagnosed with acute 
lymphoblastic leukemia in our institute and their treatment outcome, when treated 
with different BFM protocols over the years. 
2. To evaluate the clinical outcome in adolescent patients with acute lymphoblastic 
leukemia between 15 - 20 years of age, by using pediatric treatment regimens instead 
of adult regimens as currently used. 
3. To assess the role of minimal residual disease monitoring by flow cytometry at time 













                                                           Patients and Methods:  
Our Institutional Review Board (IRB) approved this study. 
This is a combined descriptive and prospective analysis of newly diagnosed patients with 
acute lymphoblastic leukemia (ALL) diagnosed in the department of hematology at Christian 
medical college, Vellore. 
Duration of the study: 1
st 
of July 2012 till 28
th 
of February 2014.  
Definitions: 
Diagnosis- The diagnosis of acute lymphoblastic leukemia was made according to the WHO 
Classification of Tumors of Hematopoietic and Lymphoid Tissues Fourth Edition. 
The presence of ≥ 20% blasts was mandatory either in the peripheral blood or on the bone 
marrow. The presence of < 20 % blasts was acceptable only in those with recurrent genetic 
abnormalities. 





Table 9: (5, 89) Definitions used in the study 
Treatment response 
Prednisolone response (PR) Determined after 7 days of monotherapy with prednisone and 
one IT dose of MTX on day 1                                            
Presence of < 1000 blasts in peripheral blood on day 8 was 
defined as Poor PR and ≥1000/ ml blasts as Good PR 
Complete remission Defined as < 5% blasts in the regenerating BM, absence of 
leukemic blasts in blood and CSF, and no evidence of 
localized disease. 
Treatment outcome 
End induction failure  Defined as not having achieved CR after the initial induction 
chemotherapy. 
Relapse Defined as recurrence of X25% lymphoblasts in BM and/or 
localized leukemic infiltrates at any site. 
 Very early relapse Relapse within 18 months of the initial therapy 
 Earrly relapse Relapse > 18 months from initial therapy and < 6 months after 
cessation of frontline therapy 
 Late Relapse after 6 months of frontline therapy 
Survival definitions 
Overall survival Defined for all patients; measured from the date of diagnosis to 
the date of death from any cause. 
Event free survival Defined for all patients; measured from the date of diagnosis to 
relapse from CR or death from any cause. If patient has 




All patients seen and diagnosed as having acute lymphoblastic leukaemia in the department of 
haematology will be eligible for this study. They will be enrolled after getting written informed 
consents and where applicable assent forms.  
Variables:  
Objective 1: The data analysis for the adult ≥ 15 years with acute lymphoblastic leukaemia will 
be a retrospective and a descriptive study. This will be done by retrieval of the records from 
2004 till 2012 and their data will be analysed to assess the effectiveness of the currently used 
adult GMALL (modified BFM) protocol for any future changes. 
 
Appendix – Protocol attached.  
1] (Modified BFM) Adult GMALL  
 
Objective 2: There has been a change in the protocol design of the pediatric population 
diagnosed with acute lymphoblastic leukaemia from 2008 in our department. For patients with 
resources, the protocol has been changed to a BFM 95 regimen to improve their response rates 
and reduce their long-term toxicity. The present study is thus a retrospective as well as a 
prospective attempt to assess the response rates and assess the results of the BFM ALL 95 
involving children < 15 years of age being treated in our institute from 2008 to February 2014. 
These results will be compared to non BFM 95 protocols being currently used in our department.   
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Appendix - Protocols attached: 
2a] Intermediate risk BFM 95 (private ward)  
2b] Intermediate risk (Radiotherapy based protocol) (General ward)  
3] Standard risk BFM 95  
4] Standard risk (Non Methotrexate/Non radiotherapy based study protocol)  
 
Objective 3: Adolescents (≥ 15 ≤ 20 years) have so far being treated with the adult based 
modified GMALL regimens and their results from our institute have been published. The 5 year 
EFS was 46.7 %. By using established paediatric regimen, like the intermediate risk BFM 95, 
we aim to improve this response rates to approximately 60%. We anticipate at least 50 
adolescents to be treated between the mentioned study period of May 2012 to February 2014.  
 
Appendix – Protocol attached. 
2a] Intermediate risk BFM 95 (private ward) 
2b] Intermediate risk (Radiotherapy based protocol) (General ward)  
 
 
Objective 4: The MRD study will be a prospective study and will include children and adults 
being treated in the department of haematology, who will undergo testing for the minimal 
residual disease by flow cytometry, by characterizing the leukaemia associated 
immunophenotype (LAIP) at diagnosis, using a combination of 6 tubes containing different 
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antibody combinations, which have recently been standardized in our department. We plan to do 
this analysis for a total of 100 cases initially. MRD assessment via flow has recently been 
standardized study in our department.(88) The outcome will be compared between the patients 
who are MRD negative versus those who are MRD positive.(90)   
 
The following recently standardized antibody combinations will be used.(88) 
 FITC PE PerCp APC 
Tube 1 CD20 CD10 CD45 PerCP CD19 
Tube 2 CD22 CD34 CD45 PerCP CD19 
Tube 3 CD38 CD10 CD34 PerCP-cy5.5 CD19 
Tube 4 CD11a CD10 CD45 PerCP CD19 
Tube 5 CD 38 CD 10 CD 34 PerCP-cy5.5 CD 19 
Tube 6 CD123 CD 10 CD 34 PerCP-cy5.5 CD 19 
Fluor chromes: 
 FITC: Fluorescein isothiocyanate 
 PE: Phycoerythrin 
 PerCp: Peridinin- chlorophyll -protein complex 
 APC: Allophycocyanin 
 
Data Sources/measurement:  Clinical data will be retrieved from the outpatient and in-patient 
records in the case of historical data. For prospective cases enrolled on this study the data will 
be collected and recorded in real time. 
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Bias: Since all consecutive patients with newly diagnosed ALL will be enrolled in this study, 
we do not anticipate any bias in our study.  
 
Statistical methods: The adult data analysis is only a descriptive study as there is no change in 
the protocol, which was used earlier. The adolescent study group will be a prospective study to 
see the outcome of paediatric regimens in this age group. The data derived from the paediatric 
patients will be compared with non BFM 95 regimens being used previously and the changes 
will be reported. Any significant variable will also be reported. The MRD study is an 
exploratory study to assess its role as a stratification criterion. 
Descriptive statistics were calculated for all variables. Differences in proportions were assessed 
using the χ2 or Fisher exact statistic. Differences in means were tested using a Mann-Whitney-U 
test or t-test as appropriate. The probability of survival we estimated with the use of the product-
limit method of Kaplan and Meier for overall survival and event-free survival and compared by 
the log-rank test. All survival estimates are reported ± 1 SE. The relationships of clinical 
features to outcome were analyzed by Cox proportional hazard model. All P values were 2-
sided, with values of .05 or less indicating statistical significance. Statistical analysis was 




                                                       Results  
     Figure 1: Age distribution of acute lymphoblastic leukemia (Jan 2004- Feb 2014) 
  








Pediatric ( < 15 yrs ) Adolescent ( ≥ 15 ≤ 20 yrs ) Adults ( > 20 yrs )
 
 25 
Objective 1: Adult descriptive study 
                  A retrospective and a prospective study 
Table 1: Study period and number of cases 
Study duration N 
Jan 2004 – June 2012  ( > 15 years) 392 
July 2012 – Feb 2014 ( > 20 years) 63 
Total cases analyzed 455 
 
Table 2: Baseline characteristics 
Variables 
Adult GMALL Group 
n (%) / Median (range) 
( n – 455 ) 
Age (years) 26 (15-67) 
Sex (male) 321 (70.5) 
Physical findings : 
 
• Hepatomegaly (cm) 
 
3 (1 -20) 
• Splenomegaly (cm) 3 (1 -15) 
• CNS Disease (%) 64 (14.1) 
• Pleural Effusion (%) 18 (4.0 ) 
• Mediastinal mass (%) 34 (7.5 ) 
• Testicular mass (%) 2  (0.6 ) 
Lab Parameters : 




9.5 (0.3 – 531.4) 
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Cytogenetic risk stratification: (91) 
a. Poor risk – (i) t (9:22), (ii) t (4:11), (iii) Complex karyotype,   
                               (iv)  iAmp 21, (v) Low hypodiploidy/near triploidy,    
                               (vi) t (17:19). 
b. Standard risk - All others including normal karyotype.  
                     
 
Table 3:  Immunophenotyping, cytogenetics and molecular genetics 
Variables 
 
Adult GMALL Group 
n (%) / Median (range) 
n – 455 
IPT :                                n 447 (98.2) 
 B cell 333 (73.2) 
 T cell 114 (25.1) 
Cytogenetics®                n            404 (88.7) 
 Standard 301 (74.6) 
 Poor 103 (25.5) 
RT PCR :                        n 348 (76.5) 
 B ALL 319 (91.6) 




 BCR ABL1 60 (18.8 ) 
 TEL AML 6 (1.8 ) 
 MLL 4 (1.2 ) 
 E2A  PBX 14 ( 4.3) 




















                      
 
 
® Overall risk stratification in adult acute lymphoblastic leukemia:  
 Standard risk - (i) Good prednisolone response,                                                                                
                                   (ii) Absence of t (9:22) and t (4:11)    
                             (iii) End induction remission.  
  High risk     -    (i) Poor prednisolone response,   
                            (ii) Presence of t (9:22) and t (4:11)   





Table 4: Risk status and treatment response 
Variables 
Adult GMALL Group 
n (%) / Median (range) 
n – 455 
Overall risk:   ® 
 
 SR 331 (72.7) 
 HR 124 (27.2) 
Treatment taken                                  n 455 (100) 
Prednisolone response  (PR) assessed 314   (69) 
 Good PR 260 (82.8) 
 Poor prednisolone response 54 (17.2) 




























Table 5:  Follow up of outcome 
Variables 
Adult GMALL Group 
n (%) / Median  (range) 
n = 455 
Relapse 132 (29.0) 
• Very Early 93 (20.4) 
• Early 21 (4.6) 
• Late 18 (4.0) 
Total Deaths 179 (39.3) 
• Progressive disease 140 (78.2) 
• Infection 39 (21.8) 
Current status 
 
Alive 276 (60.7) 
Completed therapy in CCR 
(Continuous complete remission) 
123 (27 ) 
On treatment in CR 
(Complete remission) 
103 (22.6) 
5 year EFS 50.1 ± 2.9  % 
5 year  OS 51.6 ± 2.9  % 
Median Follow up 65  months 
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Alive CR2 (n =3) 
 
 
 Deaths (n = 50) (10.9 %) 
 No follow up (n = 1)  
CCR (n = 123) (27 %) 
Relapse (n = 18) 
(3.9 %) 
 
    Relapse (n = 51) (11.2 %) 
Death (n = 5) (1.0 %) 
No follow up (n = 21) (4.6 %) 
BMT (Alive) (n = 1) (0.06 %)  
Ongoing therapy prior to starting 
maintenance (In CR) (n = 15) (3.2 %) 
Deaths (n = 15) 
 
      CR (n = 379) (83.2 %) 
         Total cases (n=455) 
 
 End induction assessment (n=408) (89.6 %) 
 
No assessment end induction (n=47) (10.3 %) 
 
• Induction deaths (n= 29) (6.3 %)      
• Lost to follow up (LFU) (n= 13) (2.8 %)  
• Palliation (n =3) (0.6 %) 
• On induction therapy (n = 2) (0.4 %) 
 
   Residual disease (n = 29) (6.3 %) ** 
Palliation with 
maintenance (n = 8) 
(1.7 %) 
Palliation 
(n = 21) (4.6 %) 
Started maintenance 
 (n = 286) (62.8 %) 
 Not reached maintenance (n = 93) (20.4 %) 
 
Ongoing therapy  
(n = 145) (31.8 %) 
Completed maintenance  






(n = 55) 
(12.0 %) 
(All died)                
                    
CR (n = 88) (19.3%) 
Deaths (n – 2) (0.04 %) 
Adult acute lymphoblastic leukemia flow chart (Jan 2004 to Feb 2014) 




**   End Induction residual 
disease (n = 29) 
Adult acute lymphoblastic leukemia flow chart (Jan 2004 to Feb 2014)                                                           
(Flow chart 2) 
Completed maintenance 
(n = 3)  
Alive CR2 (n = 2)  
Relapse and died (n = 1) 
Relapsed after achieving hematological 
remission (n = 3) All died. 
Deaths (n = 15)  
 
No follow 
up (n = 1) 
                    
Palliation with maintenance (n = 
8) (1.7 %) 
Palliation (n = 21) 
Achieved CR but all 




 (n = 3) 
                    
 31 
Survival statistics: (Figures 3a and 3b) 
The event free survival (EFS) and the overall survival (OS) were calculated using the 
Kaplan- Meier estimates. 
OS in adult acute lymphoblastic leukemia:  (figure 3a)  
At the time of this analysis, the 5 year overall survival of the entire adult cohort (n = 455) 
was 51.6 ± 2.9 % with a median follow up of 65 months.  
For OS, death due to any cause was considered as an event. For the purpose of this analysis, 
patients who had relapsed during therapy and then subsequently lost to follow up were 
considered as dead, 30 days after the last follow up. 
EFS in adult acute lymphoblastic leukemia:  (figure 3b) 
An event was considered whenever there was a relapse or death. In cases where death was 
secondary to relapse and progressive disease, the date of relapse was considered an event in 
that patient. 
 At the time of this analysis, the 5 year event free survival of the entire adult cohort (n = 455) 




Figure 3a: Overall survival           Figure 3b: Event free survival 
 
 
    
 
 
Figure 3a: Kaplan Meier curve for overall survival of adults (≥ 15 years) with acute 
lymphoblastic leukemia (n = 455).  
With a median follow up period of 65 months, the five year survival was 51.6 ± 2.9 %. 
 
Figure 3b: Kaplan Meier curve for event free survival of adults (≥ 15 years) with acute 
lymphoblastic leukemia (n = 455).  






n = 455 
5 yr EFS: 50.1 ± 2.9 % 
n = 455 
5 yr OS: 51.6   ± 2.9 % 
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Objective 2a results: 
 Standard risk acute lymphoblastic leukemia (SR ALL): 
 
Since 2008, 67 children with acute lymphoblastic leukemia have been stratified into the 
standard risk category.  Out of these, 23 children opted for the medium dose methotrexate 
(MTx) based therapy of BFM 95 protocol and 44 children opted for the non-methotrexate / 
non-radiotherapy (study protocol) based chemotherapy.   
 
                                                                                           
Table 6: Standard risk inclusion criteria :  (Jan 2008 to Feb 2014) 
Variables 
Study protocol 






Age (years) > 1 <  6 > 1 <  6 
Total count (per cmm) < 20,000 < 20,000 
Prednisolone response Good Prednisolone response Good Prednisolone response 
High risk cytogenetics t (9:22), t (4:11) are excluded t (9:22), t (4:11) are excluded 
Immunophenotype No T cell No T cell 
Myeloid markers Not a criteria No myeloid markers 
CNS / Testis 
involvement 
Not a criteria Not a criteria 
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Table 7:  Baseline characteristics 
Variables 
SR ( Study protocol ) 
n (%) / Median (range) 
(n = 44) 
SR (BFM 95) 
n (%) / Median (range) 
(n = 23) 
P value 
Age (years) 4 (2 – 6 ) 3 (1 – 6 ) 0.645 
Sex (male) 30 (68.2 ) 13 (56.5 ) 0.424 
Physical findings : 
• Hepatomegaly (cm) 
 
3 ( 1 – 5 ) 
 
2 (1 – 5 ) 
 
0.678 
• Splenomegaly (cm) 2 ( 1 – 6 ) 2 (1 – 3 ) 0.631 
• CNS Disease (%) 0 1 ( 4.3 ) 0.343 
• Pleural Effusion (%) 0 0 - 
• Mediastinal mass (%) 0 0 - 
• Testicular mass (%) 0 0 - 
Lab Parameters : 




Table 8: Cytogenetics, molecular genetics and risk status 
Variables 
SR (Study protocol ) 
n (%) / Median (range) 
(n = 44) 
SR (BFM 95) 
n (%) / Median (range) 
(n = 23) 
 
P value 
Cytogenetics :** 41 (93.1 ) 21 (91.3 ) 
0.438 
 Favourable 28 (68.3 ) 15 (71.4 ) 
 Intermediate 10 (24.3 ) 6 (28.6 ) 
 Poor 3 ( 7.3 ) - 
RT PCR : 43 (97.7 ) 22 (95.7 ) 1.000 
 BCR ABL - - - 
 TEL AML 5 (11.4 ) 4 (17.3 ) 0.467 
 MLL - - - 
 E2A PBX - - - 
 No result 38(88.3) 18(81.8) 1.000 
** Cytogenetic risk stratification: (92) 
a. Favourable risk:    (i) Hyperdiploidy  
b. Poor risk:               (i) t (9:22), (ii) t (4:11), (iii) Complex karyotype, (iv) iAmp 21,  
                                            (v) Low hypodiploidy/near triploidy  (vi)  t (17:19). 
c. Intermediate risk - All others, including normal karyotype. 
There was no statistically significant difference between the two groups in their baseline    
 laboratory features. 
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Table 9: Treatment response 
Variables 
SR (Study protocol) 
n (%) / Median 
(range) (n = 44) 
SR (BFM 95) 
n (%) / Median 




 SR MD MTx - 23 
- 
 
 SR  (No MTX/ No RT) 44 - 
Prednisolone  Response (PR): 
                                             N 
28 (63.6) 13 (56.5) 
 
 GPR (Good) 28 (100 ) 13(100) 1.000 
End Induction Remission 
status 
42 (95.4) 23 (100)  
1.000 
 
 CR (Complete  
remission) 
42 (100 ) 23 (100 ) 
End Induction Not assessed 2 (4.5 ) - - 
 Induction deaths 0(0) 0(0) - 
 Ongoing treatment 
Induction phase 
2 (4.5 ) - - 
Received maintenance therapy: 
                 Yes 35 (87.5 ) 21 (91.3 ) 
0.154 
                  No 9  (20.4 ) 2  (8.6 ) 
• Pre maintenance phase 4(44.4) 2(100) 
 
• Relapse 1(11.1) 0(0) - 




There was a higher incidence of relapse seen in the children treated with the study protocol in 
comparison to those treated with the BFM 95 protocol, though the actuarial median follow up 
was shorter in the children treated with the BFM 95 protocol. 
 
 
Table 10: Follow up of outcome 
Variables 
SR (Study protocol ) 
       n (%) / Median   
              (range) 
              (n = 44) 
         SR (BFM 95) 
        n (%) / Median   
              (range) 
  (n = 23) 
P value 
Relapse 7 (15.9 ) 1 (4.3 ) 0.247 
 Very early 2 (4.5 ) 1 (4.3 ) 0.416 
 Early 2 (4.5) - 
- 
 Late 3 (6.8) - 
Total Deaths 4 (9.1) 1 (4.3) 
1.000 Cause of death 
 Progressive disease 4 (100 ) 1 (100) 
 Infection - - - 
Current status 
 
CR – Completed treatment              16 (36.3) 5 (21.7 )   0.342 
CR – On Treatment 21 (47.7) 17 (73.9 ) 0.072 
Induction deaths - - - 
OS                  Alive 40 (90.9 ) 22 (95.6 ) 0.483 
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 Survival statistics: (Figures 4a – 4b) 
The overall survival (OS) and the event free survival (EFS) were calculated using the 
Kaplan- Meier estimates. 
OS in standard risk acute lymphoblastic leukemia:  (Figure 4a)  
At the time of this analysis, the 3 year overall survival of the BFM 95 based cohort (n = 23) 
was 95 ± 4.9 % with an actuarial median follow up of 25 (1.5 - 65) months and 3 year overall 
survival of the non methotrexate/non radiation based study protocol was 90.1 ± 5.6 % with an 
actuarial median follow up of 27 months (1.5 - 68) months. For the purpose of this analysis, 
patients who had relapsed during therapy and then subsequently lost to follow up were 
considered as dead, 30 days after the last follow up. 
A log rank comparison among those treated with the BFM 95 and the non methotrexate/non 
radiation based study protocol did not show a statistically significant survival difference. (P = 
0.752). 
EFS in standard risk acute lymphoblastic leukemia:  (Figure 4b) 
At the time of this analysis, the 3 year event free survival of the BFM 95 based cohort (n = 
23) was 95 ± 4.9 % with an actuarial median follow up of 25 (1.5 – 65) months.  The 3-year 
event free survival for the non methotrexate/non radiation (study protocol) based cohort was 
86.5 ± 6.5 % with an actuarial median follow up of 17 (1 - 64) months. There was no 
significant statistical difference between the two cohorts. An event was considered whenever 
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there was a relapse or death. In cases where death was secondary to relapse and progressive 
disease, the date of relapse was considered an event in that patient.  
A log rank comparison among those treated with the BFM 95 and the non methotrexate/non 





































Figure 4a: Overall survival                 Figure 4b: Event free survival 
 
                                         
 
 
Figure 4a: Kaplan Meier curves for overall survival (OS) in children (>1 < 6 years) with 
standard risk B cell acute lymphoblastic leukemia treated with BFM-95 protocol (n =23) and 
the non methotrexate/non radiation based study protocol ((n = 44). 
With an actuarial median follow up period of 25(1.5 - 65) months and  27(1.5 - 68) for those 
treated with the BFM 95 protocol and those with the Non MTx/Non RT based study 
protocol; the three year overall survival was 95 ± 4.9 % and 90.1 ± 5.6 % respectively. (P 
value= 0.752) 
 
Figure 4b: Kaplan Meier curves for event free survival (EFS) in children (>1 < 6 years) 
with standard risk B cell acute lymphoblastic leukemia treated with BFM-95 protocol (n = 
23) and the non methotrexate/non radiation based study protocol (n = 44).  
With an actuarial median follow up period of 25(1.5 - 65) months and  17(1- 64) months for 
those treated with the BFM 95 protocol and those with the Non MTx/Non RT based study 
protocol; the three year event free survival was 95 ± 4.9 % and 86.5 ± 6.5 % respectively.   
(P value= 0.391)                                      
 
                                              
       
 
 
    No MTx/No RT protocol   
               3yr OS:  90.1 ± 5.6 % 
 
P = 0.752  No MTx / No RT  protocol               
       3 yr EFS – 86.5 ± 6.5 % 
 
  BFM 95 protocol  
3 yr EFS:  95 ± 4.9 % 
 
P = 0.391 
BFM 95 protocol          
3 yr OS:  95 ± 4.9 % 
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Objective 2b 











          Note: 
         Additional criteria for stratification into Intermediate risk in the non methotrexate/               




Since 2004, 285 children with acute lymphoblastic leukemia have been stratified into the 
intermediate risk category. 251 children opted for the non-methotrexate / radiotherapy 
based chemotherapy, which was unchanged since 2004. Beginning from July 2012, 34 
children opted for the methotrexate based therapy of intermediate risk BFM 95 protocol. 
Table 11: Inclusion criteria of intermediate risk group 
 
Jan 2004 to Feb 2014 –  Radiation based protocol (Non methotrexate) 
 
  Jan 2008 to Feb 2014 –  BFM 95 (Methotrexate based) protocol 
Variables 
 
Age (years) > 1 < 15 
Total count (per cmm) > 20,000 
Prednisolone response (PR) Good 
Immunophenotype T cell 
High risk cytogenetics Absent 
i. B cell ALL with presence of two myeloid markers on 
immunophenotype. 
ii. B cell ALL with CNS Disease. 
iii. B cell ALL with testicular disease. 
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Except a higher median size of liver, there was no significant difference between the two 
groups in terms of their baseline demographics. 
 
Table 12a: Baseline characteristics of intermediate risk group 
Variables 
BFM 95 based 
n (%) / Median (range) 
(n – 34 ) 
RT based 
n (%) / Median (range) 
(n – 251 ) 
 
P value 
Age (years) 7 (1 -14 ) 6 (1 -14) 0.988 
Sex (male) 25 (73.5 ) 164(65.3 ) 0.440 
Physical findings : 
 Hepatomegaly (cm) 
 
2 (1 – 6) 
 
3 (1 -12) 
 
0.017 
 Splenomegaly (cm) 2 (1 -11) 2 (1-16) 0.930 
 CNS Disease (%) 3 (8.8 ) 34 (13.5 ) 0.591 
 Pleural Effusion (%) 1 (2.9 ) 3(1.2 ) 0.400 
 Mediastinal mass (%) - 12 (4.8 ) 0.372 
 Testicular mass (%) 1(3.8 ) 2(1.2 ) 0.349 
Lab Parameters : 
WBC ( 10 
9 
 / Lt) 
16.7 (1.5 – 445.2) 21.3 (0.2 – 539.4) 0.542 
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Table 12 b: Immunophenotype, cytogenetics and molecular genetics  
Variables 
BFM 95 based 
n (%) / Median (range) 
(n – 34 ) 
RT Based 
n (%) / Median (range) 
(n – 251 ) 
P value 
IPT :  B cell 27 (79.4 ) 205 (81.6 ) 
0.338 
          T cell 5 (14.7 ) 42 (16.7 ) 
Cytogenetics :    n 32 (94.1 ) 220 (87.6 ) 
     0.013 
 
 Favourable 17 (53.1 ) 61 (27.7) 
 Intermediate 12  (37.4 ) 115 (52.3 ) 
 Poor 3 (9.4 ) 44 (20 ) 
RT PCR :       n 28 (82.4 ) 220  (87.6  ) 0.414 
 B ALL 27  (96 ) 197 (90 ) 
0.267 
 T ALL                   1 (4 ) 22 (10 ) 
                  B ALL  
  
- 
 BCR ABL - 14 (7.1 ) 0.383 
 TEL AML 3 (11 ) 30 (15 ) 0.778 
 MLL - 1 (0.5) 1.000 
 E2A PBX 1 (4 ) 12 (6 ) 1.000 
 No result 23(85.1) 140 (73.6) - 
** Cytogenetic risk stratification: (92) 
a. Favourable risk:    (i) Hyperdiploidy  
b. Poor risk:               (i) t (9:22), (ii) t (4:11), (iii) Complex karyotype, (iv) iAmp 21,  
                                            (v) Low hypodiploidy/near triploidy (vi) t (17:19). 




Table 13: Overall Risk status 
Variables 
BFM 95 based  
n (%) / Median (range)  
(n – 34 ) 
  RT Based  
 n (%) / Median (range) 





 IR 33 (97.1 ) 209 (83.2 ) 
0.039 
 HR* 1 (2.9 )**          42 (16.7  )*** 
* HR (High risk): (i) Poor prednisolone response    
                               (ii) End Induction failure  
   (iii) High risk cytogenetics – t (9:22), t (4:11) 
** In the methotrexate based treatment arm of BFM 95, there was one patient who had a 
residual disease at the end of induction and was subsequently categorized into high risk. 
*** In the radiotherapy based treatment arm, there were 42 (16.7 %) patients who were 
later stratified as high risk due to either a poor prednisolone response or philadelphia 
positivity, but continued to be treated with the intermediate risk protocol due to 
insufficient finances required for a high risk protocol and a transplant.  Overall, there were a 
significant number of high risk cases who were treated with the radiotherapy based 
protocol in comparison to the methotrexate (BFM 95) based treatment regimens. 
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Table 14: Treatment response 
Variables 
 BFM 95 based  
n (%) / Median  
(range) n – 34  
  RT based  
n (%) / Median 








) 29 (85.3 ) - - 
HD MTx  (5gms/m
2
) 5 (14.7 ) - - 
IR RT/No MTx - 251 (100 ) - 
Prednisolone  Response (PR): 24 (70.5 ) 182  (73 ) - 
 GPR (Good) 24 (100 ) 153 (84.1) 0.030 
 PPR (Poor) -    29 (15.9) 
 
End Induction status : 34 (100 ) 240  (95.6) 1.000 
 CR (Complete  remission) 33 (97.1 ) 231 ( 96.2) 
0.782 
 RD (Residual disease) 1 (2.9 ) 9  (3.7 ) 
No end Induction BM - 11 (4.3 ) - 
• Induction deaths - 6 - 
• Lost to follow up - 5 - 
Received maintenance:  Yes                  26 (76.4 ) 194 (77.2 ) 
0.915 
                                          No 8 (23.4 ) 57 (22.7 ) 
• Ongoing  pre-maintenance 7(87.5) 18 (31.5 ) - 
• Deaths (Relapse + Infection) 1 (2.9 ) 17 (29.8 ) - 
• BMT - 1 (1.7 ) - 
• No follow up - 21 (36.8 ) - 
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Table 15: Follow up of outcome of intermediate risk group 
Variables 
BFM 95 Based 
( < 15 yrs ) 
n (%) / Median  (range)  
n – 34 
RT Based  
( < 15 yrs ) 
n (%) / Median  (range)  
n - 251  
 
P value 
Relapse - 48 (19.1 ) 0.002 
 Very early - 21 (8.3 ) 
      0.05 
 
 Early - 19 (7.6 ) 
 Late - 8 (3.2 ) 
 No relapse 34(100) 203 (80.8) 





1 (100 )               40 (85.1 ) 
 Infection -                5 (10.6 ) 
 CNS Bleed -                 2 (4.3 ) 
Current status 
CCR – (Continous 
complete remission post 
completion of treatment)  
2  (5.8 ) 90  (35.8 ) < 0.001 
CR – On Treatment 31 (91.1 ) 96  (38.2 ) <.0.001 
Induction deaths 0 6 (2.3 ) 
 
OS                  Alive 33 (97.1 ) 204 (81.3 ) 0.025 
 
There was no relapse seen in the BFM 95 treatment arm, though the period of follow up 
was short. In comparison, there were 48 children who relapsed in the radiotherapy based 
treatment regimens and this was statistically significant. 
 47 
Survival statistics: (Figures 5a - 5b) 
The overall survival (OS) and the event free survival (EFS) were calculated using the 
Kaplan- Meier estimates. 
OS in intermediate risk acute lymphoblastic leukemia:  (Figure 5a)  
At the time of this analysis, the 2 year overall survival of the BFM 95 based cohort (n = 34) 
was 96.9 ± 3.1 % with an actuarial median follow up of  27 (1 - 47) months and 2 year 
overall survival of the radiotherapy based cohort was 87.9 ± 2.3 % with an actuarial median 
follow up of  35 (1 - 116) months. For the purpose of this analysis, patients who had relapsed 
during therapy and then subsequently lost to follow up were considered as dead, 30 days after 
the last follow up. 
A log rank comparison among those treated with the BFM 95 and the radiation based study 
protocol did not show a statistically significant survival difference. (P = 0.163). 
EFS in intermediate risk acute lymphoblastic leukemia:  (Figure 5b) 
At the time of this analysis, the 2 year event free survival of the BFM 95 based cohort (n = 
34) was 96.9 ± 3.1 % with an actuarial median follow up of 27 (1 - 47) months.  The 2-year 
event free survival for the radiotherapy based cohort was 85.6 ± 2.4 % with an actuarial 
median follow up of 18 (1 -116) months. There was no significant statistical difference 
between the two cohorts.  
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An event was considered whenever there was a relapse or death. In cases where death was 
secondary to relapse and progressive disease, the date of relapse was considered an event in 
that patient. 
A log rank comparison among those treated with the BFM 95 and the radiation based study 
protocol did not show a statistically significant survival difference. (P = 0.103). 

















    Figure 5a: Overall survival                                       Figure 5b: Event free survival 
 
                    
Figure 5a: Kaplan Meier curves for overall survival (OS) in children (>1 < 15 years) with 
intermediate risk acute lymphoblastic leukemia treated with BFM-95 protocol (n =34) and 
the Radiation based (RT) study protocol ((n = 251). 
With an actuarial median follow up period of 27(1 - 47) months and 35(1-116) months for 
those treated with the BFM 95 protocol and those with the RT based study protocol; the three 
year overall survival was 96.9 ± 3.1 % and 87.9 ± 2.3 % respectively. (P value = 0.163) 
 
Figure 5b: Kaplan Meier curves for event free survival (EFS) in children (>1 < 15 years) 
with intermediate risk acute lymphoblastic leukemia treated with BFM-95 protocol (n = 34) 
and the radiation based study protocol (n = 251).  
With an actuarial median follow up period of 27 (1 - 47) months and  18 (1-116) months for 
those treated with the BFM 95 protocol and those with the radiation (RT) based protocol; the 
two year event free survival was 96.9 ± 3.1 % and 85.6 ± 2.4 % respectively. (P value = 
0.103)                                      
 
                                              
 
 RT based n = 251 
  2 yr OS - 87.9 ± 2.3 % 
 
 
  P = 0.163  
 RT based n = 251                         
2 yr EFS – 85.6 ± 2.4 % 
 
 
  P = 0.103 
 BFM 95 based   n = 34                  
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                                                             Objective 3: 
A comparison of the clinical outcome in adolescents (≥ 15 ≤ 20 yrs) with acute 
lymphoblastic leukemia (ALL) treated with Intermediate risk pediatric-based regimens as 
against those treated with the adult GMALL regimens. 
Since Jan 2004, 181 adolescents (≥ 15 ≤ 20 yrs) with ALL have been treated.  
 Jan 2004 to July 2012: 150 adolescents treated with adult modified GMALL regimen.  
 July 2012: 31 adolescents treated with  Intermediate risk pediatric-based regimens 
Table 16: Baseline characteristics 
Variables 
          Adolescent ALL 
              (≥15 ≤20 yrs) 
(Pediatric Protocols ) 
n (%) / Median (range)  
               (n – 31) 
      Adolescent ALL  
           (≥15 ≤20 yrs) 
(Adult Protocols ) 
n (%) / Median (range)  
               (n – 150)  
P value 
Age (years) 17 ( 15 -20 ) 17 (15 -20 ) 0.692 
Sex (male) 24 (77.4) 115 (76.7) 1.000 





3 (1 – 10) 0.451 
Splenomegaly (cm) 6 (2 - 20) 3 (1 - 14) 0.009 
CNS Disease (%) 7 (22.6) 22 (14.7) 0.286 
Pleural Effusion (%) 1 (3.2 ) 5 ( 3.3) 1.000 
Mediastinal mass (%) 0 (0%) 0 (0%) 0.215 
Testicular mass (%) 1 (4.3 ) 0 0.167 
Lab Parameters : 
WBC ( 10 
9 
 / Lt) 
24.1 (0.7 – 442.6 ) 
 




Table 17:  Immunophenotyping, cytogenetics and molecular genetics 
Variables 
Adolescent ALL 
(≥15 ≤20 yrs) 
(Pediatric Protocols ) 
n (%) / Median (range) 
(n – 31) 
Adolescent ALL 
(≥15 ≤20 yrs) 
(Adult Protocols ) 
n (%) / Median (range) 
(n – 150) 
P value 
IPT :  B cell 20 (64.5  ) 110 (73.3 ) 
0.502 
T cell 11 ( 35.5  ) 38 ( 25.3  ) 
Cytogenetics :                             
                            n 





 Standard 18 (72 ) 107 (81.6 ) 
 Poor 7 (28 ) 24   (18.3 ) 
RT PCR :             n 23(74.1) 115(76.6) 
0.812  T ALL 3(13) 13(11.3) 
 B ALL 20(86.9) 102(88.6) 
B ALL    
 BCR ABL 2 (10.0 ) 7 (6.8 ) 
0.564 
 TEL AML - 4 (3.9 ) 
 MLL - - 
 E2A PBX 3 (15.0 ) 8 (7.8 ) 
 No result 15 (75) 83 (81.3) 
No significant difference between the two groups 
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Table 18: Risk status, treatment and response 
Variables 
Adolescent ALL 
( ≥ 15 ≤ 20 yrs ) 
(Pediatric Protocols) 
   n (%) / Median (range) 
( n = 31) 
Adolescent ALL 
( ≥ 15 ≤ 20 yrs ) 
(Adult Protocols) 
n (%) / Median (range)  
 (n = 150) 
P  value 
Overall risk : 30* 150 
0.262  SR/IR 21(67.7 ) 119 (79.3 ) 
 HR 9 (30.0 ) 31 (20.6 ) 
Protocols : 
    - 
IR MD MTx (2gms/m
2
) 9 (29.0) - 
IR HD  MTx (5gms/m
2
) 5 (16.1 ) - 
IR RT/No HDMTx 17 (54.8 ) - 
Modified GMALL - 150 (100 ) 
Cranial RT  ** 
23   [IR RT protocol (B cell  
and T cell) = 17] +  
    [IR MTx (T cell) = 6] 
150 (100 ) 0.000 
Prednisolone response 
(PR):                     n 
               23 (74.1 ) 111 (74 ) 
0.765  GPR (Good) 20 (87 ) 92 (82.9 ) 
 PPR (Poor) 3 (13 ) 19 (17.1 ) 
PR not assessed  7(22.5)   39 (26) 
 
* One patient was not stratified due to insufficient data 
** Indication of irradiation in pediatric protocol  
(i) Adolescents (B cell and T cell) on Intermediate risk radiation based protocol  
(ii) Adolescents with T - ALL on Intermediate risk Mtx based protocol  
(iii) Adolescents with B - ALL with CNS III on Intermediate risk Mtx based protocol. 
 
The only significant difference was a higher number of patients receiving cranial radiation in 
adolescents on the adult GMALL regimen. 
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( ≥ 15 ≤ 20 yrs ) 
(Pediatric Protocols)  
n (%) / Median (range)  
 n = 31 
Adolescent ALL 
( ≥ 15 ≤ 20 yrs ) 
(Adult Protocols )   
 n (%) / Median (range)  
              n = 15050) 
P value 
End Induction Remission 
status : Assessed  in 
26 (83.8 ) 137 (91.3 ) 
0.081 CR (Complete  remission) 23 (74.1 ) 128 (85.3 ) 
RD  (Residual disease) 3 (9.6 ) 9  (6.0 ) 
End induction not assessed 5 (16.1 ) 13 (8.6 ) - 
 Induction deaths 4 (80) 6 (46.1) - 
 Ongoing Induction  1 (20) - - 
 No follow up - 7 (53.8) - 
Received maintenance:                      
                                      Yes 
15 (48.3 ) 111 (74.0 ) 
0.599 
                                       No 16 (51.6 ) 39  (26 ) 
i. In pre-maintenance phase 9(56.2) - - 
ii.  Induction Deaths 4(25) 6(15.3) 
 
iii. Death due to relapse - 21(53.8) - 
iv. Refractory disease 1(6.2) - - 
v.  No Follow up 2(12.5) 12(30.7) 
 
Relapse                              n - 41 (27.3 ) 0.000 
 Very early - 31 (20.7 ) 
0.012  Early - 6 (4.0 ) 
 Late - 4 (2.7 ) 
Overall  Alive patients 26 (83.8 ) 97 (64.6 ) 0.055 
Continous complete 
remission (CCR) 
- 53(35.3) - 
Complete remission (On 
treatment) 
23(74.1) 38 (25.3) - 
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A significantly higher relapse rate seen in adolescents treated with the adult GMALL 
regimens, but follow up was shorter in adolescents treated with pediatric regimens. 
Survival statistics: (Figures 6a - 6b) 
The overall survival (OS) and the event free survival (EFS) were calculated using the 
Kaplan- Meier estimates. 
OS in intermediate risk acute lymphoblastic leukemia:  (Figure 6a)  
At the time of this analysis, the 1 year overall survival of the adolescents treated with 
intermediate risk pediatric protocol (n = 31) was 82.3 ± 7.3 % with an actuarial median 
follow up of 8 (1 - 19) months and 1 year overall survival of adolescents treated with the 
modified adult GMALL protocol was 81.4 ± 3.2 % with an actuarial median follow up of 27 
months (1 - 118) months. For the purpose of this analysis, patients who had relapsed during 
therapy and then subsequently lost to follow up were considered as dead, 30 days after the 
last follow up. 
A log rank comparison among those treated with the intermediate risk pediatric protocol and 
the modified adult GMALL protocol did not show a statistically significant survival 
difference. (P = 0.996). 
EFS in intermediate risk acute lymphoblastic leukemia:  (Figure 6b) 
At the time of this analysis, the 1 year event free survival of the intermediate risk pediatric 
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protocol (n = 31) based cohort was 82.3 ± 7.3 % with an actuarial median follow up of 7.7 (1 
- 19) months.  The 1 year event free survival for the modified adult GMALL protocol based 
cohort was 75.9 ± 3.6 % with an actuarial median follow up of 18 (1 - 118) months. An event 
was considered whenever there was a relapse or death. In cases where death was secondary 
to relapse and progressive disease, the date of relapse was considered an event in that patient. 
A log rank comparison among those treated with the intermediate risk pediatric protocol and 
the modified adult GMALL protocol did not show a statistically significant survival 











     Figure 6a: Overall survival                           Figure 6b: Event free survival 
     
 
Figure 6a: Kaplan Meier curves for overall survival (OS) in adolescents (≥ 15 ≤ 20 yrs) 
treated with intermediate risk pediatric protocol (n = 31) and the modified adult GMALL 
protocol ((n = 150). 
With an actuarial median follow up period of 8(1 - 47) months and 27 (1-118) months those 
treated with intermediate risk pediatric protocol and the modified adult GMALL protocol;; 
the one year overall survival was 82.3 ± 7.3 % and 81.4 ± 3.2 %  respectively. 
(P value = 0.996) 
 
 
Figure 6b: Kaplan Meier curves for event free survival (EFS) in adolescents                   
(≥ 15 ≤ 20 yrs) treated with intermediate risk pediatric protocol (n = 31) and the modified 
adult GMALL protocol ((n = 150). 
With an actuarial median follow up period of 7.7(1 - 19) months and 18(1-118) months those 
treated with intermediate risk pediatric protocol and the modified adult GMALL protocol;the 




    
 
 
Pediatric protocol (n – 31)         
1 yr OS:  82.3 ± 7.3 % 
Adult protocol (n – 150)  
1 yr OS:  81.4 ± 3.2 % 
P = 0.996 
Pediatric protocol (n – 31)         
1 yr EFS:  82.3 ± 7.3 % 
Adult protocol (n – 150)  
1 yr EFS:  75.9 ± 3.6 % 
P = 0.752 
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    Objective 4: 
         Evaluation of the role of MRD by flow cytometry at end induction 
      








 Table 20:  Leukemia associated immunophenotype (LAIP) statistics 
Newly diagnosed patients in whom LAIP  attempted at diagnosis by 
flow cytometry 
n (%) 
n = 106 
(i)    NO LAIP 3(2.8) 
(ii)  LAIP identified at diagnosis 103(97) 
(a)   LAIP  available and evaluated at end induction 75(72) 
• MRD positive ( ≥ 0.01 %) 22(29.3) 
• MRD negative (< 0.01 %) 53(70.6) 
(b)   LAIP available at diagnosis but no sample received at end 
induction 
28(27) 
• Ongoing induction 3(10.7%) 
• Induction deaths 6(21.4%) 
• Samples not received 9(32.1%) 
• Discharged against medical advice 10(35.7%) 
   
Definition Values in  % 
MRD Positive ≥ 0.01 
MRD Negative < 0.01 
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Table 21:  Baseline characteristics 
Variables 
MRD  ( - ) 
n (%) / Median (range) 
n = 53 
MRD ( + ) 
n (%) / Median (range) 
n =  22 
P value 
Age (years) 6 (1 – 60) 12 (2 -49) 0.071 
Sex (male) 33 ( 62.3 ) 18 0.285 
Physical findings : 
   
 Hepatomegaly (cm) 3 (1- 8) 3 (1-8) 0.784 
 Splenomegaly (cm) 3 (1 – 14) 3 (1 -10) 0.844 
 CNS Disease (%) 9 (17.0 ) 4 1.000 
 Pleural Effusion (%) 0 0 - 
 Mediastinal mass (%) 0 0 - 
 Testicular mass (%) 1 (2.6 ) 1 (5.9 ) 0.527 
Lab Parameters : 
WBC ( 10 
9 
 / Lt) 
 
7.7 (0.7 – 174.5) 
 
17.4 (0.7 -154.6) 
 
0.118 
                                    






Table 22: Cytogenetics, molecular genetics and  risk status 
Variables 
MRD  ( - ) 
n (%) / Median (range) 
n- 53 
MRD ( + ) 
n (%) / Median (range) 





 Poor 6  ( 11.3 ) 8  (36.3 ) 
RT PCR : 51 (96.2) 21 (95.5) 1.000 
 BCR ABL 2 (3.9 ) 5 (22.7 ) 0.020 
 TEL AML 8 (16.3 ) 1 (4.5 ) 0.101 
 MLL 0(0%) 0(0%) - 
 E2A PBX 3 (6.1 ) 1 (4.5 ) 1.000 
Overall Risk : 
0.001 
 SR 16 (30.1 ) 4 (18.1 ) 
 IR 32 (60.3 ) 9 (40.9 ) 
 HR 5 (9.4 ) 9 (40.9 ) 
 










Table 23 : Protocols , response outcomes 
Variables      
MRD  ( - ) 
n (%) / Median  (range) 
n- 53 
MRD ( + ) 
n (%) / Median (range) 
n – 22 
P  value 
Protocols :        
          
 IR MD MTx 
14 (26.4 )  ( 1 later 
changed to R1R2) 
5 (22.7 ) 
0.106 
 IR  RT/No MTx  21 (39.6 ) 11 (50.0 ) 
 Modified GMALL 6 (11.3 ) 8 (36.3 ) 
 SR (No MTX/No RT ) 5 (9.4 ) 3 (3.6 ) 
 SR MD Tx 7 (13.2 ) - 
 Prednisolone  Response 
(PR):                            n                       
33 (62.6 ) 19 (86.3 ) 
0.084  GPR (Good) 32 (96.9 ) 15 (78.9 
 PPR (Poor) 1 (3 ) 4    (21) 
End Induction Remission 
status :   
0.214 
  CR (Complete  
remission) 
52 (98.1 ) 20 (90.0 ) 






Table 24: Follow up of Outcome 
Variables 
MRD  ( - ) 
n (%) / Median   
(range) 
n- 53 
MRD ( + ) 
n (%) / Median (range) 
n – 22 





  Yes 29 (54.7 ) 8 ( 36.3 ) 
     No 24 (45.2 ) 14 (63.6 ) 
i. In pre-maintenance 
phase 
21(87.5) 9 (64.2) 
 
ii. Induction Deaths - - - 
iii. Death due to 
progressive disease 
1(4.1) 3 (33.3) 
 
iv. No Follow up 1(4.1) 1 (33.3) 
 
v. Changed to R1R2 1(4.1) - - 
vi. Refractory disease – No 
     follow up 
- 2 (22.2) - 
Relapse 1 (1.8 ) 3 (13.6 ) 
 
0.073 
 Very early 1 (1.8 ) 2 (13.6 ) 
 Alive 52 (98.1) 19 (86.4 ) 
In Complete remission 
(CR), on treatment 
49 17 0.146 
 CCR (Continuous complete 
remission) 






Survival statistics: (Figures 7a - 8b) 
The overall survival (OS) and the event free survival (EFS) were calculated using the 
Kaplan- Meier estimates. 
OS in MRD (-) and MRD (+) cohort: (Figure 7a, 8a)  
At the time of this analysis, the 1 year overall survival of the MRD (-) cohort (n = 53) was 
97.4 ± 2.6 % with an actuarial median follow up of 8.3 (1-19) months and 1 year overall 
survival of MRD (+) cohort (n = 22) was 83.1 ± 9.0 % with an actuarial median follow up of 
7.5 (1-13) months. For the purpose of this analysis, patients who had relapsed during therapy 
and then subsequently lost to follow up were considered as dead, 30 days after the last follow 
up. 
A log rank comparison among those treated with the MRD (-) cohort and the MRD (+) 
cohort showed a statistically significant survival difference. (P = 0.035).  
 
EFS in MRD (-) and MRD (+) cohort: (Figure 7b, 8b) 
At the time of this analysis, the 1 year event free survival of the MRD (-) cohort (n = 53) was 
97.4 ± 2.5 % with an actuarial median follow up of 7.7 (1-19) months.  The 1 year event free 
survival for the MRD (+) cohort (n = 22) was 58.2 ± 18.4 % with an actuarial median follow 
up of 7.4 (1- 13) months. An event was considered whenever there was a relapse or death. In 
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cases where death was secondary to relapse and progressive disease, the date of relapse was 
considered an event in that patient. 
A log rank comparison among those treated with the MRD (-) and MRD (+) showed a 
statistically significant survival difference. (P = 0.002). 
        Figure 7a: Overall survival                                   Figure 7b: Event free survival 
 
           
Figure 7a: Kaplan Meier curves for overall survival (OS) in MRD (-) (n = 53) and MRD 
(+) patients (n = 22) 
With an actuarial median follow up of 8.3 (1-19) months and 7.5 (1-13) months; the one year 
overall survival of the MRD (-) cohort (n = 53) was 97.4 ± 2.6 % and for the MRD (+) cohort 
(n = 22) was 83.1 ± 9.0 % respectively. (P value = 0.035).  
 
Figure 7b: Kaplan Meier curves for event free survival (EFS) in MRD (-) and MRD (+) 
patients. 
With an actuarial median follow up of  7.7 (1-19) months and  7.4 (1- 13) months; the one 
year event free survival of the MRD (-) cohort (n = 53) was 97.4 ± 2.5 % and for the MRD 
(+) cohort (n = 22) was 58.2 ± 18.4 % respectively.  (P value = 0.002). 
 
         
MRD (-) n = 53 
1 yr EFS – 97.4 % ± 2.5% 
MRD (+) n = 22 
1 yr EFS – 58.2% ± 18.4% 
P = 0.002 
MRD (+) n = 22 
1 yr OS – 83.1% ± 9.0% 
MRD (-) n = 53 
1 yr OS – 97.4 % ± 2.6% 
P = 0.035 
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 Figure 8a: Overall survival       Figure 8b: Event free survival                                      
 
                                                      
 
 
Figure 8a: Comparison of Kaplan Meier curves for overall survival (OS) of MRD (-) (< 
0.001%)] and MRD strongly (+) (>1 %) 
 
With an actuarial median follow up of 8.3 (1-19) months, the 6 months and 1 year OS in 
MRD (-) cohort (n = 53) is 1 yr OS 97.4 ± 2.6 %. With a median follow up of 6 months, the 6 
months OS in MRD strongly (+) cohort (n = 6) is 30 ± 23.9 %. 
A log rank comparison between the two groups of MRD (-) and MRD strongly (+) showed a 
significant survival difference. (P = 0.000) 
 
Figure 8b: Comparison of Kaplan Meier curves for event free survival (OS) of MRD (-) 
(< 0.001%)] , MRD (+) (>0.001%)] and MRD strongly (+) ( >1 %) 
 
With an actuarial median follow up of 7.7 (1-19) months, the 6 months and 1 year EFS in 
MRD (-) cohort (n = 53) is 97.4 ± 2.6 %. With an actuarial median follow up of 7.7 (1-13) 
months, the 6 months and 1 year EFS in MRD (+) cohort (n = 16) is 75 ± 21.7 %. With a 
median follow up of 6 months, the 6 months OS in MRD strongly (+) cohort (n = 6) is 20 ± 
17.9 %. 
A log rank comparison between the two groups of MRD (-) and MRD strongly (+) showed a 
significant survival difference. (P = 0.000) 
 
MRD (+) (> 1 %) (n =6) 
 6 months EFS 20 ± 17.9 %          
MRD (+) (n = 16) 
 1 yr EFS 75 ± 21.7 % 
MRD (-) (n = 53)  
1 yr EFS 97.4 ± 2.5 % 
 
P = 0.000 
MRD (-) (n = 53)  
 1 yr OS 97.4 ± 2.6 % 
MRD (+) (> 1 %) (n = 6) 
6 months OS: 30 ± 23.9 % 






Objective 1:  
This study reports the baseline demographics, laboratory features including the 
immunophenotype, cytogenetic and their molecular data and the long-term outcomes of adult 
ALL following treatment with a modified GMALL protocol. 
On comparing the baseline demographics, we found a median age of 26 years; much lower 
than the reported median age of 33 years in many adult ALL trials. (26) The large number of 
adolescent patients can explain the reported lower median age in the present study. We also 
found a male predominance in our study cohort. 
Extra medullary manifestations in the form of CNS involvement (14.1 %) was found to be 
much higher than the available reported literature of around 5 %. (93) 
Among the available laboratory data, the median WBC count was 9.5 x 10 
9 
/Lt. The 
incidence of B cell, T cell ALL and Philadelphia positivity in our adult study was also similar 
to that reported in literature (42) .  
Treatment outcome was available in 455 adults. The standard risk as well as high-risk 
patients was all treated with the same modified adult GMALL protocol. Imatinib was added 
in all patients with Philadelphia positivity. 
End induction complete remission rates in our study group was 83.2 %, which is comparable 
to most of the adult reported studies.(26) We also found an induction death rate of 6.3 %, 
predominantly due to neutropenic bacterial sepsis.  
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27 % of our patients are presently in complete continuous remission (CCR) and additionally 
22.6 % of our patient cohort is receiving chemotherapy and is in complete remission. 29 % of 
our patient cohort relapsed, with most of them having a very early relapse. 39.3 % of our 
patients died, with majority (78.2 %) of them having died due to progressive disease and 
21.8 % deaths due to infection. 
Overall, with a median follow up period of 65 months, the five-year event free survival was 
50.1 ± 2.9 % and five year overall survival was 51.6 ± 2.9 %. (26) The higher outcomes in 
our study could also be due to a larger number of young adults treated in our patient cohort. 
This reported outcome is significant in terms of available literature being reported from a 
developing country, where in cancer treatment related government funding is much less than 
the developed countries.  
Major costs involved in treatment of adult ALL are attributed to the use of high dose 
methotrexate as part of consolidation instead of the cranial irradiation. The overall costs 
involved in the treatment of a single patient is less than 8000 $, amounting to approximately 
5, 00,000 Indian currency.  
Considering the costs involved due to the socio economic status and the results achieved, this 







(i) Standard risk acute lymphoblastic leukemia:  
A comparison of the two standard risk protocols (SR BFM 95 and SR study protocol) used in 
our department did not demonstrate any significant difference in their baseline presenting 
demographics or their baseline molecular or cytogenetic profile at presentation.  
On comparing the two groups on the basis of their relapse rates, though there was a lower 
incidence of relapse in the BFM 95 group, there was no significant statistical difference 
between the two groups. More follow up is needed to accurately identify the relapse rate in 
the two groups.  
Overall, there was no significant difference in the 3 year OS and the EFS between the two 
groups. The overall outcomes of the children treated with the BFM 95 regimens was found to 
be similar to the published literature (57).  
A significant difference between the two groups is the total amount of cost involved. A 
standard risk B cell ALL treated on the BFM 95 regimens requires atleast 7,000 $ while a 
standard risk B cell ALL treated on non-methotrexate / non-radiation based (study) protocol 
requires a maximum of 6,000 $.  
Though the actuarial median follow up is short, the non methotrexate / non radiation based 
study protocol can be considered as an effective regimen in economically deprived children, 




(ii) Intermediate risk acute lymphoblastic leukemia: 
A comparison of the two intermediate risk protocols (IR BFM 95 and Radiation based 
protocol) used in our department did not demonstrate any significant difference in their 
baseline presenting features.  
The significant difference in the cytogenetic and the molecular profile between the two 
groups could be attributed to few high risk children who were continued to be treated on the 
radiation based treatment regimen due to financial limitations, thereby unable to afford high 
risk protocol and a transplant.  
On comparing the two groups on the basis of their relapse rates, the radiation-based protocol 
had a much higher incidence of relapse in comparison to the BFM 95 based protocol, though 
the follow up was much shorter in the latter. 
Overall, there was no significant difference in the 2 year OS and the EFS between the two 
groups. The overall outcomes of the children treated with the BFM 95 regimens was found to 
be similar to the published literature (57).  
A significant difference between the two groups is the total amount of cost involved. An 
intermediate risk ALL treated on the BFM 95 regimens requires atleast 7,500 $ while 
radiation (non-methotrexate) based protocol requires a maximum of 6,500 $.  
Though the actuarial median follow up is short in the BFM 95 based protocol, based on the 2 
year outcomes, we can conclude that the radiation based study protocol can be considered as 
an effective regimen in economically deprived children, with a little support from the state 
funding agencies.  
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Objective 3:  
A comparison of the two adolescent age groups treated with pediatric intermediate risk 
protocol and the adult GMALL protocol, in our department did not demonstrate any 
significant difference in their baseline presenting demographics or their baseline molecular or 
cytogenetic profile at presentation. 
A significant difference was the use of cranial irradiation for every adolescent in the adult 
GMALL group, whereas in adolescents with B cell leukemia on pediatric intermediate risk 
group protocol receiving the methotrexate based therapy did not receive cranial irradiation 
unless they have CNS III disease. All adolescents with the T cell leukemia on pediatric 
intermediate risk group protocol received at least prophylactic  
A higher number of relapses were seen in the adolescent age group receiving the adult 
GMALL group but this can be explained by the extremely short follow up available in group 
receiving pediatric intermediate risk group protocol. There were no major toxicities noted in 
the adolescent group receiving pediatric regimens. 
The three year OS and EFS in adolescents treated with adult GMALL protocol were 64.8 ± 
4.0 % and 64.4 ± 4.1 % respectively.  
Though, follow up data of the overall survival and event free survival of the two groups at 
the end of one year does not show any statistically significant difference, the superiority of 
pediatric protocols over the adult protocols as demonstrated in various international trials 
remains to be established in the Indian cohort. A much longer follow up would be required 
for the same, though there appears to be a trend towards improvement. 
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The issue of cost difference between the two protocols also needs a special mention. Those 
treated with the adult GMALL regimens would require atleast 8000 $ for their complete 
therapy as compared to a total of 6500 to 7500 $ for those treated with the intermediate risk 
pediatric based protocol. 
 
Objective 4:  
Usefulness of minimal residual disease as a prognostic marker has already been explored. 
Using flow cytometry to identify LAIP (leukemia associated immunophenotype) has helped 
in further stratifying B cell acute lymphoblastic leukemia (ALL). Though multiple end points 
have been shown to have their individual significance, we had chosen end induction bone 
marrow sample for flow cytometry using 6 recently standardized tubes containing specific 
antibodies against specific leukemia associated antigens.  
Using the mentioned combination of antibodies, LAIP could be identified in 97 % of the total 
B cell leukemia, which is comparable to the published studies. (88)  
As shown in the results, there was only one standard risk ALL in the MRD (-) cohort who 
relapsed. Though the follow up is short, still a majority (92.4 %) of the total MRD (-) cohort 
were in complete remission (CR) inspite of this cohort having significant number (9.4 %) of 
high-risk cases.  
Among the MRD (+) cohort, 2 patients who had a residual disease at the end of induction 
were found to be strongly MRD positive (> 1 %). Both patients opted for palliative therapy. 
Among the entire MRD (+) cohort, there were 3 relapses in comparison to the MRD (-) 
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cohort. Out of these 3 patients, one was a standard risk adult ALL, one intermediate risk 
pediatric ALL and the third was a high risk Philadelphia positive ALL. Though the numbers 
are small, it is in the standard and the intermediate risk ALL, the usefulness of MRD by 
flowcytometry is demonstrated and an early intensification of the therapy or a bone marrow 
transplant might yield better results in the near future.  


















I. Using the current modified GMALL regimens in adults (≥ 15 years); treatment 
outcomes were comparable to those reported in the international literature. This has 
special implications in resource limited countries where government sponsored 
funding is limited and majority of the cost of therapy has to be borne by the patient 
and his family. 
II. Using BFM 95 regimens in standard risk and intermediate risk children (≥ 1 < 15 
years) with acute lymphoblastic leukemia, short term outcomes were similar to that 
reported in the international literature. There was no major difference noted in the two 
standard risk and two intermediate risk protocols. Long term follow up would be 
required to accurately establish its effectiveness in the Indian cohort. 
III. Using pediatric regimens in adolescent age group (≥15 ≤ 20 years) did not reveal any 
significant difference in the overall outcome as compared to the adult regimens. 
Though the follow up is short, pediatric regimens are feasible in adolescents with 
minimal toxicity. It remains to be seen whether using pediatric regimens will improve 
long term survivals in the Indian cohort, though there appears to be a trend towards 
improvement in their outcomes with pediatric regimens. 
IV. Using flow cytometry in detecting minimal residual disease can significantly identify 
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 Post induction marrow in remission  
 No translocation t (9; 22) or t(4;11) 
 Good Prednisolone Response in B lineage with counts < 30,000/cmm,                 
 T lineage <1,00,000/cmm 
 
PRE-INDUCTION (1 week) 
 
1. Dexamethasone 5 mg/m
2
 iv daily Days 1 & 2 
2. Prednisolone 60 mg/m
2
 p/o daily Day 3 to Day 7 
 
 
INDUCTION (Phase I: 2 - 5 wks) 
 
1.  Daunorubicin 30 mg/m
2
 iv weekly x 4 
2.  Vincristine 1.4 mg/m
2
 (max 2 mg) iv weekly x 4 
3.  L'Asparaginase 70,000 U/ m
2
 (total dose) iv/im/sc in divided doses of  
     10,000 U daily 
4.  Prednisolone 60 mg/ m
2
 daily x 3 weeks and then taper over 10 days 
 
1 week after completion of Phase I, BM to assess remission status 
 
Phase II: 6 - 9 wks 
 
1. Cyclophosphamide 650 mg/m
2
 iv Days 1, 15 and 29 
2. AraC 75 mg/m
2
 iv x 4 days followed by 3 days rest 
    Repeat: 4 cycles 
 
 
CNS PROPHYLAXIS (Given Concurrently with Phase II Induction) 
 
1.  Intrathecal Methotrexate 10 mg/m
2
 (max 12.5mg) weekly x 4 
2.  2400 Rads Cranial RT prophylaxis 
  
      
                                       Three weeks rest after Phase II 
 
             Appendix 1: Adult ALL ≥ 15 years   




CONSOLIDATION (13 - 17 wks) 
 
1. Intrathecal Methotrexate 10 mg/m
2
 (max 12.5mg) x 1 
2. AraC 75 mg/m
2
 iv daily x 5 days 
3. VP-16 50 mg/M
2
 iv daily x 5 days 
 
3 weeks rest 
 
1. Intrathecal Methotrexate 10 mg/m
2
 (max 12.5 mg) x 1 
2. AraC 75 mg/m
2
 iv daily x 5 days 
3. VP-16 50 mg/m
2
 iv daily x 5 days 
 
3 weeks rest 
 
REINDUCTION (Phase I : 20 - 24 wks 
 
1.  Vincristine 1.4 mg/m
2
 (max 2 mg) iv weekly x 4 
2.  Adriamycin 25 mg/m
2
 iv weekly x 4 
3.  Dexamethasone 10 mg/m
2
 (max 10 mg) p/o daily x 4 wks and then taper  
     Over 10 days 
 
 Phase II: 25 - 26 wks 
 
1.  Cyclophosphamide 650 mg/m
2
 iv x 1 
2.  AraC 75 mg/m
2
 iv daily x 4 days followed by 3 days rest 
     Repeat: 2 cycles 
 
Two weeks rest 
 
MAINTENANCE (29 - 136 wks ) 
 
1. 6-Mercaptopurine 60 mg/m
2
 p/o daily x 2 years 
2. Methotrexate 20 mg/m
2
 p/o once a week x 2 years 
3. Vincristine 1.4 mg/m
2
 (max 2 mg) iv Day 1 
4. Dexamethasone 6 mg/m
2
 Days 1 - 5 
    Repeat vincristine/dexamethasone every month x 2 years 
5. Intrathecal Methotrexate 10 mg/m
2







Pediatric ALL : PROTOCOL IV 
Intermediate Risk 
NO RADIOTHERAPY, HDMTX PROTOCOL (ALL  BFM 1995) 
 Age - 6 yr - 15 yrs  
 WBC > 20,000/cmm 
 Prednisolone good response 
 Precursor B, CALLA immunophenotype, T-cell immunophenotype 
 No translocation t(9;22) or t(4;11) 
 t ( 1;19) translocation present 
 Pro B cell without 11q23. 
 CNS disease or suspicious CNS disease.  




1. Dexamethasone 6 mg/ m2 iv Days 1 & 2                                Dose-                Date started- 
2. Prednisolone 60 mg/ m2 p/o daily Days 3 – 7                Dose -        Day 8 Pred Response-  




Phase I:  2 - 5 wks 
1. Vincristine 1.5 mg/ m2 iv weekly x 4  (Dose:      )(Day 8,-        Day15-    Day 22-   Day 29-          
2. Daunorubicin 30 mg/ m2 iv weekly x 4  (Dose:     )(Day 8,-     Day15-    Day 22-   Day 29-          
3. L'Asparaginase* 5,000 U/ m2/day IV every third day X 8 doses  (Dose-                   )  
* Leunase to be started 12 hours after VCR. Doses can be rounded up to 10,000 or 5000 IU. 
(Day12-      Day15-         Day18-        Day21-        Day24-         Day27-     Day30-    Day 33-                                                
4. Prednisolone 60 mg/ m2 p/o divided in 3 doses x 3 weeks and then taper over 10 days 
5. Inj Methotrexate IT stat day 12           Date- 
 
1 week after completion of Phase I, BM and CSF to assess remission status         Date- 
 
Phase II: 6 - 9 wks 
1. Cyclophosphamide 1000 mg/ m2 iv Day 1 & Day 29  (Dose-           )(Day 1-          Day 29-        
2. AraC 75 mg/ m2 iv/sc daily x 4 days (Days 1 - 4) followed by 3 days rest.  (Dose-          ) 
    Repeat x Total 4 cycles of Ara-C 
1st cycle : Date from              to                          3. Intrathecal MTX 
2nd cycle :Date from              to                          Dates: 2nd week- 
3rd cycle : Date from              to  
4th cycle : Date from              to                                      4th week- 
3. Intrathecal Methotrexate weekly x 2                 
4. 6-Mecapto-purine- 60 mg/m2, PO for 28 days  evening, fasting without milk.  
               Dose-                                  Date from-             to-       
                                                                                              




                 Appendix 2a 




12 - 20 wks        Date of starting:                              Date of completion: 
                           Date of counts:                               Date of counts: 
1. 6-Mercaptopurine* 50 mg/ m2 p/o daily x 8 weeks             Dose- 
2. Methotrexate* 20 mg/ m2  p/o once a week x 8 weeks      Dose- 
* in the evening on a fasting stomach without milk. Co-trimoxazole to be taken on Wed & Thu 




Phase I: 23 - 27 wks 
1. Vincristine 1.5 mg/ m2   iv weekly x 4(Dose:      )(Day 1,-        Day 8-          Day 15-        Day 21-      ) 
2. Adriamycin 30 mg/ m2  iv weekly x 4(Dose:      )(Day 1,-        Day 8-          Day 15-        Day 21-      ) 
3. L'Asparaginase* 40,000 U/ m2 (total) iv given in divided doses of 10,000 U on  days 2, 5,9 & 12 
* Leunase to be started 12 hours after VCR. Doses can be rounded up to 10,000 or 5000 IU. 
        (Dose:                     )(Day 2,-        Day 5-            Day 9-         Day 12-      ) 
4. Dexamethasone 10 mg/ m2   p/o daily x  4 weeks and then taper over 10 days(Dose-      ) 
 
Phase II: 28 - 30 wks 
1. Cyclophosphamide 1000 mg/ m2   iv Day 1            Dose-           (Date-         ) 
2. AraC 75 mg/ m2   iv/sc  daily x 4 days (Day 1 - 4) followed by 3 days  rest. (Dose-          ) 
     Repeat x Total 2 cycles of Ara-C 
1st cycle : Date from              to          
2nd cycle :Date from              to 
 




33 - 137 wks Date of starting:                              Date of completion: 
1. 6-Mercaptopurine* 50 mg/ m2 p/o daily x 2 years                     (Dose-        ) 
2. Methotrexate* 20 mg/ m2 p/o once a week x 2 years               (Dose-         ) 
3. Inj Vincristine 1.4 mg/m2 once a month x 2 years                   (Dose-        ) 
4, Tab Dexa 6 mg/m2 daily for 5 days once a month x 2 years   (Dose-        ) 
5. Inj MTx IT stat once every three months x 2 years                  (Dose-        ) 
* in the evening on a fasting stomach without milk. Co-trimoxazole to be taken on Wed & Thu 
 
                                                 Reference – ALL BFM 1995 
                                                  Modified May, 2009 




    
 95 
Pediatric ALL : PROTOCOL III 
Intermediate Risk 
NO HDMTX , WITH  RADIOTHERAPY 
 Age >6 years 
 WBC >20,00cmm   
 T cell immunophenotype (any aberrant markers) 
 t(1 ;19) 
 Pro B cell ALL without 11q23. 
 CNS disease or  testicular disease at diagnosis 
 (+ prednisolone good response + marrow in remission – Post Ph I Induction) 
 Lower Socio-economic status. 
 
( 1 week ) 
 
1. Dexamethasone 6 mg/ m2   iv  Days 1 & 2          Dose-                Date started-. 
2. Prednisolone 60 mg/ m2  p/o daily  Days 3 – 7    Dose -               Day 8 Pred Response-  
3. Inj Methotrexate IT stat Day1.                              Dose-              Date-  
 
 
Phase I:  2 - 5 wks 
1. Vincristine  1.5 mg/ m2   iv weekly x 4 (Dose:      )(Day 8,-        Day15-          Day 22-      Day29-      ) 
2. Daunorubicin  30 mg/ m2   iv weekly x 4(Dose:      )(Day 8,-        Day15-        Day 22-      Day29-     ) 
3. L'Asparaginase 105,000 U/ m2   (total dose)  iv  given as: (Leunase to be started 12 hours after VCR.) 
 0.5 m2   :   5000 U A/D x 10 doses                            Doses can be rounded up to 10,000 or 5000 IU. 
 0.75 m2 : 10,000 U A/D x 8 doses 
 1.0 m2    : 10,000 U A/D x 10 doses 
 (Day 8-         Day10-         Day12-        Day14-        Day 16-         Day 18-          Day 20-           Day 22-                                                
4. Prednisolone 60 mg/ m2   p/o daily x 3 weeks and  then taper over 10 days 
1 week after completion of Phase I,  BM to assess remission status           Date- 
 
Phase II: 6 - 9 wks 
1. Cyclophosphamide 1000 mg/ m2   iv  Day 1 & Day 29 (Dose-           )(Day 1-         Day 29-            ) 
2. AraC 75 mg/ m2   iv/sc daily x 4 days (Days 1 - 4)  followed by 3 days rest. (Dose-          ) 
    Repeat x Total 4 cycles of Ara-C 
1st cycle : Date from              to          
2nd cycle :Date from              to 
3rd cycle : Date from              to  
4th cycle : Date from              to  
Given Concurrently with Phase II Induction 
 
1. Intrathecal Methotrexate  weekly x 4  Dates: 1st-              
                                                                                                  2nd-               
                                                                                                  3rd-           
                                                                                                  4th-  
2. Cranial RT       (No RT < 1 yr)       Date of starting:                              Date of completion: 
 a. Prophylactic  >1yr             12 Gy 
 b. Therapeutic  >1 yr <2 yr   12 Gy  








12 - 20 wks        Date of starting:                              Date of completion: 
                           Date of counts:                               Date of counts: 
1. 6-Mercaptopurine* 50 mg/ m2 p/o daily x 8 weeks             Dose- 
2. Methotrexate* 20 mg/ m2  p/o once a week x 8 weeks      Dose- 
* in the evening on a fasting stomach without milk. Co-trimoxazole to be taken on Wed & Thu 




Phase I: 23 - 27 wks 
1. Vincristine 1.5 mg/ m2   iv weekly x 4(Dose:      )(Day 1,-        Day 8-          Day 15-        Day 21-      ) 
2. Adriamycin 30 mg/ m2  iv weekly x 4(Dose:      )(Day 1,-        Day 8-          Day 15-        Day 21-      ) 
3. L'Asparaginase* 40,000 U/ m2 (total) iv given in divided doses of 10,000 U on  days 2, 5,9 & 12 
* Leunase to be started 12 hours after VCR. Doses can be rounded up to 10,000 or 5000 IU. 
        (Dose:                     )(Day 2,-        Day 5-            Day 9-         Day 12-      ) 
4. Dexamethasone 10 mg/ m2   p/o daily x  4 weeks and then taper over 10 days(Dose-      ) 
 
Phase II: 28 - 30 wks 
1. Cyclophosphamide 1000 mg/ m2   iv Day 1            Dose-           (Date-         ) 
2. AraC 75 mg/ m2   iv/sc  daily x 4 days (Day 1 - 4) followed by 3 days  rest. (Dose-          ) 
     Repeat x Total 2 cycles of Ara-C 
1st cycle : Date from              to          
2nd cycle :Date from              to 
 




33 - 137 wks Date of starting:                              Date of completion: 
1. 6-Mercaptopurine* 50 mg/ m2 p/o daily x 2 years                     (Dose-        ) 
2. Methotrexate* 20 mg/ m2 p/o once a week x 2 years               (Dose-         ) 
3. Inj Vincristine 1.4 mg/m2 once a month x 2 years                   (Dose-        ) 
4, Tab Dexa 6 mg/m2 daily for 5 days once a month x 2 years   (Dose-        ) 
5. Inj MTx IT stat once every three months x 2 years                  (Dose-        ) 
* in the evening on a fasting stomach without milk. Co-trimoxazole to be taken on Wed & Thu 
 
                                                 Reference – ALL BFM 1995 
                                                  Modified May, 2009 







Pediatric ALL : PROTOCOL II 
Standard Risk 
NO RADIOTHERAPY, HDMTX PROTOCOL 
(ALL IC BFM 2002) 
 Age > 1 yr, < 6 yrs  
 WBC < 20,000/cmm 
 Prednisolone good response 
 Precursor B, CALLA immunophenotype (no T immunophenotype, no aberrant markers) 
 No translocation t(9;22) or t(4;11) 
 No CNS disease 




1. Dexamethasone 6 mg/ m2 iv Days 1 & 2                         Dose-                Date started-. 
2. Prednisolone 60 mg/ m2 p/o daily Days 3 – 7                Dose -         Day 8 Pred Response  




Phase I:  2 - 5 wks 
1. Vincristine 1.5 mg/ m2 iv weekly x 4  (Dose:      )(Day 8,-        Day15-    Day 22-   Day 29-          
2. Daunorubicin 30 mg/ m2 iv weekly x 2  (Dose:     )(Day 8-         Day15-            ) 
3. L'Asparaginase* 5,000 U/ m2/day IV every third day X 8 doses  (Dose-                   ) 
* Leunase to be started 12 hours after VCR. Doses can be rounded up to 10,000 or 5000 IU. 
(Day12-      Day15-         Day18-        Day21-        Day24-         Day27-     Day30-    Day 33-                                                
4. Prednisolone 60 mg/ m2 p/o divided in 3 doses x 3 weeks and then taper over 10 days 
5. Inj Methotrexate IT stat day 12           Date- 
 
1 week after completion of Phase I, BM and CSF to assess remission status         Date- 
 
Phase II: 6 - 9 wks 
1. Cyclophosphamide 1000 mg/ m2 iv Day 1 & Day 29  (Dose-           )(Day 1-          Day 29-        
2. AraC 75 mg/ m2 iv/sc daily x 4 days (Days 1 - 4) followed by 3 days rest.  (Dose-          ) 
    Repeat x Total 4 cycles of Ara-C 
1st cycle : Date from              to                          3. Intrathecal MTX 
2nd cycle :Date from              to                          Dates: 2nd week- 
3rd cycle : Date from              to  
4th cycle : Date from              to                                      4th week- 
3. Intrathecal Methotrexate weekly x 2                 
4. 6-Mecapto-purine- 60 mg/m2, PO for 28 days  evening, fasting without milk.  
               Dose-                                  Date from-             to-       
                                                                                              
    2 WEEKS  REST 
PREINDUCTION 
INDUCTION 





12 - 20 wks  -Medium Dose Methotrexate-(See Protocol) 
1. MP: 6-Mercaptopurine- 25 mg/m2/d, PO, day: 1 – 56,   Dose- 
            in the evening on a fasting stomach without milk.  
2. MD MTX: Medium-dose methotrexate- 2,000 mg/m2/d, PI, over 24 h,  
             q 14 days (x 4) on day: 8, 22, 36, 50.  
           • 1/10 of the total dose (200 mg/m2) should be administered PI over 30      
              minutes as a loading dose.  
           • 9/10 of the total dose (1,800 mg/m2) is to be given PI over 23.5 h.  
3. LCV-Rescue-15 mg/m2 i.v. x 3 at h: +42, +48, +54 
4. MTX IT: Intrathecal methotrexate 1 h after the start of MTX infusion. 
             a. <1yr             6 mg    b. 1 - 2yr 8 mg    
  c. 2 - 3yr        10 mg    d. >3yr           12 mg 
 
                                     TWO WEEKS REST 
 
 
Phase I: 23 - 27 wks 
1. Vincristine 1.5 mg/ m2 iv weekly x 4    (Dose:      )(Day 8,-        Day 15-          Day 22-        Day 29-       
2. Adriamycin 30 mg/ m2 iv over 1 hour , weekly x 4 (Dose:      )(Day 8,-     Day 15-     Day 22-   Day29      
3. L'Asparaginase* 10,000 U/ m2 /dose iv/im/sc given 10,000 U x 4 doses 
   * Leunase to be started 12 hours after VCR. Doses can be rounded up to 10,000 or 5000 IU. 
        (Dose:                     )(Day 9,-        Day 12-            Day 16-           Day 19-      ) 
4. Dexamethasone 10 mg/ m2 p/o daily in 3 divided doses x 4 weeks and then taper over 10 days..  
 
Phase II: 28 - 30 wks 
1. Cyclophosphamide 1000 mg/ m2 iv Day 1  (Dose-           )(Date-         ) 
2. AraC 75 mg/ m2 iv/sc daily x 4 days (Day 1 - 4) followed by 3 days  rest.  
    Repeat x Total 2 cycles of Ara-C                (Dose-          ) 
1st cycle : Date from              to          
2nd cycle :Date from              to 
3. 6 TG- 60 mg/m2  PO, 
4. Inj MTx IT stat day 1 and day 8(Dose:      )(Day 1-        Day 8 -           ) 
 
TWO WEEKS REST 
 
 
33 - 137 wks           Date of starting:                              Date of completion: 
1. 6-Mercaptopurine* 50 mg/ m2 p/o daily x 2 years                              (Dose-        ) 
2. Methotrexate* 20 mg/ m2 p/o once a week on Sunday x 2 years       (Dose-        ) 
3. Inj. Methotrexate IT every monthly x 4 doses from 2nd month 
            Dose-                              2nd month-                             4th month- 
                                                    3rd month-                             5th month- 
   * in the evening on a fasting stomach without milk. Co-trimoxazole to be taken on Wed & Thu 
Ref erence:   ALL IC BFM 2002  
                                                                                      
 






                                          Appendix 4: Standard risk  
                         Non Methotrexate/No radiation based study protocol 
 
 
 Age > 1 yr, < 6 yrs  
 WBC < 20,000/cmm 
 Prednisolone good response 
 Pre B, CALLA immunophenotype (no T immunophenotype, no aberrant markers) 
 No translocation t(9;22) or t(4;11) 




1. Dexamethasone 6 mg/ m
2 
iv Days 1 & 2 
2. Prednisolone 60 mg/ m
2
 p/o daily Days 3 - 7 




Phase I:  2 - 5 wks 
 
1. Vincristine 1.5 mg/ m
2 
iv weekly x 4 (Day 8,15,22,29) 
2. Daunorubicin 30 mg/ m
2 
iv weekly x 2 (Day 8,15) 
3. L'Asparaginase 5,000 U/ m
2
/day IV every third day X 8 doses (days12,15,18,21,24,27,30,33) 
    ( minimum number of doses=8) 
4. Prednisolone 60 mg/ m
2 
p/o daily x 3 weeks and then taper over 10 days 
5. Inj Methotrexate IT stat day 15 
 
1 week after completion of Phase I, BM and CSF to assess remission status 
 
Phase II: 6 - 9 wks 
 
1. Cyclophosphamide 1000 mg/ m
2
 iv Day 1 & Day 29 
2. AraC 75 mg/ m
2 
iv/sc daily x 4 days (Days 1 - 4) followed by 3 days rest.  
    Repeat x Total 4 cycles of Ara-C 
3. Intrathecal Methotrexate weekly x 4   
 a. <1yr             6 mg    b. 1 - 2yr 8 mg   
   
 c. 2 - 3yr        10 mg    d. >3yr           12 mg 
 
   NO CRANIAL PROPHYLAXIS 







12 - 20 wks 
 
1. 6-Mercaptopurine 50 mg/ m
2
 p/o daily x 8 weeks 
2. Methotrexate 20 mg/ m
2
 p/o once a week x 8 weeks 
3. Inj MTx IT at day 28 – single dose 
   




Phase I: 23 - 27 wks 
 
1. Vincristine 1.5 mg/ m
2
 iv weekly x 4 
2. Adriamycin 30 mg/ m
2
 iv weekly x 4 
3. L'Asparaginase 10,000 U/ m
2 
/dose iv/im/sc given 10,000 U on days 1, 4, 7 & 11 
4. Dexamethasone 10 mg/ m
2 
p/o daily x 4 weeks and then taper over 10 days 
5. Inj MTx IT stat day 1 and day 18 
 
Phase II: 28 - 30 wks 
 
1. Cyclophosphamide 1000 mg/ m
2 
iv Day 1 
2. Ara C 75 mg/ m
2
 iv/sc daily x 4 days (Day 1 - 4) followed by 3 days rest.  
    Repeat x Total 2 cycles of Ara-C 
 




33 - 137 wks 
 
1. 6-Mercaptopurine 50 mg/ m
2 
p/o daily x 2 years (2 1/2 years for boys) 
2. Methotrexate 20 mg/ m
2
 p/o once a week x 2 years (2 1/2 years for boys) 
3. Inj Vincristine 1.4 mg/m
2
 once a month x 2 years (2 1/2 years for boys) 
4, Tab Dexa 6 mg/m
2
 daily for 5 days once a month x 2 years(2 1/2 years for boys) 







Hospital No NAME AGE SEX YearDate of Diagnosis Liversize Spleensize CNS CNSStagePleural EffusionTestis WBC BM BlastIPT Status IPTMRD At diagnosis RTPCR BCR_ABL TEL_AML MLL_AF4 E2A / PBX Cytogenetic CTG RiskRisk group Status at Starting TxTreatment Taken Protocols Induction start dateRelapse Date of RelapseDate of deathcause of death
118086F Sadab Khan 15 1 2012 1-8-2012 2 2 2 1 2 2 23.7 95 1 1 2 1 2 2 2 2 Not available 4 1 1 1 5 1-21-2012 2 3-2-2012 2
200892F Hemanth 15 1 2012 5-23-2012 0 0 2 1 2 2 2.3 84 1 1 2 1 2 2 2 2
46,XY,+5,dic(
7;9)(p11- 3 1 1 1 5 5-23-2012 2 6-18-2012 2
132370F Nayana C P 16 2 2012 2-7-2012 0 0 2 1 2 3 8.9 96 1 1 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 2-15-2012 2 5
224274F Dega Sruthi 16 2 2012 6-11-2012 0 0 1 3 2 3 23.1 92 1 1 2 1 2 2 2 2
44~47,XX,t(7;
20)(q36;q12), 3 1 1 1 5 6-18-2012 2 5
127701F
Onhattupoyil 
Anvarsadath 17 1 2012 2-3-2012 3 5 2 1 2 2 3.3 29 1 1 2 1 2 2 2 2
46,XY,t(1;9)(p
31 or p32;p13 1 1 1 1 5 2-10-2012 2 5
159512F Nethaji 17 1 2012 3-21-2012 2 3 2 1 2 2 4.8 98 1 1 2 1 2 1 2 2
86~92,XXYY,-
1,- 5 1 1 1 5 3-28-2012 2 5
108137F Karthika K 18 2 2012 1-6-2012 0 0 2 1 2 3 9.8 21 1 1 2 1 2 2 2 2
48,XX,+X,+8[
18]/48,idem,t( 3 1 1 1 5 1-13-2012 2 5
133550F Lenin S 18 1 2012 3-5-2012 0 5 2 1 2 2 17.7 92 1 1 2 1 2 2 2 1
46,XY,der(19)
t(1;19)(q23;p1 2 1 1 1 5 3-5-2012 2 5
140271F Prosenjit Barua 18 1 2012 2-27-2012 0 0 2 1 2 2 2 85 1 3 2 2 2 2 2 2
46,XY,r(1)(p3
6.3q44),del(4) 3 1 1 1 5 2-29-2012 2 5
211660F Dhana Lakshmi A 18 2 2012 5-30-2012 3 0 1 3 2 3 103.1 90 1 1 2 1 2 2 2 2
THERE ARE 
NO 4 3 1 1 5 5-31-2012 2 5
227665F Harsha S K 20 1 2012 6-23-2012 0 3 2 1 2 2 6.4 100 1 1 2 1 2 2 2 2
46,XY,del(3)(q
22 or 5 1 1 1 5 6-30-2012 2 5
212165F Ramya G 23 2 2012 5-29-2012 0 0 2 1 2 3 1.2 98 1 1 2 1 2 2 2 2
46,XX,r(17)(p
13q25)[4]/46, 5 1 1 1 5 6-15-2012 1 10-29-2012 12-29-2012 2
148051F
Mohammed 
Mozaffar Hossain 24 1 2012 3-21-2012 0 0 2 1 2 2 9.5 82 1 3 2 2 2 2 2 2 46,XY[19] 5 1 1 1 5 3-28-2012 1 7-20-2012 8-17-2012 1
227813F Karthikeyan D 24 1 2012 6-30-2012 0 0 2 1 2 2 6.2 0 1 1 2 1 2 2 2 1
46,XY,del(6)(p
11.2),der(9)t(6 2 1 1 1 5 7-10-2012 1 12-10-2013 2-22-2014 1
193051F Sampa Baidya 25 2 2012 5-12-2012 0 0 2 1 2 3 2.9 7 1 1 2 1 2 2 2 2 46,XX[10] 5 1 1 1 5 5-23-2012 1 11-14-2012 12-13-2012 1
226809F Vatturi Subbarao 25 1 2012 6-16-2012 0 0 2 1 2 2 3 94 1 1 2 1 1 2 2 2
46~47,X,-Y,-
9,t(9;22)(q34; 3 3 1 1 5 6-25-2012 2 9-3-2012 1
211604F Gowtham Kumar B 26 1 2012 5-31-2012 0 0 2 1 2 2 13.8 98 1 1 2 1 2 2 2 2
47,XY,+8[19]/
46,XY[1cell] 1 1 1 1 5 6-9-2012 1 10-5-2012 2-25-2013 1
211928F Rajabharathi 31 1 2012 6-2-2012 0 0 1 3 1 2 531.4 87 1 3 2 1 2 2 2 2
45~47,XY,del(
6)(q21q24),- 3 3 1 1 5 6-9-2012 2 5
112643F Subbiah M 34 1 2012 1-18-2012 3 4 1 3 2 2 5.4 96 1 1 2 1 2 2 2 2 46,XY[12] 5 1 1 1 5 1-26-2012 2 9-23-2012 2
130839F
Tirupati Ashok 
Kumar 35 1 2012 2-9-2012 0 0 2 1 2 2 96.8 88 1 1 2 1 2 2 2 2
46,XY,del(9)(p
21)[13]/46,XY[ 5 3 1 1 5 2-18-2012 1 6-25-2013 6-25-2013 1
193196F Senthil Kumar S 36 1 2012 4-30-2012 0 6 1 3 2 2 27.1 80 1 1 2 1 2 2 2 2
46,XY,del(9)(p
21 or 5 1 1 1 5 5-9-2012 1 9-28-2012 10-28-2012 1
133359F Basi K K 45 1 2012 2-13-2012 0 0 2 1 2 2 5.8 46 1 1 2 1 2 2 2 2
47,XY,der(9)?i
ns(9;?)(p13;?) 3 1 1 1 5 2-22-2012 2 5
038021F Rakesh Kumar 15 1 2011 9-22-2011 0 0 2 1 2 2 72 30 1 3 2 2 2 2 2 2
42~45,XY,-
Y,der(9)t(9;?1 3 1 1 1 5 9-22-2011 2 5
073314F Twinkle Kumari 15 2 2011 11-14-2011 2 2 2 1 2 3 2.6 100 1 1 2 1 2 1 2 2
45,X,-X,-
16,+mar?der( 3 1 1 1 5 11-14-2011 2 5
853124D Prabhu M 15 1 2011 1-6-2011 2 0 1 3 2 2 0.8 93 1 1 2 1 2 2 2 2
45,XY,dic(9;1
2)(p11-12;p11- 1 1 1 1 5 1-6-2011 2 5
870875D Rishabh Singh 15 1 2011 2-9-2011 1 0 2 1 2 2 1.2 92 1 1 2 1 2 2 2 2 46,XY[19] 5 1 1 1 5 2-9-2011 2 5
877055D Neeraj Kumar 15 1 2011 2-4-2011 2 0 2 1 2 2 1.2 90 1 3 2 2 2 2 2 2 46,XY[20] 5 1 1 1 5 2-14-2011 2 5
928509D Tanu Dey 15 2 2011 4-27-2011 0 0 2 1 2 3 4.1 20 1 1 2 1 2 2 2 2
60~62,XXX,+
1,+2,+4,+5,+6 1 1 1 1 5 5-4-2011 1 10-11-2011 11-11-2011 1
003214F Stephen G 16 1 2011 8-19-2011 4 10 2 1 2 2 11 52 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 8-19-2011 2 5
916739D Baskar B 16 1 2011 4-18-2011 0 0 2 1 2 2 2.4 98 1 1 2 1 2 2 2 2
THIS IS AN 
INCOMPLET 4 1 1 1 5 4-19-2011 2 5-15-2011 2
935653D Divaya Bharathi L 16 2 2011 6-4-2011 4 0 2 1 2 3 13.3 95 1 1 2 1 1 2 2 2
46,XX,del(4)(q
28),t(9;22)(q3 3 3 1 1 5 6-13-2011 1 10-21-2011 11-21-2011 1
975353D Abdul Ajeez 16 1 2011 7-12-2011 5 2 2 1 2 2 2 96 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 7-21-2011 2 5
006024F Wazda Tabasshum 17 2 2011 9-7-2011 3 0 1 3 2 3 37.8 85.5 1 3 2 2 2 2 2 2
46,XX,ins(1;?)
(p22;?),t(14;1 3 1 1 1 5 9-10-2011 2 5
007357F Archana Kumari 17 2 2011 8-13-2011 5 3 2 1 2 3 4.6 86 1 1 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 9-12-2011 2 5
916312D Ankaiah Anthony V 17 1 2011 4-2-2011 0 0 1 3 2 2 15.2 82 1 2 2 1 2 2 2 2
55~56,XY,+X,
+der(1)del(1)( 1 1 1 1 5 4-2-2011 1 7-20-2012 2-11-2013 1
939190D Lavanya Priya M 17 2 2011 5-12-2011 0 0 2 1 2 3 63.3 79 1 3 2 1 2 2 2 2
46,XX,t(7;12)(
q36;q13)[7]/4 5 3 1 1 5 5-13-2011 2 5
948459D Asasur Sardar 17 1 2011 5-23-2011 0 4 2 1 2 2 89.8 98 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 6-1-2011 2 5
994380D Saheb Hossain 17 1 2011 7-27-2011 3 4 2 1 2 2 4.8 93 1 1 2 1 2 2 2 2
45,XY,del(4)(q
31),dic(9;12)( 1 1 1 1 5 7-28-2011 2 5
085328F Suhail K 18 1 2011 12-3-2011 6 8 2 1 2 2 1.4 100 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 12-15-2011 2 5
880586D Allen 18 1 2011 2-11-2011 4 5 1 3 2 2 183.4 97 1 3 2 2 2 2 2 2
46,XY,t(11;14
)(p13;q11)[18] 5 3 1 1 5 2-19-2011 1 12-31-2011 1-30-2012 1
966711D Shaik Sharuddin 18 1 2011 6-24-2011 5 9 2 1 2 2 185.4 96 1 1 2 1 2 2 2 2
PRELIM: A 
PARTIAL 5 3 1 1 5 7-1-2011 2 5
982305D Ramaswamy S 18 1 2011 7-12-2011 4 0 1 3 2 2 12.7 61 1 3 2 2 2 2 2 2
89~93,XXYY,
del(6)(q13),del 3 1 1 1 5 7-21-2011 2 5
985265D Gopal Mandal 18 1 2011 8-20-2011 4 6 2 1 2 2 173.3 85 1 1 2 1 2 2 2 2 Not Done 4 3 1 1 5 8-22-2011 2 5
046087F Harikrishnan V 19 1 2011 10-11-2011 2 3 2 1 2 2 424.5 80 1 3 2 2 2 2 2 2 46,XY[20] 5 3 1 1 5 10-13-2011 1 3-20-2012 4-20-2012 1
868827D Khairul Mandal 19 1 2011 2-4-2011 0 3 2 1 2 2 9.7 54 1 1 2 1 1 2 2 2 46,XY[20] 5 3 1 1 5 2-4-2011 2 5
959678D Thendral 19 2 2011 6-18-2011 0 0 2 1 2 3 41.6 85 1 1 2 1 2 2 2 2
51~56,XX,+X,
+ins(4;?)(q?2 1 3 1 1 5 6-27-2011 2 5
653058B Geetha 23 2 2011 2-18-2011 2 0 2 1 2 3 9.5 45 1 1 2 1 1 2 2 2
46,XX,t(9;22)(
q34;q11.2)[13 3 3 1 1 5 3-25-2011 1 9-24-2012 10-24-2012 1
937829D Sarwath Nashrin 23 2 2011 5-24-2011 2 0 2 1 2 3 3.9 70 1 1 2 1 2 2 2 2 Not Done 4 1 1 1 5 6-6-2011 2 5
969645D Jiten Majhi 24 1 2011 7-22-2011 4 2 2 1 2 2 2.7 90 1 3 2 2 2 2 2 2 46,XY[20] 5 1 1 1 5 7-25-2011 1 6-25-2012 7-29-2012 1
055934F Prashanth Patil 26 1 2011 10-19-2011 2 2 2 1 2 2 3.8 92 1 3 2 2 2 2 2 2
46,XY,?add(1
0)(p15)[3]/46, 5 1 1 1 5 10-27-2011 2 5
105524F Kumar S 26 1 2011 12-31-2011 0 0 2 1 2 2 45 100 1 1 2 1 2 2 2 2 Not Done 4 1 1 1 5 1-3-2012 2 2-18-2012 2
842302D Piyrishaw 28 1 2011 1-5-2011 6 15 2 1 1 2 67.3 76 1 3 2 1 2 2 2 2 46,XY[6] 5 3 1 1 5 1-20-2011 2 5
977460D Sakeer V K 28 1 2011 7-2-2011 0 0 2 1 2 2 2.5 70 1 1 2 2 2 2 2 2 46,XY[20] 5 1 1 1 5 7-14-2011 2 5
983639D Riswan Babu 28 1 2011 7-19-2011 0 0 2 1 2 2 16.5 93 1 3 2 2 2 2 2 2 46,XY[20] 5 1 1 1 5 7-29-2011 2 5
064391B
Subash Chandra 
Bose 29 1 2011 2-3-2011 4 0 2 1 2 2 1.9 35 1 3 2 2 2 2 2 2
46,XY,del(11)(
q21),del(12)(p 5 1 1 1 5 2-15-2011 2 5
054166F Kandaswamy A 31 1 2011 10-20-2011 0 0 2 1 2 2 6.9 86 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 10-20-2011 2 11-2-2011 2
984016D Govindaraj 33 1 2011 7-28-2011 4 0 2 1 2 2 331.6 91 1 3 2 2 2 2 2 2 46,XY[7] 5 3 1 1 5 7-28-2011 2 5
902811D
Shailesh Sudhanshu 
Topnu 35 1 2011 3-15-2011 4 5 2 1 2 2 1.7 5 1 1 2 1 1 2 2 2 46,XY[20] 5 3 1 1 5 3-21-2011 2 5
967339D Ramesh T 35 1 2011 6-18-2011 4 0 1 3 2 2 56.4 85 1 3 2 2 2 2 2 2 Not Done 4 3 1 1 5 6-25-2011 2 5
032661F Papathi P 36 2 2011 9-27-2011 3 0 2 1 2 3 2.7 32 1 1 2 1 2 2 2 2 Not Done 4 1 1 1 5 10-6-2011 2 5
009141F Suman Devi 37 2 2011 8-20-2011 0 0 2 1 2 3 30 98 1 3 2 2 2 2 2 2
47,XX,+22[2]/
46,XX[18] 1 1 1 1 5 8-25-2011 2 5
028511F Sabareeswaran N 37 1 2011 9-17-2011 2 0 2 1 2 2 0.7 72 1 1 2 1 2 2 2 2
51~52,XY,+3,
dic(7;9)(p11- 1 1 1 1 5 9-18-2011 1 3-22-2012 9-7-2012 1
010989F Sim Sumith Mathew 38 1 2011 12-2-2011 0 0 1 3 2 2 10.5 0 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 12-12-2011 2 5
875161D Dilshad S K 38 2 2011 2-10-2011 0 0 2 1 2 3 9.9 95 1 1 2 1 2 2 2 2
46~47,XX,-
X,del(X)(q2?6 3 3 1 1 5 2-20-2011 2 4-30-2011 2
484022A Mary Bernadath 41 2 2011 12-27-2011 0 0 2 1 2 3 2.2 85 1 1 2 1 2 2 2 2
62~67,XXX,+
1,+2,-3,+4,- 3 1 1 1 5 1-6-2012 2 2-10-2012 2
103646F Uma Maheswari 42 2 2011 12-28-2011 0 5 2 1 2 2 234 85 1 1 2 1 1 2 2 2
44~46,XX,-
5,add(5)(q35), 3 3 1 1 5 1-7-2012 2 5-13-2012 1
920204D Boopalan A 43 1 2011 4-9-2011 0 0 2 1 2 2 59.2 90 1 3 2 2 2 2 2 2
46,XY,del(11)(
q14q21),- 3 3 1 1 5 4-9-2011 2 5-1-2011 2
889589D
Kisan Gopala 
Sawant 45 1 2011 2-24-2011 0 0 2 1 2 2 6.2 85 1 1 2 1 2 2 2 1
46,XY,der(19)
t(1;19)(q23;p1 2 1 1 1 5 3-5-2011 2 5
007966F Gangadaran S 48 1 2011 8-19-2011 0 0 2 1 2 2 7.6 61 1 3 2 1 2 2 2 2 46,XY[20] 5 3 1 1 5 8-20-2011 2 5
870742D Anbuselvi 49 2 2011 1-25-2011 0 2 2 1 2 3 47.1 90 1 1 2 1 1 2 2 2
45,XX,dic(9;1
2)(p11- 3 3 1 1 5 1-27-2011 2 5
901281C
Venkata 
Satyanarayana V 52 1 2011 5-27-2011 2 0 1 3 2 2 4.5 65 1 1 2 1 2 2 2 2
67~74,XXY,+
Y,+1,+1,-3,- 3 1 1 1 5 6-6-2011 2 2-7-2012 2
911125D Dharmaraj C 55 1 2011 3-29-2011 0 0 2 1 2 2 1.6 90 1 1 2 1 2 2 2 2
55~56,XY,+X,
der(3)?inv(3)( 1 1 1 1 5 4-15-2011 2 5
043658B Mahaveer Kumar J 56 1 2011 6-20-2011 0 0 2 1 2 2 284.6 90 1 1 2 1 1 2 2 2
44~47,XY,add
(1)(p36) 3 3 1 1 5 6-20-2011 1 9-4-2012 9-16-2012 1
674005D Daniel S 15 1 2010 4-10-2010 0 0 2 1 2 2 7 60 1 3 2 2 2 2 2 2
46,XY,+6,add(
7)(q36) or 3 1 1 1 5 4-13-2010 2 5
653650D
Wanshaphrang 
Kharumnuid 16 1 2010 3-15-2010 3 6 2 1 1 2 1 58 1 2 2 2 2 2 2 2 46,XY[20] 5 1 1 1 5 3-15-2010 1 5-14-2010 5-27-2010 1
660814D Raghvender Sahdev 16 1 2010 3-20-2010 0 3 2 1 2 2 40 89 1 3 2 2 2 2 2 2
46,XY,del(7)(q
31),der(17)?in 5 1 1 1 5 3-20-2010 2 5
669532D Shiv Kumar Jha 16 1 2010 4-3-2010 0 0 2 1 1 2 11 46 1 3 2 2 2 2 2 2 Not Done 4 1 1 1 5 4-13-2010 1 3-29-2011 5-26-2011 1
749393D Aishwarya Jha 16 2 2010 8-3-2010 4 0 2 1 2 3 14.7 80 1 3 2 2 2 2 2 2 46,XX[20] 5 3 1 1 5 8-12-2010 2 5
804498D Sheik Karam 16 1 2010 10-29-2010 0 4 2 1 2 2 1177 84 1 3 2 2 2 2 2 2
88~93,XXYY,-
4,i(7)(q10),+2 5 1 1 1 5 10-31-2010 1 9-13-2011 6-18-2012 1
824119D Deepti Barman 16 2 2010 11-10-2010 0 0 2 1 2 3 25.4 94.5 1 1 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 11-18-2010 2 12-22-2010 2
619627D Kiranraj R 17 1 2010 1-15-2010 3 2 2 1 2 2 3.2 78 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 1-23-2010 1 8-9-2011 1-22-2012 1
686590D Pandivel S. 17 1 2010 5-6-2010 6 6 2 1 2 2 12 92 1 3 2 2 2 2 2 2 46,XY[20] 5 1 1 1 5 5-13-2010 2 5
696967D Rishfan Nazeer 17 1 2010 5-13-2010 2 0 2 1 2 2 0.8 96 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 5-16-2010 2 5
753306D Balaji K 17 1 2010 8-7-2010 4 2 1 3 2 2 92.4 91 1 1 2 1 2 2 2 2
"45,XY,del(9)(
p21),add(20)( 5 1 1 1 5 8-14-2010 2 5
834821D
Mohammed Ajmal K 
V 17 1 2010 11-26-2010 2 0 2 1 2 2 9.1 38 1 1 2 1 2 2 2 2
59~65,XY,+X,
+Y,+1,+2,+4,+ 1 1 1 1 5 11-29-2010 2 5
630085D Revathi A. 18 2 2010 2-6-2010 2 1 2 1 2 3 9.1 24 1 1 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 3-2-2010 1 10-28-2011 4-16-2012 1
702166D Libin Louis 18 1 2010 5-21-2010 3 3 2 1 2 2 47.6 40 1 1 2 1 2 2 2 2
46,XY,t(5;11)(
q31;q2?5),i(8) 3 3 1 1 5 5-28-2010 2 7-28-2010 1
716927D Sajed Khan 18 1 2010 6-26-2010 0 0 2 1 2 2 3 88 2 5 2 2 2 2 2 2
"46,XY,del(5)(
q13q33),i(8)(q 5 1 1 1 5 7-13-2010 2 5
775888D Dilip Kumar 18 1 2010 9-6-2010 0 0 2 1 2 2 7 4 1 3 2 2 2 2 2 2 Not Done 4 3 1 1 5 9-18-2010 1 3-1-2011 4-29-2011 1
804282D Kumaresan 18 1 2010 10-28-2010 3 3 2 1 2 2 25 0 1 3 2 2 2 2 2 2 46,XY[20] 5 1 1 1 5 10-28-2010 2 5
830320D Vineet Jose 18 1 2010 11-18-2010 0 0 2 1 2 2 12 77 1 3 2 2 2 2 2 2 46,XY[20] 5 1 1 1 5 11-25-2010 2 11-30-2010 2
853388D Ethiraj A 19 1 2010 12-30-2010 3 0 2 1 2 2 28 93 1 3 2 2 2 2 2 2
46,XY,del(17)(
q22)[10]/46,X 5 1 1 1 5 12-30-2010 2 5
623429D Mushabheer 20 1 2010 1-22-2010 0 0 2 1 2 2 0.7 98 1 1 2 1 2 2 2 2
46,XY,i(9)(q10
)[14]/46,XY[6] 5 1 1 1 5 1-23-2010 2 5
848206D Gyendey Zam 20 2 2010 12-17-2010 0 0 1 3 2 3 198 90 1 3 2 2 2 2 2 2
46~47,XX,+4,-
7,add(14)(q32 3 3 1 1 5 12-17-2010 2 2-11-2011 1
703362D Aswini M P 21 2 2010 5-22-2010 0 0 1 3 2 3 182 98 1 1 2 1 2 2 2 2 47,XX,+8[20] 5 1 1 1 5 5-30-2010 2 5
627089D
Mohammed Zafar 
Ekbal 22 1 2010 1-29-2010 0 0 2 1 2 2 7.2 44 1 1 2 1 2 2 2 2
47,X,+der(X),-
Y,+del(4)(q22 3 1 1 1 5 1-29-2010 1 7-17-2010 11-7-2010 1
661054D Senthil Kumar R 23 1 2010 3-24-2010 6 0 2 1 1 2 90 75 1 3 2 2 2 2 2 2 46,XY[20] 5 1 1 1 5 3-31-2010 2 5
691558D Tania Ahmed 23 2 2010 5-13-2010 2 0 2 1 2 3 8.2 40 1 1 2 1 2 2 2 2
46,XX,dup(1)(
q21q22)[2]/46 5 1 1 1 5 5-16-2010 1 6-1-2013 7-3-2013 1
797650D Vinu T Thottumkal 23 1 2010 10-1-2010 0 2 2 1 2 2 9 80 1 1 2 2 2 2 2 2
45,X,-
Y[7]/45,idem,d 5 1 1 1 5 10-22-2010 2 5
815053D Savithri Devi 25 2 2010 11-17-2010 3 0 2 1 2 3 71 82 1 1 2 1 2 2 2 2 46,XX[20] 5 3 1 1 5 11-30-2010 2 4-4-2011 1
837278D Arul Shanthi S 25 2 2010 12-11-2010 0 0 2 1 2 3 26.9 74 1 1 2 1 2 2 2 2
47,XX,der(6)t(
1;6)(q2?1?3;q 1 1 1 1 5 12-24-2010 2 1-12-2011 2
827333D Lakshmi E 26 2 2010 11-15-2010 4 0 2 1 2 3 9.4 98 1 1 2 1 2 2 2 2
46,XX,t(3;6)(q
29;q14),del(9) 5 1 1 1 5 11-19-2010 1 7-2-2011 9-19-2011 1
651443D Kuber Sampath P 27 1 2010 3-12-2010 0 1 2 1 2 2 7.2 74 1 1 2 1 2 2 2 2
46,XY,der(2)?i
AMP21[3]/46, 3 1 1 1 5 3-14-2010 2 5
772434D Akila Kailasam 29 2 2010 9-17-2010 0 4 2 1 2 3 2.2 85 1 2 2 1 2 2 1 2
"46,XX,t(4;11)
(q21;q23)[6]/4 3 3 1 1 5 10-18-2010 1 3-4-2011 4-10-2011 1
680166D Nandita Roy 30 2 2010 4-23-2010 0 0 2 1 2 3 146 65 1 3 2 2 2 2 2 2 46,XX[20] 5 1 1 1 5 4-30-2010 1 5-14-2011 6-16-2011 1
753331D Vijayalakshmi G 32 2 2010 8-9-2010 0 0 2 1 2 3 48 92 1 3 2 2 2 2 2 2 46,XX[20] 5 1 1 1 5 8-17-2010 2 5
749160D Sahidul Hoque 39 1 2010 8-9-2010 8 8 2 1 1 2 322 60 1 3 2 2 2 2 2 2
46,XY,add(20)
(p13)[16]/46,X 5 1 1 1 5 8-14-2010 2 5
742455D Tapan Karmakar 40 1 2010 7-27-2010 5 0 1 3 2 2 20.7 76 1 1 2 1 2 2 2 2 46,XY[20] 5 3 1 1 5 7-30-2010 2 5
748390D
Mizanur Rahman 
MD 42 1 2010 8-7-2010 0 0 2 1 2 2 2.5 75 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 8-21-2010 2 5
785376D Kalaiarasi R. 42 2 2010 9-16-2010 0 0 2 1 2 3 4.2 42 1 1 2 1 1 2 2 2
44~48,XX,-
X,+5,+8,t(9;22 3 3 1 1 5 9-27-2010 2 5
037484C Usha Rani 50 2 2010 9-18-2010 0 0 2 1 2 3 1.8 13 1 1 2 1 1 2 2 2
63~64,XXX,+
X,+1,-2,-3,-4,- 3 3 1 1 5 9-27-2010 1 1-31-2011 7-7-2011 1
613352D Gowri. N 50 2 2010 2-17-2010 0 0 2 1 2 3 15.9 75 1 1 2 1 2 2 2 2 46,XX[16] 5 1 1 1 5 2-28-2010 1 10-15-2010 12-9-2010 1
711143D Johnson T 50 1 2010 6-10-2010 0 0 2 1 2 2 17 0 1 3 2 2 2 2 2 2
Not To 
Process 4 1 1 1 5 6-15-2010 2 5
806793D Iva Saha 50 2 2010 10-20-2010 1 3 2 1 2 3 19.4 87 1 1 2 1 2 2 2 2
45,XX,der(20)
t(18;20)(q11.2 5 1 1 1 5 10-23-2010 1 3-17-2011 4-25-2011 1
639300D
Amashraful Islam 
Siddique 51 1 2010 2-20-2010 1 0 1 3 2 2 4.4 0 1 1 2 1 2 2 2 2 46,XY[4] 5 1 1 1 5 3-24-2010 1 9-29-2012 11-2-2012 1
701388D Sundaram Sankar 55 1 2010 5-19-2010 0 0 2 1 2 2 1.3 90 1 1 2 1 2 2 2 2 46,XY[9] 5 1 1 1 5 5-29-2010 2 5
653644D Radha 60 2 2010 3-22-2010 0 0 2 1 2 3 1.1 45 1 1 2 2 2 2 2 2 46,XX[20] 5 1 1 1 5 3-26-2010 2 5
694174D
Sivakami 
Chenniappan 62 2 2010 5-8-2010 0 0 2 1 2 3 6.5 94 1 1 2 1 2 2 2 2
47~48,XX,-X,-
10,del(13)(q1 1 1 1 1 5 5-10-2010 2 5
448339D Sheik Hossain Ali 15 1 2009 4-22-2009 0 0 2 1 2 2 51.3 91 1 1 2 1 2 2 2 2
46,XY,t(5;5)(q
13;q32?3)[18] 5 1 1 1 5 5-7-2009 1 6-25-2010 7-21-2010 1
384699D Ananu Adhikari 16 1 2009 1-6-2009 4 5 2 1 2 2 4.9 28 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 3-14-2009 1 6-19-2009 7-23-2009 1
460607D Sathish K G 16 1 2009 5-18-2009 4 8 2 1 2 2 6.3 95 1 1 2 1 2 2 2 2
45,XY,del(6)(q
21q24),del(9)( 3 1 1 1 5 5-25-2009 2 5
494191D
Beeda Manipal 
Reddy 16 1 2009 7-11-2009 2 2 1 3 1 2 392 90 1 3 2 2 2 2 2 2
46,XY,add(19)
(q13.4),?del(1 5 3 1 1 5 7-22-2009 1 11-3-2009 3-4-2010 1
508176D Banumathi 16 2 2009 7-28-2009 2 0 1 3 2 3 10 90 1 1 2 1 2 2 2 2
42~45,XX,add
(4)(p16),add(5 3 1 1 1 5 8-8-2009 2 5
508738D Geetha 16 2 2009 7-29-2009 0 0 2 1 2 3 414 83 1 1 2 1 2 2 2 2
46,XX,t(17;19
)(q22;p13 or 3 1 1 1 5 8-5-2009 1 12-22-2009 4-15-2010 1
533838D Pawan Kumar 16 1 2009 9-4-2009 4 1 2 1 2 2 11.3 87 1 1 2 1 2 2 2 2
50~55,XY,+X,
trp(1)(q21q32) 1 1 1 1 5 9-19-2009 2 5
395023D Najumudeen K. 17 1 2009 1-22-2009 0 3 1 3 2 2 154 76 1 3 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 1-29-2009 2 5
540551D Prasad C 17 1 2009 9-12-2009 3 1 1 3 2 2 94.4 94.5 1 3 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 9-21-2009 2 5
447792D Mincy Domnic 20 2 2009 4-22-2009 2 3 2 1 2 3 6.8 22 1 1 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 4-24-2009 2 5
486479D Phanindra Sai I 21 1 2009 6-23-2009 1 3 2 1 2 2 16.1 86 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 7-2-2009 2 5
538592D
Nimitha Elizabeth 
Mathew 22 2 2009 9-10-2009 1 1 1 3 2 3 8.4 80 1 1 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 9-19-2009 2 5
591327D Rajakumari R 22 2 2009 12-2-2009 2 5 2 1 2 3 174.4 92 1 1 2 1 2 2 2 2
47,XX,+7[7]/4
9,idem,+9,+22 1 1 1 1 5 12-3-2009 1 10-12-2010 2-21-2011 1
570485D Pampi Ghosh 23 2 2009 10-26-2009 0 0 2 1 2 3 9 69 1 1 2 1 2 2 2 2 46,XX[12] 5 1 1 1 5 11-5-2009 2 5
594955D Arun P. John 23 1 2009 12-2-2009 0 0 2 1 2 2 158 70 1 2 2 2 2 2 2 2
45~46,XY,t(6;
11)(q14;p15),- 3 3 1 1 5 12-2-2009 2 5
382750D James Tamang 24 1 2009 1-6-2009 0 0 2 1 2 2 1 60 1 3 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 1-18-2009 1 3-18-2009 4-24-2010 1
530199D Kiruba Sankar 25 2 2009 8-31-2009 2 0 1 3 2 3 1.7 16 1 1 2 1 2 2 2 2
46,XY,?t(4;15;
11)(q21;q21;q 3 1 1 1 5 9-10-2009 2 5
424339D Celiya K P 26 2 2009 3-13-2009 0 0 2 1 1 3 8 40 1 3 2 2 2 2 2 2
Not To 
Process 4 1 1 1 5 3-19-2009 2 5
506511D Hameena Sulfiqer 26 2 2009 7-22-2009 1 1 1 3 2 3 13.9 0 1 1 2 1 2 2 2 2 Not Done 4 1 1 1 5 8-5-2009 2 5
555222D Nalira K. 26 2 2009 10-8-2009 2 2 2 1 2 3 4.9 3 1 1 2 1 2 2 2 2
46,XX,del(6)(q
15)[2]/46,XX[ 5 1 1 1 5 10-24-2009 2 5
391576D Hemagiri 28 1 2009 1-17-2009 0 0 2 1 2 2 1.9 12 1 1 2 1 2 2 2 2 46,XY[2] 5 1 1 1 5 1-28-2009 2 5
429142D Radha R 28 2 2009 3-24-2009 6 2 2 1 2 3 186 93 1 1 2 1 2 2 2 2
46,XX,del(6)(q
21q24),der(19 2 1 1 1 5 3-31-2009 2 5
475712D Bikash Rui Das 28 1 2009 6-8-2009 0 0 2 1 2 2 46 83 1 3 2 2 2 2 2 2
46,XX,der(3)?
add(3)(p25)[8] 5 1 1 1 5 6-18-2009 1 12-16-2011 1-23-2012 1
519119D Tapas Patra 32 1 2009 8-24-2009 3 3 2 1 2 2 11.9 21 1 1 2 1 1 2 2 2 46,XY[20] 5 3 1 1 5 8-24-2009 2 5
442618D Mallikarjuna A.J. 33 1 2009 4-11-2009 2 0 2 1 2 2 7.8 57 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 4-20-2009 2 5
490233D Sivakami R 36 2 2009 7-3-2009 0 0 1 3 2 3 29.5 58 1 1 2 1 1 2 2 2
46~47,XX,dic(
7;9)(p11- 3 3 1 1 5 7-12-2009 1 3-16-2011 4-6-2011 1
515816D Sanjeev Khare 36 1 2009 8-5-2009 0 0 2 1 2 2 5.4 76 1 1 2 1 2 2 2 2  46,XY[4] 5 1 1 1 5 8-17-2009 2 5
449067D Ashok Gnanaraj 37 1 2009 4-25-2009 2 6 1 3 2 2 37.2 87 1 1 2 1 1 2 2 2
46,XY,t(9;22)(
q34;q11.2)der 3 3 1 1 5 5-5-2009 2 5
563659D Sumathi S 38 2 2009 10-17-2009 0 7 2 1 2 3 26.4 98 1 1 2 1 1 2 2 2
46,XX,t(9;22)(
q34;q11.2)[17 3 3 1 1 5 11-9-2009 2 2-10-2010 2
426027D Indira P R 39 2 2009 3-18-2009 20 10 2 1 2 3 7.7 96 1 1 2 1 2 2 2 2 46,XX[19] 5 1 1 1 5 3-31-2009 2 5
488494D Dandapani A 39 1 2009 6-26-2009 2 3 2 1 2 2 116.9 98 1 1 2 1 1 2 2 2
53~57,XY,+X,
+2,+4,+6,del( 3 3 1 1 5 7-10-2009 1 10-19-2009 11-21-2009 1
450921D Amar Saduka 40 1 2009 4-28-2009 3 3 2 1 2 2 3.7 11 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 5-6-2009 2 5
518233D Vijaya Rani S. 40 2 2009 8-17-2009 3 6 2 1 2 3 147.1 75 1 1 2 1 1 2 2 2
THERE ARE 
NO 4 3 1 1 5 8-21-2009 1 1-12-2012 2-12-2012 1
390758D Jai Sankar M 42 1 2009 1-16-2009 2 5 2 1 2 2 0.9 35 1 1 2 1 1 2 2 2
46,XY,t(7;19)(
q32;q13.3)[20 5 3 1 1 5 1-24-2009 1 7-17-2012 5
555859D Kandhaswamy C 42 1 2009 10-6-2009 7 0 2 1 2 2 78 93 1 3 2 2 2 2 2 2 Not Done 4 1 1 1 5 10-14-2009 2 11-14-2009 2
577386D Ranganathan D G 42 1 2009 12-15-2009 1 5 2 1 2 2 2.9 81 1 1 2 1 2 2 2 2
67~73,XXY,+
Y,-2,-3,+5,- 3 1 1 1 5 12-22-2009 1 8-25-2010 10-24-2010 1
536888D Krishnammal. P 45 2 2009 9-9-2009 2 2 2 1 2 3 2 10 1 1 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 9-18-2009 1 9-22-2012 1-17-2013 1
435457D Arokiasamy M. 46 1 2009 4-2-2009 4 0 2 1 2 2 1 69 1 1 2 1 2 2 2 2
45,XY,dic(9;1
2)(p11-12;p11- 1 1 1 1 5 4-24-2009 2 5
550882D Santosh Rai 46 1 2009 9-30-2009 2 0 2 1 2 2 89.4 83 1 1 2 1 1 2 2 2
42~44,XY,-4,-
7,der(9)t(9;22) 3 3 1 1 5 10-12-2009 1 4-15-2012 9-9-2012 1
599045D Pandian P 47 1 2009 12-9-2009 0 0 2 1 2 2 6.9 95 1 1 2 1 1 2 2 2
45,XY,-
7,t(9;22)(q34; 3 3 1 1 5 12-17-2009 2 7-8-2010 2
436063D Rana Bahadur Tara 48 1 2009 4-3-2009 4 0 2 1 2 2 2 39 1 1 2 1 1 2 2 2 46,XY[20] 5 3 1 1 5 4-16-2009 2 5
382149D Somasundaram P 50 1 2009 1-2-2009 0 0 2 1 2 2 9.2 96 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 1-5-2009 2 5
535496D
Don Chanrika 
Divakar 51 1 2009 9-14-2009 1 0 2 1 2 2 4.2 62 1 1 2 1 2 2 2 2 46,XY[7] 5 1 1 1 5 9-25-2009 1 6-20-2011 7-20-2011 2
458219D Subramanian B 56 2 2009 5-9-2009 2 0 1 3 2 3 3.6 86 1 2 2 1 2 2 1 2 46,XY[20] 5 3 1 1 5 5-20-2009 2 5
465280D Balakrishnan 58 1 2009 5-23-2009 3 2 2 1 2 2 61 92 1 3 2 2 2 2 2 2
46,XY,?del(12
)(p12)[3]/46,X 5 3 1 1 5 5-30-2009 2 8-3-2009 1
390485D Kadeeja 60 2 2009 1-30-2009 0 3 2 1 2 3 62.4 80 1 1 2 1 2 2 2 2
46,XX,inv(9)(p
11q12)[20] 5 1 1 1 5 1-30-2009 1 5-21-2009 7-1-2009 1
543179D Palanisamy K 60 1 2009 9-22-2009 0 0 1 3 2 2 1.6 98 1 1 2 1 1 2 2 2 Not Done 4 3 1 1 5 9-29-2009 2 5
471752D Rajammal T 63 2 2009 6-4-2009 0 0 2 1 2 3 6.8 0 2 1 2 2 2 2 2 2 Not done 4 1 1 1 5 6-19-2009 2 5
267369D Mrinmoy Biswas 15 1 2008 7-3-2008 3 0 2 1 2 2 0.7 74 1 1 2 1 2 2 2 2
45,XY,dic(7;9)
(p11;p11)[5]/4 5 1 1 1 5 7-4-2008 2 5
274095D Annitha Esther Pal 15 2 2008 7-18-2008 0 0 2 1 2 3 12.26 93 1 1 2 1 2 2 2 1
46,XX,der(19)
t(1;19)(q23;p1 2 1 1 1 5 7-23-2008 1 12-30-2008 5-6-2009 1
214733D Vasanth 16 1 2008 4-3-2008 5 0 2 1 2 2 0.4 64 1 1 2 1 1 2 2 2
46,XY,t(9;22)(
q34;q11.2)[4]/ 3 3 1 1 5 4-14-2008 2 5
232562D Katam Ragaveni 16 2 2008 5-14-2008 3 2 2 1 2 3 16.1 24 1 3 2 1 2 2 2 2 46,XX[12] 5 1 1 1 5 5-17-2008 2 5
261588D Fujit Mahato 16 1 2008 6-20-2008 4 2 2 1 2 2 58.1 92 1 1 2 1 2 2 2 1
46,XY,der(19)
t(1;19)(q23;p1 2 1 1 1 5 6-30-2008 1 9-11-2009 1-22-2010 1
272385D Tajender Singh 16 1 2008 9-18-2008 5 9 2 1 2 2 3.9 98 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 9-18-2008 1 9-1-2009 11-13-2009 1
278912D Shuchintha S 16 1 2008 7-22-2008 10 0 2 1 2 2 4.3 17 1 1 2 1 2 2 2 2 46,XY[19] 5 1 1 1 5 8-9-2008 2 5
302412D Mohammed Irshad 17 1 2008 8-28-2008 2 7 1 3 2 2 22.4 90 1 1 2 1 2 2 2 2
46~47,XY,+6,
del(6)(q21q24 3 1 1 1 5 8-29-2008 1 1-30-2010 3-19-2010 1
308228D Nirmal Kumar Raj 17 1 2008 9-8-2008 3 3 2 1 2 2 42.7 94 1 1 2 1 2 2 2 2
46,XY,del(18)(
p11) 5 1 1 1 5 9-8-2008 1 9-21-2009 2-8-2010 1
346862D Indumathi 17 2 2008 11-10-2008 0 0 2 1 2 3 1 75 1 1 2 1 2 2 2 2
48~56,XX,+X,
+4,+6,+9,+10, 1 1 1 1 5 11-19-2008 2 5
377727D Chidananda 17 1 2008 12-23-2008 0 0 1 3 2 2 2.4 70 1 1 2 2 2 2 2 2
46,XY,der(7)?i
(7)(q10)[20] 5 1 1 1 5 12-26-2008 2 5
205227D Arun Kumar R S 18 1 2008 5-10-2008 4 4 2 1 2 2 8.6 28 1 1 2 1 2 2 2 2
47~49,XY,+X,
+5,+8,del(12)( 1 1 1 1 5 5-10-2008 2 5
284192D
Hari Shankar Prusty 
B 18 1 2008 8-4-2008 2 0 2 1 2 2 1 70 1 3 2 1 2 2 2 2
81~84,XXYY,-
Y,-1,-2,-4,-12,- 5 1 1 1 5 8-26-2008 2 5
306749D Prasanjit Paul 18 1 2008 9-4-2008 4 0 2 1 2 2 4.1 27 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 9-8-2008 2 5
326271D Rajalakshmi 18 2 2008 10-3-2008 0 0 2 1 2 3 3.8 90 1 1 2 1 2 2 2 2
46,XX,add(15
)(q26)[3]/46,X 5 1 1 1 5 10-3-2008 2 5
378880D Nishanth K 18 1 2008 12-30-2008 0 0 2 1 2 2 0.9 90 1 1 2 2 2 2 2 2 46,XY[7] 5 1 1 1 5 1-1-2009 2 5
166328D Gnanasekar K 19 1 2008 1-14-2008 6 7 2 1 2 2 14.5 88 1 1 2 1 2 2 2 2
46,XY,i(2)(p10
)der(2)i(2)(q10 3 3 1 1 5 1-22-2008 2 4-3-2008 1
245372D
Samuel Joseph 
Pangani 19 1 2008 5-24-2008 0 0 2 1 2 2 162.7 98 1 1 2 1 2 2 2 2
47,XY,+21[2]/
46,XY[7] 1 1 1 1 5 7-1-2008 2 5
320812D Naveen B S 19 1 2008 9-24-2008 0 0 2 1 2 2 1.2 94 1 1 2 1 2 2 2 2 46,XY[18] 5 1 1 1 5 10-1-2008 2 5
285537D Anjan Chatterjee 20 1 2008 8-2-2008 0 0 2 1 2 2 1.5 83 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 8-6-2008 2 5
326034D Jitendra Kumar 20 1 2008 10-1-2008 2 9 2 1 1 2 730 56 1 3 2 2 2 2 2 2 46,XY[5] 5 1 1 1 5 10-1-2008 2 5
209215D
Lenka Gangadhara 
Naidu 21 1 2008 3-26-2008 0 0 2 1 2 2 7 93 1 1 2 1 1 2 2 2
59~78,XXY,+
X,-Y,- 3 3 1 1 5 3-29-2008 2 5-18-2008 1
257881D Dinesh Kumar 22 1 2008 6-14-2008 0 0 1 3 2 2 4 96 1 3 2 2 2 2 2 2 46,XY[20] 5 1 1 1 5 6-28-2008 2 5
186028D Kamaladevika 23 2 2008 2-15-2008 5 3 1 3 2 3 233.8 90 1 1 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 3-7-2008 1 4-14-2009 4-22-2009 1
227585D Rakesh S 23 1 2008 4-28-2008 3 0 2 1 2 2 39 93 1 3 2 1 2 2 2 2
45,XY,-5,-
7,del(7)(p15) 3 3 1 1 5 5-4-2008 2 5
203262D Parimala 24 2 2008 3-20-2008 4 5 2 1 2 3 1.2 95.5 2 5 2 1 2 2 2 2 46,XX[17] 5 1 1 1 5 4-1-2008 1 12-27-2010 3-9-2011 1
321223D
Shaik Asma 
Nasreen 24 2 2008 9-24-2008 3 2 2 1 2 3 104.7 98 1 1 2 1 2 2 2 1 46,XX[15] 5 1 1 1 5 9-29-2008 1 9-16-2009 12-1-2009 1
375618B Arunachalam K 24 1 2008 7-31-2008 0 0 2 1 2 2 20.2 70 1 1 2 1 2 2 2 2 46,XY[17] 5 1 1 1 5 8-2-2008 2 5
313545D Rajesh Yadav 25 1 2008 9-16-2008 8 10 1 3 1 2 27 26 1 3 2 2 2 2 2 2 Not Done 4 1 1 1 5 9-30-2008 1 5-29-2013 6-29-2013 1
343800D Shijo Varghese 26 1 2008 11-3-2008 3 0 2 1 2 2 10.2 70 1 1 2 1 2 2 2 2 46,XY[18] 5 1 1 1 5 11-3-2008 2 5
376995D
Mohammd Seraz 
uddin 26 1 2008 12-22-2008 0 0 2 1 2 2 2 0 1 3 2 2 2 2 2 2
46,XY,t(10;14
)(q24;q11)[13] 5 1 1 1 5 12-26-2008 2 5
198584D Nagana Gowda T 28 1 2008 3-6-2008 6 8 2 1 2 2 26 89 1 1 2 1 2 2 2 2
43~46,XY,del(
6)(q16q24),t(9 3 1 1 1 5 3-7-2008 2 5
301607D Vinodhini M 29 2 2008 8-27-2008 4 3 2 1 2 3 96 93 1 3 2 2 2 2 2 2
46,XX,add(7)(
p22),inv(14)(q 5 1 1 1 5 8-28-2008 2 5
327318D Siva Kumar K. 31 1 2008 10-3-2008 0 0 1 3 2 2 3.9 40 1 1 2 1 2 2 2 2
46,XY,del(9)(q
21q22)[4]/47,i 5 1 1 1 5 10-12-2008 1 2-17-2009 2-22-2010 1
360946D Rajina Begam 31 2 2008 12-6-2008 0 0 2 1 2 3 17.4 38 1 1 2 1 1 2 2 2
46,XX,t(9;22)(
q34;q11.2)[1c 3 3 1 1 5 12-13-2008 1 3-2-2010 4-5-2010 1
201373D Patricia Phillips 32 2 2008 3-12-2008 3 0 2 1 2 3 1.7 76 1 1 2 1 1 2 2 2
46,XX,?t(9;22
)(q34;q11.2)[1 3 3 1 1 5 3-14-2008 2 5
342895D Soosan Mathew 32 2 2008 10-27-2008 3 3 2 1 2 3 318.2 82 1 3 2 1 2 2 2 2 46,XX[20] 5 3 1 1 5 11-4-2008 2 5
204641D Amsaveni 34 2 2008 3-16-2008 1 3 2 1 2 3 1.9 10 1 1 2 1 2 2 2 2
48~51,XX,+X,
+4,- 1 1 1 1 5 3-29-2008 2 5
228482D Jothi K 35 2 2008 4-29-2008 0 0 2 1 2 3 0.9 0 1 1 2 1 1 2 2 2
47,XX,del(9)(p
13),+mar[cp5]/ 5 3 1 1 5 5-9-2008 2 5
308987D Ramila Sweettlin 35 2 2008 9-6-2008 1 3 2 1 2 3 6.3 95.2 1 2 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 9-9-2008 1 1-20-2009 3-2-2009 1
197774D Sunandini Levan 36 2 2008 3-9-2008 0 2 2 1 2 3 2.5 2 1 1 2 1 2 2 2 2
46,XX,t(11;19
)(q23;p13.3),d 3 1 1 1 5 3-9-2008 2 5
204294D Ananthakumar K 36 1 2008 3-17-2008 0 0 2 1 2 2 0.9 74 1 1 2 1 2 2 2 2
46,XY?del(17)
(p11.2)[3]/46, 5 1 1 1 5 3-25-2008 1 3-23-2010 5-5-2010 1
311839D Rajesh Srivastav 40 1 2008 9-10-2008 4 0 1 3 2 2 3.9 98 1 1 2 1 2 2 2 2
Not to 
Process 4 1 1 1 5 9-15-2008 1 9-4-2009 10-9-2009 1
193297D Santhi M 41 2 2008 3-5-2008 1 0 1 3 2 2 16.1 65 1 2 2 1 2 2 2 2
46,XX,add(17
)(p13)[8]/46,X 5 1 1 1 5 3-7-2008 2 5
196355D George 41 1 2008 3-8-2008 0 0 2 1 2 2 4 40 1 3 2 1 2 2 2 2
16 OF THE 
18 5 1 1 1 5 5-5-2008 1 3-28-2012 6-9-2012 1
270584D Narendran N 44 1 2008 7-8-2008 2 1 2 1 2 2 4.3 2 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 7-12-2008 1 3-4-2009 4-30-2009 1
915096C Arulmani 47 1 2008 8-22-2008 4 2 2 1 2 2 12.5 90 1 1 2 1 2 2 2 2
47,XY,+4[7]/4
6,XY[12] 1 1 1 1 5 8-24-2008 2 5
346811D Perumal P 49 1 2008 11-7-2008 6 7 2 1 2 2 8.3 15 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 11-19-2008 1 2-24-2009 4-11-2009 1
348373D Gopalakrishnan 53 1 2008 11-6-2008 0 0 2 1 2 2 0.4 0 1 1 2 1 2 2 2 2 46,XY[16] 5 1 1 1 5 11-7-2008 2 5
354131D Govindaswamy R V 55 1 2008 11-12-2008 0 0 2 1 2 2 2.3 94 1 1 2 1 2 2 2 2
TWO POOR 
QULAITY 4 1 1 1 5 11-14-2008 2 5
233250D Ramamoorthy D 61 1 2008 5-8-2008 0 0 2 1 2 2 11 31 1 1 2 1 2 2 2 2
46,XY,dup(1)(
q21q32),add( 3 3 1 1 5 5-30-2008 2 7-31-2008 1
337931D
Mathew Putenveetal 
Abraham 63 1 2008 10-28-2008 6 3 2 1 2 2 2.7 83 1 1 2 1 2 2 2 2 46,XY[17] 5 1 1 1 5 12-2-2008 2 5
364206D Kullammal M 65 2 2008 12-1-2008 4 0 2 1 2 2 1.9 87 1 2 2 2 2 2 2 2
36~40,XX,-
10,-16,- 3 1 1 1 5 12-4-2008 2 5
035054D Aravind E 15 1 2007 5-30-2007 6 10 2 1 2 2 289 99 1 1 2 1 2 2 2 1
46,XY,der(19)
t(1;19)(q23;p1 2 1 1 1 5 7-10-2007 2 5
158727D Renita Florence A 15 2 2007 12-22-2007 0 3 2 1 2 3 16.7 80 1 1 2 2 2 2 2 2 46,XX[20] 5 3 1 1 5 12-30-2007 2 5
068580D Nelson Babu M 16 1 2007 7-23-2007 0 4 2 1 2 2 427 90 1 1 2 1 2 2 2 2
46,XY,der(3)?
add(3)(q29)?i 5 3 1 1 5 7-25-2007 1 12-13-2007 1-13-2008 1
966475C Abdul Raheim M 16 1 2007 1-23-2007 0 0 2 1 2 2 366.3 90 1 3 2 2 2 2 2 2
46,XY,del(6)(q
21q2?4)[3] 5 1 1 1 5 1-23-2007 1 6-25-2007 7-25-2007 1
969755C Sheetal Basnet 16 2 2007 1-29-2007 0 0 2 1 1 3 38 59 1 3 2 2 2 2 2 2 46,XX[20] 5 1 1 1 5 2-6-2007 2 5
014343D
Phaneendra Kumar 
G 17 1 2007 4-21-2007 2 3 2 1 2 2 1.8 8 1 1 2 1 2 2 2 2
40~46,XY,del(
9)(p21),-12,- 3 1 1 1 5 4-28-2007 2 5
045077D Allwyan Franklin 17 1 2007 6-13-2007 8 14 1 3 2 2 254.2 96 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 6-20-2007 2 5
061454D
Bishnu Prasad Rao 
S 17 1 2007 7-12-2007 0 0 2 1 2 2 24.5 82 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 7-12-2007 2 5
048119D Shanmugapriya A. 18 2 2007 6-20-2007 2 2 1 3 2 3 27.3 83 1 1 2 1 2 2 2 2
47,XX,+9[7]/4
5~47,XX,+11, 1 1 1 1 5 6-30-2007 2 5
960236C Roshan C P 18 1 2007 1-17-2007 0 0 2 1 2 2 1.3 90 1 1 2 1 2 2 2 2
45,XY,dic(9;1
2)(p13;p13)[4] 1 1 1 1 5 1-17-2007 2 5
972293C Dinesh A 18 1 2007 2-2-2007 0 0 2 1 2 2 1.2 91 1 1 2 1 2 2 2 2
46,XY,der(9)?
add(9)(p24)?t( 5 1 1 1 5 2-2-2007 2 5
085830D Keerthana R 19 2 2007 8-25-2007 5 3 1 3 2 3 4.9 86 1 2 2 1 2 2 2 2
65~77,XXX,+
X,-X,+1,+2,- 3 1 1 1 5 8-27-2007 2 5
103167D Meganathan 19 1 2007 9-21-2007 0 0 2 1 2 2 51.9 67 1 1 2 1 2 2 2 2
44~47,XY,i(9)
(q10),-10,- 5 1 1 1 5 9-22-2007 1 2-22-2008 8-30-2008 1
124517D Paneerselvam B 19 1 2007 10-23-2007 5 3 1 3 2 2 319 67 1 3 2 2 2 2 2 2
46,XY,t(11;14
)(p13;q11)[20] 5 1 1 1 5 10-31-2007 2 5
015170D Bharat D Dambal 20 1 2007 5-7-2007 2 0 2 1 2 2 0.5 0 2 5 2 1 2 2 2 2
ONLY ONE 
POOR 4 1 1 1 5 5-17-2007 2 5
117312D Aditya K.V.N 20 1 2007 10-10-2007 0 8 2 1 2 2 19.3 94 1 1 2 1 2 2 2 2
42~45,XY,der
(7)?dic(7;9)(p 3 3 1 1 5 10-17-2007 1 7-9-2010 8-5-2010 1
133521D Dipjyoti Baruah 20 1 2007 11-7-2007 0 0 2 1 2 2 4.8 0 1 1 2 1 2 2 2 2
46,XY,i(7)(q10
)[7]/ 46,XY[17] 5 1 1 1 5 11-18-2007 2 5
987692C Sivasakthivel R 20 1 2007 3-5-2007 0 0 2 1 2 2 229.2 56 1 3 2 1 2 2 2 2
46~49,XY,der
(1)t(1;?)(p32;? 1 3 1 1 5 3-5-2007 1 2-1-2008 3-22-2008 1
130460D Kamal Jit Singh 21 1 2007 11-5-2007 5 7 2 1 2 2 6.7 55 1 1 2 1 1 2 2 2
46,XY,der(8)?i
(8)(q10) or 3 3 1 1 5 11-7-2007 2 5
957267C Stalin 21 1 2007 1-8-2007 0 0 1 3 2 2 2.5 55 1 1 2 1 2 2 2 2
46,XY,-
X,del(12)(p13) 3 1 1 1 5 1-8-2007 2 5
970690C Ranjan Kumar Sahu 21 1 2007 1-30-2007 2 2 2 1 2 2 3.9 61 1 1 2 1 2 2 2 2
46,XY,+8,dic(
9;12)(p13;p11 1 1 1 1 5 1-30-2007 2 5
990088C Kinlay Rabgay 21 1 2007 3-13-2007 0 0 2 1 2 2 17.8 90 1 1 2 1 2 2 2 2
45,XY,-
20[3]/46,XY[1 5 1 1 1 5 3-13-2007 2 5
982167C Bharathi P 22 2 2007 2-26-2007 0 0 2 1 2 3 9.3 70 1 1 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 3-5-2007 2 4-13-2007 2
009522D Swadhini V. 24 2 2007 4-12-2007 0 2 2 1 2 3 9.1 83 1 1 2 1 2 2 2 2
46,XX,del(12)
(p13)[2]/46,X 5 1 1 1 5 4-13-2007 2 5
025203D Johanan James 24 1 2007 5-12-2007 5 5 2 1 1 2 202 70 1 3 2 2 2 2 2 2
47,XY,+15[3]/
46,XY[7] 1 1 1 1 5 5-19-2007 2 5
128667D Selvarasa Deni Jude 24 1 2007 10-30-2007 3 0 2 1 2 2 7 0 1 3 2 1 2 2 2 2 46,XY[19] 5 1 1 1 5 11-6-2007 1 3-13-2009 4-16-2009 1
975364C Baskar C 24 1 2007 2-9-2007 0 0 2 1 2 2 25.8 80 1 1 2 1 1 2 2 2 46,XY[20] 5 3 1 1 5 2-9-2007 2 5
013166D Siva Subramani S 25 1 2007 4-23-2007 0 0 2 1 2 2 2.4 8 1 1 2 1 1 2 2 2
46,XY,t(9;22)(
q34;q11)[7]/4 3 3 1 1 5 5-2-2007 2 5
040089D Rajendra Prasad A. 26 1 2007 6-4-2007 3 1 2 1 2 2 5.2 49 1 1 2 1 2 2 2 2 46,XY[8] 5 1 1 1 5 7-3-2007 2 5
073804D Dr Ashok Kumar R 26 1 2007 7-30-2007 0 5 2 1 2 2 44.4 87 1 1 2 1 2 2 2 2 46,XY[30] 5 3 1 1 5 8-8-2007 1 9-9-2011 1-27-2012 1
124323D Subhalaxmi Rath 26 2 2007 10-22-2007 0 0 2 1 2 3 6.4 36 1 1 2 1 2 2 2 2 46,XX[19] 5 3 1 1 5 10-29-2007 2 5
118257D Indumathi 27 2 2007 10-11-2007 0 0 2 1 2 3 3 84 1 3 2 2 2 2 2 2
46,XY,t(10;11
)(p13;q21)[10] 3 1 1 1 5 10-20-2007 2 5
981651C Rajat Mondal 27 1 2007 2-23-2007 6 4 2 1 2 2 4 37 1 1 2 2 2 2 2 2
46,X,-
Y,+mar[10]/46 5 1 1 1 5 5-13-2007 2 5
133764D
Kunal Divyakumar 
Randeria 28 1 2007 11-12-2007 0 0 2 1 2 2 2.9 10.8 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 11-12-2007 2 5
074508D Akila C. 29 2 2007 8-19-2007 0 3 2 1 2 3 7.5 0 1 1 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 8-19-2007 2 5
092363D Malar 29 2 2007 9-3-2007 11 4 2 1 2 3 37.5 88 1 1 2 1 2 2 2 1
46,XX,t(1;19)(
q23;p13.3)[10 2 1 1 1 5 9-10-2007 1 3-14-2008 4-14-2008 1
143814D Gayathri R. 29 2 2007 11-23-2007 0 0 2 1 2 3 351.4 95 1 2 2 1 2 2 1 2
46,XX,t(4;11)(
q21;q23)[18]/ 3 3 1 1 5 11-23-2007 2 5
031988D Desikachari M J 30 1 2007 5-23-2007 6 3 2 1 2 2 309 95 1 3 2 2 2 2 2 2
47,XY,+8,-
14,+22[3]/47, 1 1 1 1 5 5-23-2007 2 5
157226D Sajitha Sivaprakasan 30 2 2007 12-21-2007 0 0 1 3 2 3 21 40 1 3 2 1 2 2 2 2
47,XX,+4[7/9
2,XXXX[3]/46, 1 1 1 1 5 12-21-2007 1 4-18-2012 5-12-2013 1
118984D Sathiya R 33 2 2007 10-15-2007 0 0 2 1 2 3 2 82 1 2 2 2 2 2 2 2
46,XX,i(7)(q1
0)[15]/45,idem 5 3 1 1 5 10-15-2007 1 3-25-2008 4-25-2008 1
004197D Shanthi S. 37 2 2007 4-3-2007 0 0 2 1 2 3 240.4 94 1 1 2 1 1 2 2 2
45~46,XX,-
9,del(9)(q21),- 3 3 1 1 5 4-6-2007 1 10-27-2009 8-30-2010 1
055631D Suchan Mishra 37 1 2007 6-30-2007 2 0 2 1 2 2 1.9 74 1 3 2 2 2 2 2 2
41~48,X,-
Y,+del(1)(p32) 3 1 1 1 5 7-13-2007 2 5
125521D Ashifuzzaman 39 1 2007 10-24-2007 6 4 2 1 2 2 7.2 85 1 1 2 1 2 2 2 2
42~45,XY,-
16,+19,- 3 1 1 1 5 11-2-2007 1 1-25-2010 5-29-2010 1
979394C Anup Saha 39 1 2007 3-22-2007 4 2 2 1 2 2 5.1 48 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 3-22-2007 1 1-23-2010 2-25-2010 1
151657D Seethalakshmi R 44 2 2007 8-12-2007 0 0 2 1 2 2 12.5 30 1 1 2 2 2 2 2 2 Not Done 4 3 1 1 5 12-10-2007 1 9-22-2009 6-25-2010 1
063931D Saju Joseph 45 1 2007 7-14-2007 0 0 2 1 2 2 10.1 0 2 5 2 1 2 2 2 2 46,XY[15] 5 1 1 1 5 7-14-2007 2 5
970612C Chitra Vasudevan 48 2 2007 1-29-2007 3 0 2 1 2 3 10.4 25 1 1 2 1 2 2 2 2 45,XX,-20[18] 5 1 1 1 5 1-29-2007 1 7-25-2008 5
020641D Kamal Kishore Shaw 52 1 2007 5-4-2007 3 0 2 1 1 2 2 0 1 3 2 2 2 2 2 2 Not Done 4 1 1 1 5 5-13-2007 2 5
074927D Debebrata Misra 54 1 2007 8-2-2007 0 0 2 1 2 2 0.8 0 1 1 2 1 2 2 2 2 46,XY[3] 5 1 1 1 5 8-10-2007 2 9-8-2007 2
994737C Elizabeth Sr. 56 2 2007 3-15-2007 0 0 2 1 2 3 3.4 27 1 1 2 1 1 2 2 2
45,XX,der(4)d
el(4)(q12)t(4;9 3 3 1 1 5 3-19-2007 2 5
033525D Vaseekaran G. 63 1 2007 5-24-2007 0 0 2 1 2 2 6.5 91 1 1 2 1 1 2 2 2
46,XY,der(9)t(
9;22)(q34;q11 3 3 1 1 5 5-25-2007 2 5
042389D
Ramappa 
Nindodappa Patil 67 1 2007 6-14-2007 4 0 2 1 2 2 4.8 15 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 6-21-2007 1 10-1-2007 12-24-2007 2
753137C Md. Nasiruddin Khan 15 1 2006 1-4-2006 4 0 2 1 2 2 1.9 99 1 1 2 1 2 2 2 2 46, XY[1] 5 1 1 1 5 1-5-2006 1 6-26-2007 7-26-2007 1
781435C Praful Dev K 15 1 2006 2-27-2006 2 1 2 1 2 2 57 98 1 1 2 1 2 2 2 2
45, XY,-4,-8,-
9,- 5 1 1 1 5 3-1-2006 1 6-29-2010 6-21-2011 2
831055C Riju Atta 15 1 2006 5-31-2006 3 2 2 1 2 2 246.5 89 1 1 2 1 2 2 2 2
46,XY,del 
(4)(?q32) [10] 5 1 1 1 5 6-30-2006 2 5
917157C Vineeth E K 15 1 2006 10-25-2006 2 2 2 1 2 2 1.2 90 1 1 2 1 2 2 2 2
46, XY, 
del(6)(q21q24 5 1 1 1 5 10-25-2006 2 5
947234C Siva Kumar 15 1 2006 12-16-2006 0 0 2 1 2 2 242.3 98 1 3 2 2 2 2 2 2 46,XY[10] 5 3 1 1 5 12-16-2006 2 5
774434C Thasleena V.K. 16 2 2006 2-14-2006 4 2 2 1 2 3 430.7 95 1 3 2 1 2 2 2 2
46,XX,del(6)(q
21;q25)[2]/46, 5 1 1 1 5 2-18-2006 2 5
853347C Femi Francis 16 2 2006 7-10-2006 0 0 2 1 2 3 8.1 27 1 1 2 1 2 2 2 2
46,X,i(X)(q10) 
[11] / 45,X,-X 5 1 1 1 5 7-10-2006 2 5
757225C Nagarjuna B. 17 1 2006 1-7-2006 0 0 2 1 2 2 2.7 2 1 1 2 1 2 2 2 2
ONLY TWO 
METAPHASE 4 1 1 1 5 1-20-2006 2 5
828095C Venkatesan 17 1 2006 5-29-2006 3 3 2 1 2 2 86.3 63 1 3 2 1 2 2 2 2
42-45,XY,-18,-
21,-22 [cp 5] 3 1 1 1 5 6-3-2006 2 7-30-2006 1
849133C Abu Backer Siddique 17 1 2006 7-1-2006 5 3 2 1 2 2 3.3 20 1 1 2 1 2 2 2 2
46,XY,i(9)(q10
) [16] 5 1 1 1 5 7-1-2006 1 1-16-2007 7-1-2007 1
876067C Surya Chanakya K 17 1 2006 8-15-2006 5 2 2 1 2 2 145.7 91 1 1 2 1 2 2 2 2 Not done 4 3 1 1 5 8-17-2006 2 10-8-2006 1
881329C Siva Kumar K 17 1 2006 8-25-2006 7 0 2 1 2 2 2.5 94 1 1 2 1 2 2 2 2
45, XY, 
dic(9;12)(p11; 1 1 1 1 5 8-25-2006 2 5
758796C Shake Mohiuddin 18 1 2006 2-6-2006 1 4 2 1 2 2 31 62 1 1 2 1 2 2 2 2
47, XY, 
+21[4]/46, 1 1 1 1 5 2-7-2006 2 5
784274C Shayan Mukherjee 18 1 2006 3-2-2006 4 7 2 1 2 2 114 38 1 3 2 2 2 2 2 2
87-91,XXYY,-
2,-4,-4,-5,-6,- 5 1 1 1 5 3-3-2006 2 5
803304C Keka Ghosh 18 2 2006 4-11-2006 0 0 2 1 2 3 4.2 29 1 1 2 1 2 2 2 2 46, XX[19] 5 1 1 1 5 4-24-2006 1 12-5-2012 1-5-2013 1
816877C Arun Kumar N 18 1 2006 5-4-2006 2 0 2 1 2 2 5.5 66 1 1 2 1 2 2 2 2
49, XY, +X, 
+7, +8[2]/49, 1 1 1 1 5 5-8-2006 2 5
828283C Rohit Chakravarty 18 1 2006 6-3-2006 0 0 2 1 2 2 65.7 90 1 1 2 1 2 2 2 2
48,XY,+4,+21 
[2] /46,XY [2] 1 3 1 1 5 6-4-2006 2 7-27-2006 1
758970C Agustin R 19 1 2006 1-18-2006 0 3 2 1 2 2 3.5 18 1 1 2 1 2 2 2 2
52, XY, 
+6,+7,+8,+11, 1 1 1 1 5 1-19-2006 2 5
811390C Kashyap 20 1 2006 4-24-2006 0 0 2 1 2 2 7.5 47 1 2 2 1 2 2 2 2 46,XY [20] 5 3 1 1 5 4-24-2006 1 1-11-2007 28-07-2007 1
836203C Deepak Kumar 21 1 2006 2-25-2006 0 0 2 1 2 2 9 1 1 1 2 2 2 2 2 2 46,XY[20] 5 3 1 1 5 6-25-2006 2 5
851921C Bakkiyaraj P 21 1 2006 7-5-2006 2 3 2 1 2 2 10.5 55 1 1 2 1 2 2 2 2
53~56,XY,+X,
+2,+4,+5,+6,+ 1 1 1 1 5 7-5-2006 2 5
942535C Alphy Kurien 21 1 2006 12-6-2006 0 0 2 1 2 2 1.3 0 1 2 2 1 1 2 2 2 46,XY[2] 5 3 1 1 5 12-6-2006 1 7-24-2008 8-24-2008 1
764613C Prakash 23 1 2006 1-24-2006 5 3 2 1 2 2 11 45 1 1 2 1 2 2 2 2 46,XY [20] 5 1 1 1 5 1-25-2006 2 5
896258C Babu 23 1 2006 10-5-2006 0 0 2 1 2 2 7.5 26 1 3 2 2 2 2 2 2 46, XY[18] 5 1 1 1 5 10-5-2006 2 5
923898C Pintu Basak 23 1 2006 11-10-2006 2 2 2 1 2 2 23.5 98 1 2 2 1 2 2 2 2
43~47,XY,del(
6)(q21q25),+7 3 1 1 1 5 11-10-2006 2 12-20-2007 1
812132C Sandhya 24 2 2006 5-1-2006 7 3 2 1 2 3 70.4 88 1 1 2 1 2 2 2 1
46,XX,der(19)
t(1;19)(q23;p1 2 1 1 1 5 5-1-2006 1 9-16-2008 2-13-2009 1
903173C
Auvla Laxmi 
Prasanna 24 2 2006 10-4-2006 0 0 2 1 2 3 1.4 0 1 2 2 1 2 2 2 2 46,XY[9] 5 1 1 1 5 10-4-2006 1 3-8-2010 9-5-2010 1
757247C John Moses G 25 1 2006 1-7-2006 0 0 2 1 2 2 1.1 18 1 3 2 1 2 2 2 2 46, XY[5] 5 1 1 1 5 1-13-2006 2 5
914715C Mita Samanta 25 2 2006 10-26-2006 0 0 2 1 2 3 10.5 22 1 3 2 2 2 2 2 2
46, XX, 
del(6)(q21q24 5 1 1 1 5 10-26-2006 1 12-30-2010 3-24-2011 1
779391C Abhjit Das 26 1 2006 2-28-2006 3 0 2 1 1 2 102 40 1 3 2 2 2 2 2 2 Not done 4 1 1 1 5 2-28-2006 2 5
839500C Anu Radha Jaiswal 26 2 2006 6-28-2006 1 3 2 1 2 3 12.4 0 1 3 2 2 2 2 2 2
44-46,XX,-8,-
9,-14,+ mar 5 1 1 1 5 6-29-2006 2 5
864620C Karthik T S 26 1 2006 7-27-2006 4 2 2 1 2 2 184.6 98 1 3 2 1 2 1 2 2 46,XY [20] 5 3 1 1 5 7-27-2006 2 10-3-2006 2
896113C Raja 27 1 2006 9-20-2006 0 4 2 1 2 2 14.2 85 1 3 2 2 2 2 2 2 46, XY[15] 5 1 1 1 5 9-21-2006 2 5
818873C Velmurugan P 28 1 2006 7-19-2006 3 2 2 1 2 2 1.2 90 1 3 2 1 2 2 2 2 46,XY[6] 5 1 1 1 5 7-19-2006 2 5
946506C Doddi Prasad 29 1 2006 12-13-2006 0 0 2 1 2 2 1.8 91 1 2 2 1 2 2 2 2 46,XY[6] 5 1 1 1 5 12-13-2006 1 4-20-2010 1-17-2011 1
865812C Rajeswari T 30 2 2006 9-29-2006 0 3 2 1 2 3 0.5 0 1 3 2 2 2 2 2 2 46, XX[2] 5 1 1 1 5 9-29-2006 1 1-6-2007 4-10-2007 1
906830C Nikunj Kishore Benu 30 1 2006 10-9-2006 0 0 2 1 2 2 7.9 32 1 1 2 1 1 2 2 2
46,XY,t(9;22)(
q34;q11.2)[4]/ 3 3 1 1 5 10-9-2006 2 4-1-2007 2
941205C Durga Devi A 31 2 2006 12-7-2006 6 3 2 1 2 3 246.6 88 1 3 2 2 2 2 2 2 Not done 4 3 1 1 5 12-13-2006 2 5
753536C Prince 33 1 2006 1-4-2006 3 0 1 3 2 2 20.7 13 1 1 2 1 2 2 2 2
66, XXY,-1, -
2, -3, -4,-7,-8,- 3 1 1 1 5 1-5-2006 1 3-27-2006 5-18-2006 1
894622C Karakatty F 34 1 2006 9-16-2006 0 0 2 1 2 2 1.1 23 1 1 2 1 2 2 2 2 46, XY[8] 5 1 1 1 5 9-16-2006 2 5
863074C Anwar Basha 36 1 2006 7-25-2006 3 0 2 1 2 2 118.7 99 1 1 2 1 2 2 2 2 46, XY[20] 5 3 1 1 5 7-25-2006 2 5
801650C Suraja K.C. 37 2 2006 4-4-2006 6 14 2 1 2 3 0.5 96 1 1 2 1 2 2 2 2 46, XX[15] 5 1 1 1 5 7-4-2006 2 10-5-2006 2
850468C Prasanna Kumar 37 1 2006 7-12-2006 0 0 2 1 2 2 23.3 99 1 1 2 1 2 2 2 2
47,XY,+X,der(
3)?t(3;3)(q21; 4 3 1 1 5 7-12-2006 1 12-4-2006 1-8-2007 1
810542C Gopu V 38 1 2006 4-24-2006 3 5 2 1 2 2 86.7 84 1 1 2 1 2 2 2 2
45,XY,-
7,del(8)(p?22 2 3 1 1 5 4-24-2006 2 9-18-2006 1
936999C Murugan V 38 1 2006 11-27-2006 0 0 2 1 2 2 10.3 45 1 1 2 1 1 2 2 2
46,XY,t(9;22)(
q34;q11)[2] 3 3 1 1 5 11-27-2006 1 12-29-2009 2-5-2010 1
849596C Karunakaran R 39 1 2006 7-1-2006 0 0 2 1 2 2 2.9 0 1 1 2 1 2 2 2 2
46,XY,del(20)(
q12) [2] / 5 1 1 1 5 7-1-2006 2 5-4-2007 2
863552C Shanmugam R 39 1 2006 7-25-2006 2 3 2 1 2 2 155 93 1 1 2 1 2 2 2 2 46,XY[2] 5 1 1 1 5 7-25-2006 1 1-5-2007 8-2-2007 1
872499C Nagarajan M 42 1 2006 8-10-2006 0 0 1 3 2 2 88.7 89 1 1 2 1 2 1 2 2 46,XY [18] 5 1 1 1 5 8-10-2006 1 12-24-2007 4-5-2008 1
885472C Celine Thomas 43 2 2006 9-2-2006 4 3 2 1 2 3 3.3 20 1 2 2 1 2 2 2 2
35-36,X,-X,-3,-
4,-5,6,-7,-8,-9,- 3 1 1 1 5 9-2-2006 1 11-10-2007 10-12-2007 1
909729C Rajamani N 45 1 2006 10-13-2006 0 2 2 1 2 2 5.2 25 1 1 2 1 1 2 2 2 46, XX [8] 5 3 1 1 5 10-13-2006 1 4-23-2008 8-22-2008 1
915040C Kamal kumar sarkar 48 1 2006 10-21-2006 0 0 2 1 2 2 2.5 0 1 2 2 1 1 2 2 2
46, XY, 
t(9;22)(q34;q1 3 3 1 1 5 11-2-2006 1 1-29-2008 10-1-2009 1
928260C Ramasamy 50 1 2006 11-14-2006 6 0 2 1 2 2 3.7 0 1 1 2 1 2 2 2 2 Not done 4 1 1 1 5 11-14-2006 1 9-7-2007 8-19-2007 1
889966C Ramadevi 54 2 2006 9-12-2006 8 8 1 3 2 3 9.9 58 1 1 2 1 2 2 2 2
48, XX,+X, 
del(3)(q13), 3 1 1 1 5 9-12-2006 2 7-5-2007 2
853180C Nisthar 56 1 2006 7-10-2006 0 0 2 1 2 2 8.6 26 1 1 2 1 2 2 2 2 46,XY[3] 5 1 1 1 5 7-10-2006 1 5-12-2007 6-12-2007 1
806051C Debnarayan Dey 57 1 2006 4-12-2006 2 0 2 1 2 2 1.9 0 1 1 2 1 2 2 2 2 46,XY [12] 5 1 1 1 5 5-19-2006 2 5
797179C
Rema 
Venkiteswaran 58 2 2006 3-25-2006 0 0 2 1 2 3 34.9 76 1 1 2 1 1 2 2 2
46,XX,t(9;22)(
q34;q11) [17] / 3 3 1 1 5 3-29-2006 1 6-12-2007 7-12-2007 1
855542C Satyanarayana L 59 1 2006 7-12-2006 2 0 2 1 2 2 6.8 35 1 1 2 1 1 2 2 2
46,XY,t(9;22),
(q34;q11),del( 3 3 1 1 5 7-13-2006 2 5
788228C Ramappan A K 67 1 2006 3-11-2006 0 0 2 1 2 2 5.5 20 1 1 2 1 1 2 2 2
46,XY,t(9;22)(
q34;q11) [5] / 3 3 1 1 5 3-15-2006 2 5
669912C Surendar 15 1 2005 8-3-2005 4 2 2 1 2 2 3 12 1 1 2 1 2 2 2 2 46,XY [16] 5 1 1 1 5 8-4-2005 2 5
691741C Manash Saha 15 1 2005 9-6-2005 0 0 2 1 2 2 8.9 0 1 1 2 1 2 2 2 2
47,XY,del(1)(q
22q31),add(4) 5 1 1 1 5 9-8-2005 1 11-14-2006 2-19-2007 1
751277C
Rakesh Kumar 
Pramanik 15 1 2005 12-28-2005 1 0 2 1 2 2 79.5 72 1 1 2 1 2 2 2 2 46, XY[20] 5 1 1 1 5 1-5-2006 2 5
634030C Sargunam 16 1 2005 5-7-2005 5 2 1 3 2 2 9.8 62 1 1 2 1 2 2 2 2 46,XY [20] 5 1 1 1 5 5-18-2005 1 3-21-2006 6-16-2006 1
665872C Wangmo 16 2 2005 7-11-2005 2 2 2 1 2 3 92.2 90 1 1 2 1 2 2 2 2
47,XX,+21 
[10] / 1 1 1 1 5 7-14-2005 2 5
697724C Rekha J 16 2 2005 9-9-2005 4 3 2 1 2 3 17.4 36 1 1 2 1 2 2 2 2
51~52, 
XX,+3,+4,+10 1 1 1 1 5 12-9-2005 1 7-23-2007 8-23-2007 2
636916C Jean Joy 17 2 2005 6-1-2005 2 2 2 1 2 3 19.6 73 1 1 2 1 1 2 2 2 46,XX [17] 5 3 1 1 5 6-9-2005 2 8-1-2005 1
731411C Janani P 17 2 2005 11-18-2005 0 0 2 1 2 3 4.1 82 1 1 2 1 2 2 2 1
46, XX, 
t(1;19)(q23;P1 2 1 1 1 5 11-19-2005 1 6-8-2006 9-25-2006 1
581461C Jambay Dorti 19 1 2005 1-12-2005 5 1 2 1 2 2 15.3 0 2 5 2 1 2 2 2 2 46, XY[17] 5 1 1 1 5 1-20-2005 2 5
590696C Abdul Rahman.K.T. 19 1 2005 2-2-2005 0 5 2 1 2 2 19.1 65 1 1 2 1 2 2 2 1 Not done 4 1 1 1 5 2-2-2005 1 9-8-2006 10-17-2006 1
613899C Mustafa.G.M. 19 1 2005 4-12-2005 4 0 2 1 2 2 9 34 1 1 2 1 2 2 2 2
47, XY, 
+21[3]/46, 1 1 1 1 5 4-13-2005 1 5-5-2006 6-19-2006 1
655141C Gobinda talukdar 19 1 2005 6-21-2005 4 6 2 1 2 2 12.6 56 1 1 2 1 2 1 2 2 46, XY[20] 5 3 1 1 5 6-27-2005 2 5
702281C Saranyan .P 19 1 2005 9-16-2005 0 0 2 1 2 2 1.6 28 1 1 2 1 2 2 2 2 46, XY[2] 5 3 1 1 5 9-17-2005 2 5
636039C Mohan 20 1 2005 5-20-2005 6 7 2 1 2 2 179 60 1 3 2 2 2 2 2 2 Not done 4 1 1 1 5 5-21-2005 1 12-11-2006 1-6-2007 2
712558C Shabeer P. 20 1 2005 10-10-2005 0 0 2 1 2 2 4.7 58 1 1 2 1 2 2 2 2
45-
46,XY,del(8) 3 1 1 1 5 10-25-2005 2 5
669247C Lipika Maity 21 2 2005 8-11-2005 0 0 2 1 2 3 1.8 0 1 1 2 1 2 2 2 2 46, XX[13] 5 1 1 1 5 8-17-2005 2 5
725500C Teena Ramesh 21 2 2005 11-1-2005 2 0 2 1 2 3 39.8 65 1 3 2 2 2 2 2 2
92-93,XXX,-1,-
2,del(3)(q25q 3 3 1 1 5 11-1-2005 2 5
733721C Sudipta Banerjee 23 1 2005 11-22-2005 2 15 2 1 2 2 9.4 43 1 1 2 1 2 1 2 2 46,XY [5] 5 1 1 1 5 11-24-2005 1 5-30-2006 7-2-2006 1
574090C Raju Chettry 25 1 2005 1-12-2005 0 5 1 3 2 2 115 70 1 3 2 2 2 2 2 2
77-
81,XXYY,+1,+ 3 3 1 1 5 1-12-2005 2 5
721599C Nimmy Rajesh 25 2 2005 10-26-2005 3 0 2 1 2 3 5.2 25 1 1 2 1 2 2 2 2
47,XX,add(4)(
p16), - 3 1 1 1 5 10-26-2005 2 5
724884C
Vivek Narayan 
Vallathol 27 1 2005 10-31-2005 5 0 1 3 2 2 45.9 60 1 3 2 2 2 2 2 2 46,XY [5] 5 1 1 1 5 12-10-2005 2 5
595707C Manickam.R 30 1 2005 2-14-2005 1 3 2 1 2 2 10 24 1 1 2 1 2 2 2 2
46,XY,del(7)(q
31q34),del(9)( 5 3 1 1 5 2-14-2005 1 6-18-2005 9-19-2005 1
715474C Md. Janna Ali 32 1 2005 10-31-2005 0 0 2 1 2 2 3.3 0 1 1 2 2 2 2 2 2 46, XY[8] 5 1 1 1 5 11-14-2005 1 1-25-2011 2-25-2011 1
746671C Vijayalakshmi B 33 2 2005 12-31-2005 6 2 2 1 2 3 3.3 7 1 1 2 1 1 2 2 2
47, XX. 
+mar?der(7)[4 5 3 1 1 5 12-31-2005 2 5
623535C Sreedeep .E.K. 36 1 2005 4-27-2005 0 0 2 1 2 2 34.3 90 1 1 2 1 1 2 2 2
46,XY,t(9;22)(
q34;q11) [6] / 3 3 1 1 5 4-28-2005 1 1-20-2009 6-6-2011 1
633654C Satyam .C 43 1 2005 5-5-2005 0 0 2 1 2 2 15 55 1 1 2 1 2 2 2 2
51-
54,XXY,+2,+4 3 1 1 1 5 5-7-2005 2 6-16-2005 1
705351C Ganesan P. 43 1 2005 9-23-2005 0 6 1 3 2 2 105.8 90 1 2 2 1 2 2 1 2
46,XY 
t(4;11)(q21;q2 3 3 1 1 5 9-24-2005 2 1-7-2006 2
615373C Venkatesan R. 44 1 2005 4-7-2005 3 0 2 1 2 2 105 92 1 1 2 1 1 2 2 2
47,XY,t(9;22)(
q34;q11), 3 3 1 1 5 4-7-2005 2 7-10-2005 1
707850C Sundarapandiyan 47 1 2005 9-29-2005 0 0 2 1 2 2 56.4 89 2 5 2 1 1 2 2 2
48 -
50,XXY,+4,+5 3 3 1 1 5 9-30-2005 2 11-8-2005 1
672988C Gowthaman S.P.Dr. 49 1 2005 7-25-2005 0 0 2 1 2 2 0.4 0 1 1 2 1 2 2 2 2
45,XY,-21[4] / 
46,XY[12] 5 1 1 1 5 7-26-2005 1 6-1-2009 3-14-2012 1
607062C Ashok Sarkar 51 1 2005 3-14-2005 0 0 2 1 2 2 14.8 58 1 1 2 1 1 2 2 2
46,XY,t(9;22)(
q34;q11)[14]/ 3 3 1 1 5 3-16-2005 1 1-25-2008 1-9-2009 2
647045C Robert T. 53 1 2005 6-6-2005 0 0 2 1 2 2 4.5 0 1 1 2 2 2 2 2 2 Not done 4 1 1 1 5 6-14-2005 2 5
659684C Chandran .A.S 53 1 2005 7-15-2005 5 0 2 1 2 2 44.8 48 1 1 2 1 2 2 2 1 46, XY[20] 5 3 1 1 5 7-16-2005 1 12-10-2005 12-18-2005 1
549477C Chithra Lakshmi 16 2 2004 11-2-2004 0 0 2 1 2 3 96.6 95 1 1 2 2 2 2 2 2
47,XX,del(6)(q
15q23),der(19 2 3 1 1 5 11-3-2004 1 2-6-2008 9-1-2008 1
408968C Satish P 17 1 2004 2-14-2004 2 3 2 1 2 2 30 88 1 3 2 2 2 2 2 2
ONLY 4 
POOR 4 1 1 1 5 2-22-2004 2 5
511779C Daniel.C 17 1 2004 8-25-2004 4 1 2 1 2 2 12.3 71 1 1 2 1 2 1 2 2 Not done 4 1 1 1 5 9-1-2004 2 5
522700C
Muhammed 
Nainar.S. 17 1 2004 9-27-2004 0 0 1 3 2 2 24.7 35 1 3 2 2 2 2 2 2 Not done 4 1 1 1 5 10-22-2004 1 5-17-2005 8-1-2005 1
527884C Bharani Dharan.D 17 1 2004 9-21-2004 1 4 2 1 2 2 93 89 1 1 2 1 2 2 2 1 46, XY[7] 5 1 1 1 5 9-21-2004 2 5
556416C Priyanka Pavithran 18 2 2004 11-16-2004 0 3 2 1 2 3 11.1 69 1 1 2 1 2 2 2 2
THERE ARE 
NO 4 1 1 1 5 11-16-2004 1 9-1-2010 5
573992C
Chandan Kumar 
Mantri 18 1 2004 12-27-2004 1 0 2 1 2 2 1.9 0 1 1 2 1 2 2 2 2
THERE ARE 
NO 4 1 1 1 5 12-29-2004 1 6-5-2006 6-19-2006 1
432347C Manikandan .K 19 1 2004 2-25-2004 3 3 2 1 2 2 111 90 1 1 2 1 1 2 2 2
46,XY, 
t(9;22)(q34;q1 3 3 1 1 5 3-5-2004 2 5
432548C Sakthivel P. 19 1 2004 2-25-2004 0 0 2 1 2 2 38.4 57 1 3 2 2 2 2 2 2
ONLY 
THREE 4 1 1 1 5 2-26-2004 2 5
420487C Sauvik Pain 20 1 2004 1-31-2004 0 0 2 1 2 2 118 0 1 1 2 1 1 2 2 2
only 3 poor 
quality 4 3 2 1 5 2-4-2004 2 5
526280C Utpal Barman 21 1 2004 10-15-2004 3 4 2 1 2 2 55 94 1 3 2 1 2 2 2 2
THERE ARE 
NO 4 1 1 1 5 10-15-2004 1 1-3-2006 2-3-2006 1
541922C Murali Dhar Jana 21 1 2004 11-5-2004 0 6 2 1 2 2 13 45 1 1 2 1 2 2 2 2
46, XY, -9, 
add(12)(P11.2 1 1 1 1 5 11-9-2004 2 8-19-2005 2
439544C Sumathi 22 2 2004 3-18-2004 18 3 2 1 2 3 3.5 33 1 1 2 1 2 2 2 2
ONLY FOUR 
POOR 4 1 1 1 5 3-24-2004 2 5
360734C Raji 23 2 2004 2-24-2004 0 0 2 1 2 3 120 89 1 1 2 1 1 2 2 2
46, 
XX,dup(1)(q1 3 3 1 1 5 2-29-2004 1 4-12-2005 5-12-2005 1
413098C Balaji.T.N 23 1 2004 1-10-2004 7 8 2 1 2 2 21.1 64 1 1 2 1 2 2 2 2
56-57, XXYY, 
+4, +6, +8, 1 1 1 1 5 1-12-2004 2 5
441283C Roby M Mathew 23 1 2004 3-17-2004 4 5 2 1 2 2 26 67 1 1 2 1 1 2 2 2
46, XY, 
der(22), 3 3 1 1 5 3-18-2004 1 12-10-2004 6-10-2005 1
450469C Naveen.A.H. 24 1 2004 4-7-2004 4 7 2 1 2 2 133 89 1 3 2 2 2 2 2 2
THE 
METAPHASE 4 3 1 1 5 4-7-2004 1 4-15-2005 5-19-2005 1
555942C Freeda Mary A. 26 2 2004 11-24-2004 3 0 2 1 2 3 5.6 0 1 1 2 1 2 2 2 2 46,XX[10] 5 1 1 1 5 12-3-2004 1 11-16-2005 12-21-2006 1
509353C Krishna.T 27 1 2004 8-18-2004 1 5 2 1 2 2 25.6 67 1 1 2 1 2 2 2 2 46,XY [7] 5 1 1 1 5 10-5-2004 2 5
533592C Mamoiz 28 1 2004 10-1-2004 0 0 2 1 2 2 23.6 0 2 5 2 1 2 2 2 2
There are no 
metaphase 4 1 1 1 5 10-2-2004 1 8-2-2008 9-5-2008 1
552478C Sireesh Kumar 28 1 2004 11-10-2004 0 0 1 3 2 2 6 76 1 1 2 1 2 2 2 2
ONLY ONE 
POOR 4 1 1 1 5 11-10-2004 2 5
418548C Santhosh.M.P. 30 1 2004 1-23-2004 3 0 2 1 2 2 2.1 83 1 1 2 1 2 2 2 2 46, XY [12] 5 1 1 1 5 1-23-2004 2 5
463216C Senthil Kumaran.K 32 1 2004 5-10-2004 0 0 2 1 2 2 72.4 37 1 3 2 2 2 2 2 2 46, XY [6] 5 1 1 1 5 5-15-2004 2 5
437257C Parvata Kumari 34 2 2004 3-11-2004 0 0 2 1 1 3 55 100 1 3 2 2 2 2 2 2
FOUR POOR 
QUALITY 4 3 1 1 5 3-19-2004 1 9-16-2004 10-16-2004 1
524426C Muraleedharan.M 35 1 2004 9-21-2004 0 0 2 1 2 2 5.4 0 1 1 2 1 1 2 2 2
54,XXYY,+4, 
+5, +8, +14, 1 3 1 1 5 9-23-2004 1 8-20-2008 9-22-2008 1
532299C Rosmi D. 37 2 2004 9-29-2004 0 0 2 1 2 3 4.1 35 1 1 2 1 2 2 2 2 46,XX [3] 5 3 1 1 5 10-1-2004 2 5
476659C Sajeed A.K. 39 1 2004 1-10-2004 4 14 1 3 2 2 163 90 1 3 2 1 2 2 2 2 46,XY [6] 5 3 1 1 5 6-12-2004 1 5-17-2005 6-15-2005 1
551931C Ushsrani Sahu 44 2 2004 11-8-2004 0 0 2 1 2 3 4 4 1 1 2 1 1 2 2 2
46,XX,t(9;22)(
q34;q11) 3 3 1 1 5 11-10-2004 2 3-24-2005 2
444095C Sainudheen 51 1 2004 3-30-2004 4 2 2 1 2 2 10.9 23 1 1 2 1 2 2 2 2 46, XY [8] 5 1 1 1 5 3-31-2004 1 4-8-2005 2-14-2005 1
547612C Sophia Khanam 59 2 2004 11-10-2004 0 0 2 1 2 3 1 0 1 1 2 1 2 2 2 2 Not done 4 1 1 1 5 11-12-2004 2 5
782218F Rincy Rajan 22 2 2014 1-13-2014 6 8 2 1 2 3 6.5 89 1 1 1 1 2 2 2 2 44~47,XX,del(3)(q27),del(6)(q21q24),add(8)(q24),add(12)(q24.3),der(13)?inv(13)(q14q31),del(15)(q23)[cp3]/44~47,idem,del(9)(q21q22),+10[cp4]/92~93,idem X 2,del(9)(q21q22) X 2[cp4]/46,XX[9]3 3 1 5 1-16-2014 2 5
754237F Meena Devi 45 2 2014 2-5-2014 4 8 2 1 2 3 116.1 93 1 1 1 1 2 "46,XX,der(9;22)(q10;q10),+mar[17]/46,XX{3]"5 1 1 1 5 2-5-2014 2 5
795577F Prasad 45 1 2014 2-4-2014 4 3 2 1 2 2 1.4 54 1 1 1 1 2 46,XY[20] 5 1 1 1 5 2-5-2014 2 5
775764F Saiful Alam 50 1 2014 1-25-2014 0 0 2 1 2 1 3.1 60 1 3 2 2 3 3 3 3 46,XY[20] 5 1 1 1 5 1-31-2014 2 5
750216F Krishna Samy 58 1 2014 2-6-2014 4 0 2 1 2 2 2.8 34 1 1 1 1 1 3 3 3 "46,XY,t(9;12)(q34;q13)[2] 46,XY[18]"5 3 1 1 5 2-6-2014 2 5
699798F Devi P 20 2 2013 10-14-2013 0 0 3 7 2 3 49.2 94 1 3 2 2 3 3 3 3 "43~45,XX,der(X)t(X;?)(p11.2;?),del(2)(q32~34),del(4)(q31),-9,der(10)t(10;?)(p11.2 or p12;?),del(11)(p11.2),add(13)(q34),add(16)(p13.3),der(17)t(?;p11.2)[cp20]"3 1 1 1 5 0-14-20 3 2 5
425151F Prasanthvaidya .S 21 1 2013 3-2-2013 0 1 2 1 2 2 2.8 82 1 1 2 1 2 2 2 2 53~58,XY,+X,del(1)(q?22q25),+3,+4,+5,+6,+8,+9,+10,+11,+14,+17,+18,+19,+21,+21,+22,+mar[cp15]/46,XY[5]1 1 1 5 3-6-2013 2 5
704608F Shaik Sanavulla 21 1 2013 11-1-2013 2 1 2 1 2 2 4.5 89 1 1 1 1 2 2 2 2 47~48,XY,+X,t(8;14)(q11.2;q32),+21[cp19]/46,XY[1cell]3 1 1 1 5 11-4-2013 2 5
659307F Uttam Sahu 22 1 2013 8-28-2013 4 0 2 1 2 2 132 86 1 3 2 1 2 2 2 2
"46,XY[3]/87~
92, 5 1 1 1 5 8-29-2013 2 5
716037F Mithun Biswas 22 1 2013 12-19-2013 0 0 2 1 2 2 3.3 90 1 1 1 1 2 2 2 2 46,XY[20] 5 1 1 1 5 12-19-2013 2 5
383051F Mathew Jose 23 1 2013 1-9-2013 2 0 2 1 2 2 1.8
9999
9 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 1-9-2013 2 5
664714F Bahabood Kottarathil 23 1 2013 9-7-2013 4 0 2 1 2 2 31.7 96 1 1 1 1 2 2 2 2 "45,XY,-9[4]/46,idem,+mar[15]/46,XY[1cell] "5 1 1 1 5 9-7-2013 1 3-7-2014 1
485375F Shanti Prakash 25 1 2013 5-29-2013 0 0 2 1 2 2 0.4 57 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 5-31-2013 2 6-2-2013 2
606464F Umesh Kumar Yada 26 1 2013 6-20-2013 0 0 2 3 2 2 1.7 84 1 3 2 2 3 3 3 3 "46~47,XY,+Y,del(6)(q21q24), del(11)(p14),?del(12)(p12)[cp13]/46,XY[7]"3 1 1 5 6-22-2013 2 8-18-2013 2
402897F Ranjan Giri 27 1 2013 2-2-2013 0 0 2 1 2 2 1.9 86 1 1 1 1 2 2 2 2 46,XY[20] 5 1 1 1 5 2-8-2013 2 5
427190F Venkatachalam M 27 1 2013 3-6-2013 1 0 2 1 2 2 7.3 61.5 1 3 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 3-22-2013 2 5
479540F Gaddamedi Ramesh 27 1 2013 5-15-2013 2 0 2 4 2 2 5.6 44 1 3 2 2 3 3 3 3 46,XY[20] 5 1 1 1 5 5-24-2013 2 5
496366F Mohammed Raffi 27 1 2013 6-12-2013 0 0 1 3 2 1 7.2 12 1 1 2 1 2 2 2 2
"44~45,XY,-
8,add(16)(q24 3 1 1 1 5 6-12-2013 2 5
468847F Kuppuswamy N 29 1 2013 7-3-2013 0 0 2 1 2 2 119.2 79 1 3 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 7-9-2013 2 5
460403F Srinivas K 30 1 2013 4-24-2013 2 2 2 1 2 2 6.5 85 1 1 2 1 1 3 3 3 46,XY[20] 5 3 1 1 5 5-3-2013 2 5
763564F Haris Iliath 30 1 2013 12-14-2013 3 0 2 1 2 2 7.3 59 1 3 2 2 3 3 3 3 46,XY[20] 5 1 1 1 5 12-14-2013 2 5
646731F Guhanathan T 32 1 2013 8-20-2013 0 0 2 1 2 2 58.1 93 1 1 1 1 1 3 3 3
"46,XY,t(9;22)
(q34;q11.2)[1 3 3 1 1 5 8-20-2013 2 5
611565F Kalyani Mukheree 33 1 2013 7-11-2013 0 0 2 1 1 3 4.4 87 1 3 2 2 3 3 3 3 "46,XX,del(1)(p21p31),del(5)(q22q32),-8,del(12)(p12)del(13)(q13q22~32),der(17)t(?;17)(?;q21) or ins(17;?)(q21;?),+mar?der(8)[cp19]/46,XX[1cell]"3 3 1 1 5 7-11-2013 2 5
628812F Arun Sasidharan 33 1 2013 7-22-2013 0 0 2 1 2 2 110.2 98 1 3 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 7-23-2013 2 5
750427F Dinakaran J 33 1 2013 12-31-2013 0 0 1 3 2 2 6.2
9999
9 1 1 2 2 3 3 3 3 46,XY[20] 5 1 1 1 5 1-23-2014 2 5
650584F Julbihar Ali 34 1 2013 8-19-2013 0 0 2 1 2 2 1.2 87 1 3 2 2 3 3 3 3 46,XY[20] 5 1 1 1 5 8-29-2013 2 5
677110F Arvind Gadiya 34 1 2013 9-16-2013 0 0 1 6 2 2 135 31 1 3 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 9-16-2013 2 10-3-2013 2
373010F Smitha Vargheese 35 2 2013 1-7-2013 2 3 2 1 2 3 2 63 1 1 2 2 3 3 3 3 46,XX[20] 5 1 1 1 5 6-16-2013 2 5
381164F Binod Paswan 36 1 2013 1-4-2013 0 0 2 1 2 2 3.1 65 1 1 2 2 3 3 3 3 46,XY[20] 5 1 1 1 5 1-30-2013 2 5
406683F Md Mizanur Rahman Akondo37 1 2013 2-25-2013 0 0 2 1 2 2 45.1 91 1 3 2 2 3 3 3 3 46,XY[20] 5 1 1 1 5 3-1-2013 2 5
418895F Ramesh A.K 37 1 2013 2-25-2013 4 2 1 3 2 2 11.4 71 1 3 2 2 3 3 3 3 Not Done 4 1 1 1 5 3-13-2013 2 5
659157F Jimcy Joy 37 2 2013 8-29-2013 0 0 2 1 2 3 4.6 93 1 2 1 1 2 2 2 2 46,XX,add(19)(p13.3)[6]/46,XX[14]5 1 1 1 5 9-2-2013 2 5
406148F Gautam Das 38 1 2013 2-18-2013 2 3 2 1 2 2 12.5 100 1 1 1 1 2 2 2 2 45,XY,-7,-9,+mar?inv(9)(p13q22)[cp14]/46,XY[6]3 1 1 1 5 2-19-2013 2 3-1-2013 2
482185F Jeya Seelan P 38 1 2013 5-25-2013 0 5 2 1 2 2 1.7 71 1 3 2 1 2 2 2 2 45,XY,-7[13]/46,XY[7]5 1 1 1 5 5-30-2013 2 5
635029F Varghese George 38 1 2013 7-23-2013 0 0 2 1 2 2 1.9 94 1 1 2 1 2 2 2 2 Not Done 4 1 1 1 5 7-29-2013 2 5
630869F Abul Wafa 39 1 2013 8-12-2013 0 0 2 1 2 2 9 95 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 8-12-2013 2 5
413215F Mercy Clara 41 2 2013 2-14-2013 3 4 2 1 2 3 7.7 83 1 1 2 1 2 2 2 2 46,X,t(X;11)(p11.4 or p21;q24 or q25),add(3)(q29)[12]/46,XX[8]3 1 1 1 5 2-16-2013 2 5
447892F Kumar s Rajeev 42 1 2013 4-2-2013 2 0 2 1 2 2 46.1 91 1 1 1 1 2 2 2 2 "47,XY,+X[11]/48,idem,+17[3]/  46,XY[6]"1 1 1 1 5 4-3-2013 2 5
384430F Mohammed Haniffa 44 1 2013 1-15-2013 0 0 2 1 2 2 8.3 96 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 1-26-2013 2 5
672100F Kirti Kumar Srivastava 46 1 2013 9-10-2013 4 2 2 3 2 2 6.4 90 1 1 1 1 2 2 2 2 45,XY,-7[19]/46,XY[1cell]5 1 1 1 5 9-11-2013 2 5
389139F Narayayana Swamy 47 1 2013 1-22-2013 0 0 2 1 2 2 1 48 1 3 2 2 3 3 3 3 "45,X,-Y,del(2)(q34),add(16)(q24)[6]/45,idem,-7,+mar[3]/46,XY[11] "3 1 1 1 5 2-1-2013 2 5
441097F Bhaskar Raju 47 1 2013 2-4-2013 1 1 2 1 2 2 13.7 91.5 1 1 1 1 2 2 2 2 46,XY,del(9)(p12)[20] 5 1 1 1 5 4-1-2013 2 5
441392F Sreeramulu Reddy N 47 1 2013 4-10-2013 3 0 2 1 2 2 1.9 91 1 1 2 1 2 2 2 2 51,X,+X,-Y,+4,+14,+17,+18,+21[cp4]/46,X,inv(Y)(p11)[19]1 1 1 1 5 4-13-2013 2 5
713588F Ilanchezian 48 1 2013 11-16-2013 1 0 2 3 2 2 0.9 69 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 11-29-2013 2 5
622582F Karthikeyan A 50 1 2013 7-11-2013 0 0 2 1 2 2 4.7 90 1 1 2 1 2 2 2 2 "33~36<2n>,XY,-2,-3,-4,-7,-12,-13,-14,-15,-16,-17,-20,+der(22)t(9;22)(q34;q11.2)[cp15]/64,idem,-6,-9,-10,-10,-22[I cell]/46,XY[4]"3 1 1 1 5 7-14-2013 2 5
374584F Sridharan S 52 1 2013 1-2-2013 0 0 2 1 2 2 4.8 72 1 2 2 2 3 3 3 3 46,XY[20] 5 1 1 1 5 1-11-2013 2 5
414586F Attakoya 58 1 2013 2-15-2013 1 1 1 3 2 2 401.8 85 1 1 1 1 2 2 2 2 46,XY,t(2;7;10)(p10;p10;p10)[20]5 1 1 1 5 2-15-2013 2 5
631330F Mani Durai M.D.K 59 1 2013 7-23-2013 2 4 2 1 2 2 2.8 60 1 2 1 1 2 2 2 2 46,XY[20] 5 1 1 1 5 7-25-2013 2 5
429082F Alagumani G 60 2 2013 3-28-2013 1 0 2 1 2 3 3.1 95 1 1 1 1 1 2 2 2 Complex karyotype with t (9;22)3 3 1 1 5 3-30-2013 2 5
322434F Rakesh Mir 20 1 2012 10-25-2012 4 0 1 3 2 2 13.4 55 1 1 1 1 2 2 2 1 Not Done 4 3 1 1 5 11-1-2012 2 1-20-2013 1
345465F Tarak Nath Das 22 1 2012 11-14-2012 2 0 2 1 2 2 53.5 96 1 3 2 2 3 3 3 3 46,XY[20] 5 1 1 1 5 12-6-2012 2 11-26-2012 2
249851F Rani Rajan 26 2 2012 7-18-2012 0 0 2 1 2 3 8.9 85 1 3 2 2 3 3 3 3 46,XX[20] 5 1 1 1 5 7-27-2012 2 5
317925F Rakesh Benedict J 27 1 2012 10-8-2012 4 0 1 3 2 2 212.9 99 1 3 2 1 2 2 2 2 46,XY[12] 5 1 1 1 5 10-15-2012 2 5
327402F Abdul Rasiq (adult) 27 1 2012 10-23-2012 0 0 2 1 2 2 0.4 51 1 1 2 1 1 3 3 3 46,XY[20] 5 3 1 1 5 10-23-2012 2 5
246418F Prabavathi 30 2 2012 7-18-2012 0 0 1 2 1 3 9.6 21 1 3 2 2 3 3 3 3 Not Done 4 1 1 1 5 7-18-2012 2 5
377078F Kencho Buthi 32 2 2012 12-27-2012 3 5 1 3 2 3 0.8 77 1 1 1 1 1 2 2 2 46,XX,t(9;22)(q34;q11.2),-12,-12,+16,-19,- 20,+21,+22,+mar,+mar[6]/46,XX[14]3 3 1 1 5 12-27-2012 1 6-10-2013 5
335844F Pankaj Khan 34 1 2012 11-3-2012 6 8 1 1 2 2 203.4 96 1 3 2 2 3 3 3 3 46,XY[20] 5 1 1 1 5 11-3-2012 2 5
351396F Arumugam M 39 1 2012 11-27-2012 0 2 2 1 2 2 2.7 82 1 1 2 1 2 2 2 2 46,XY[20] 5 1 1 1 5 12-3-2012 2 5
354964F Parthiban 39 1 2012 12-6-2012 3 7 2 1 1 3 25.4 92.5 1 3 2 2 3 3 3 3 46,XY[19] 5 1 1 1 5 12-8-2012 2 5
367346F Ceciliya 49 2 2012 12-18-2012 8 8 2 1 2 3 85.4 86 1 1 1 1 1 3 3 3 45~49,XX,+X,t(9;22)(q34;q11.2),-12,+16,add(19)(p13.3)or der(19)t(12;19)(q13;p13.3),+mar[cp18]/46,XX[1cell]3 3 1 1 5 12-18-2012 2 5
847368D Khamakhya Pada Choudhuri52 1 2012 7-20-2012 0 0 2 1 2 2 3.7 77 1 3 2 2 3 3 3 3 47,XY,+21[10]/46,XY[10] 1 1 1 5 7-24-2012 2 5
295821F Tapan Chandra Sarkar 56 1 2012 9-20-2012 0 0 1 3 2 2 4.6 67 1 1 1 1 1 2 2 2 Not done 4 3 1 1 5 9-22-2012 2 10-23-2012 2
325914F Shalini Devi 57 2 2012 11-3-2012 2 2 2 1 2 3 0.3 87 1 1 2 1 2 2 2 2 46,XX[20] 5 1 1 1 5 11-10-2012 2 5
Date of Last contactCurrent Status newOS status Os time EFS date EFS status EFS time
1-30-2012 7 1 9 1-30-2012 1 9
6-18-2012 7 1 26 6-18-2012 1 26
3-7-2014 2 0 751 3-7-2014 0 751
3-7-2014 2 0 627 3-7-2014 0 627
3-7-2014 2 0 756 3-7-2014 0 756
2-28-2014 2 0 702 2-28-2014 0 702
1-10-2014 2 0 728 1-10-2014 0 728
3-7-2014 2 0 732 3-7-2014 0 732
1-21-2014 2 0 692 1-21-2014 0 692
7-9-2012 8 0 39 7-9-2012 0 39
7-6-2012 8 0 6 7-6-2012 0 6
12-29-2012 2 1 197 12-29-2012 1 197
7-17-2012 5 1 111 7-17-2012 1 111
2-22-2014 5 1 592 2-22-2014 1 592
11-14-2012 5 1 175 11-14-2012 1 175
8-3-2012 5 1 39 8-3-2012 1 39
2-22-2013 5 1 258 2-22-2013 1 258
3-4-2014 2 0 633 3-4-2014 0 633
8-31-2012 2 1 218 8-31-2012 1 218
6-25-2013 5 1 493 6-25-2013 1 493
9-28-2012 5 1 142 9-28-2012 1 142
2-14-2014 2 0 723 2-14-2014 0 723
9-27-2011 8 0 5 0 -40808
7-30-2013 2 0 624 0 -40861
12-20-2013 2 0 1079 0 -40549
2-25-2014 1 0 1112 0 -40583
12-16-2011 2 0 305 0 -40588
10-11-2011 5 1 160 10-11-2011 1 160
2-28-2014 2 0 924 0 -40774
5-15-2011 7 1 26 5-15-2011 1 26
10-21-2011 5 1 130 10-21-2011 1 130
1-31-2014 2 0 925 0 -40745
10-4-2013 2 0 755 0 -40796
10-7-2011 8 0 25 0 -40798
1-11-2013 5 1 650 7-20-2012 1 475
1-14-2014 1 0 977 0 -40676
12-17-2013 1 0 930 0 -40695
9-3-2013 2 0 768 0 -40752
2-25-2014 2 0 803 0 -40892
12-31-2011 5 1 315 12-31-2011 1 315
2-18-2014 1 0 963 0 -40725
1-10-2014 2 0 904 0 -40745
1-14-2014 2 0 876 0 -40777
3-20-2012 5 1 159 3-20-2012 1 159
1-17-2014 1 0 1078 0 -40578
3-7-2014 2 0 984 0 -40721
9-24-2012 5 1 549 9-24-2012 1 549
9-11-2012 2 0 463 0 -40700
6-29-2012 5 1 340 6-25-2012 1 336
11-15-2011 2 0 19 0 -40843
2-18-2012 7 1 46 2-18-2012 1 46
2-4-2011 8 0 15 0 -40563
1-14-2014 2 0 915 0 -40738
1-10-2014 2 0 896 0 -40753
11-11-2011 2 0 269 0 -40589
11-2-2011 7 1 13 11-2-2011 1 13
6-22-2012 2 0 330 0 -40752
3-18-2014 2 0 1093 0 -40623
3-7-2014 1 0 986 0 -40719
2-25-2014 2 0 873 0 -40822
2-21-2014 2 0 911 0 -40780
8-7-2012 5 1 324 3-22-2012 1 186
12-20-2013 2 0 739 0 -40889
3-31-2011 7 1 39 4-30-2011 1 69
2-10-2012 7 1 35 2-10-2012 1 35
4-13-2012 5 1 97 5-13-2012 1 127
5-1-2011 7 1 22 5-1-2011 1 22
2-25-2014 2 0 1088 0 -40607
9-24-2013 2 0 766 0 -40775
3-18-2011 8 0 50 0 -40570
2-7-2012 2 1 246 2-7-2012 1 246
1-4-2013 2 0 630 0 -40648
9-16-2012 5 1 454 9-4-2012 1 442
1-10-2014 1 0 1368 1-10-2014 0 1368
4-27-2010 5 1 43 4-27-2010 1 43
5-17-2013 2 0 1154 5-17-2013 0 1154
4-26-2011 5 1 378 4-26-2011 1 378
12-13-2013 1 0 1219 12-13-2013 0 1219
5-18-2012 5 1 565 5-18-2012 1 565
12-22-2010 7 1 34 12-22-2010 1 34
12-22-2011 5 1 698 12-22-2011 1 698
3-7-2014 2 0 1394 3-7-2014 0 1394
12-17-2013 1 0 1311 12-17-2013 0 1311
2-7-2014 1 0 1273 2-7-2014 0 1273
12-27-2013 1 0 1124 12-27-2013 0 1124
3-3-2012 5 1 732 3-3-2012 1 732
6-28-2010 5 1 31 6-28-2010 1 31
12-3-2013 1 0 1239 12-3-2013 0 1239
3-29-2011 5 1 192 3-29-2011 1 192
1-7-2014 2 0 1167 1-7-2014 0 1167
11-30-2010 7 1 5 11-30-2010 1 5
3-4-2014 2 0 1160 3-4-2014 0 1160
10-18-2013 1 0 1364 10-18-2013 0 1364
1-11-2011 7 1 25 1-11-2011 1 25
2-28-2014 1 0 1370 2-28-2014 0 1370
10-6-2010 5 1 250 10-6-2010 1 250
12-27-2013 1 0 1367 12-27-2013 0 1367
6-7-2013 5 1 1118 6-7-2013 1 1118
11-8-2013 2 0 1113 11-8-2013 0 1113
3-4-2011 5 1 94 3-4-2011 1 94
1-12-2011 7 1 19 1-12-2011 1 19
8-19-2011 5 1 273 8-19-2011 1 273
12-20-2013 1 0 1377 12-20-2013 0 1377
3-4-2011 5 1 137 3-4-2011 1 137
5-17-2011 5 1 382 5-17-2011 1 382
3-7-2014 2 0 1298 3-7-2014 0 1298
10-4-2013 2 0 1147 10-4-2013 0 1147
1-10-2014 1 0 1260 1-10-2014 0 1260
8-2-2011 2 0 346 8-2-2011 0 346
11-12-2013 1 0 1142 11-12-2013 0 1142
7-7-2011 5 1 283 7-7-2011 1 283
10-26-2010 5 1 240 10-26-2010 1 240
2-21-2014 1 0 1347 2-21-2014 0 1347
3-25-2011 5 1 153 3-25-2011 1 153
10-2-2012 5 1 923 10-2-2012 1 923
12-3-2013 1 0 1284 12-3-2013 0 1284
12-27-2011 8 0 641 12-27-2011 0 641
11-30-2012 2 0 935 11-30-2012 0 935
6-25-2010 5 1 414 6-25-2010 1 414
6-19-2009 5 1 97 6-19-2009 1 97
4-5-2013 1 0 1411 4-5-2013 0 1411
3-4-2010 5 1 225 3-4-2010 1 225
11-12-2013 1 0 1557 11-12-2013 0 1557
4-15-2010 5 1 253 4-15-2010 1 253
12-3-2013 1 0 1536 12-3-2013 0 1536
6-11-2013 1 0 1594 6-11-2013 0 1594
10-22-2013 1 0 1492 10-22-2013 0 1492
8-9-2013 1 0 1568 8-9-2013 0 1568
4-5-2013 1 0 1373 4-5-2013 0 1373
2-21-2014 1 0 1616 2-21-2014 0 1616
12-17-2010 5 1 379 12-17-2010 1 379
5-28-2010 2 0 204 5-28-2010 0 204
1-25-2013 1 0 1150 1-25-2013 0 1150
2-24-2009 5 1 37 2-24-2009 1 37
1-3-2014 1 0 1576 1-3-2014 0 1576
8-2-2013 1 0 1597 8-2-2013 0 1597
3-15-2013 1 0 1318 3-15-2013 0 1318
7-23-2013 1 0 1368 7-23-2013 0 1368
9-14-2012 1 0 1325 9-14-2012 0 1325
10-15-2013 1 0 1659 10-15-2013 0 1659
12-23-2011 5 1 918 12-23-2011 1 918
9-13-2011 2 0 750 9-13-2011 0 750
12-18-2012 1 0 1338 12-18-2012 0 1338
4-5-2011 5 1 632 4-5-2011 1 632
12-6-2013 1 0 1572 12-6-2013 0 1572
3-4-2014 1 0 1764 3-4-2014 0 1764
2-10-2010 2 1 93 2-10-2010 1 93
12-13-2013 1 0 1718 12-13-2013 0 1718
10-20-2009 5 1 102 10-20-2009 1 102
10-19-2012 2 0 1262 10-19-2012 0 1262
1-12-2012 5 1 874 1-12-2012 1 874
2-21-2014 2 0 1854 2-21-2014 1 1854
11-14-2009 7 1 31 11-14-2009 1 31
9-24-2010 5 1 276 9-24-2010 1 276
12-17-2012 5 1 1186 12-17-2012 1 1186
11-5-2013 1 0 1656 11-5-2013 0 1656
8-10-2012 5 1 1033 8-10-2012 1 1033
7-8-2010 4 1 203 7-8-2010 1 203
3-12-2013 1 0 1426 3-12-2013 0 1426
9-27-2013 1 0 1726 9-27-2013 0 1726
7-20-2011 2 1 663 7-20-2011 1 663
10-23-2009 2 0 156 10-23-2009 0 156
7-3-2009 5 1 34 7-3-2009 1 34
5-21-2009 5 1 111 5-21-2009 1 111
3-26-2010 8 0 178 3-26-2010 0 178
6-18-2010 8 0 364 6-18-2010 0 364
9-11-2009 2 0 434 9-11-2009 0 434
5-5-2009 5 1 286 5-5-2009 1 286
2-25-2014 1 0 2143 2-25-2014 0 2143
6-7-2013 1 0 1847 6-7-2013 0 1847
12-22-2009 5 1 540 12-22-2009 1 540
11-3-2009 5 1 411 11-3-2009 1 411
4-23-2013 1 0 1718 4-23-2013 0 1718
2-19-2010 5 1 539 2-19-2010 1 539
1-22-2010 5 1 501 1-22-2010 1 501
10-15-2013 1 0 1791 10-15-2013 0 1791
4-2-2013 1 0 1558 4-2-2013 0 1558
9-14-2012 1 0 1588 9-14-2012 0 1588
11-12-2013 1 0 1904 11-12-2013 0 1904
11-19-2010 2 0 802 11-19-2010 0 802
9-3-2013 1 0 1796 9-3-2013 0 1796
10-22-2010 2 0 659 10-22-2010 0 659
3-3-2008 5 1 41 3-3-2008 1 41
9-23-2008 2 0 84 9-23-2008 0 84
5-6-2011 2 0 947 5-6-2011 0 947
7-19-2011 2 0 1077 7-19-2011 0 1077
12-10-2013 2 0 1896 12-10-2013 0 1896
4-18-2008 7 1 20 4-18-2008 1 20
9-10-2013 1 0 1900 9-10-2013 0 1900
4-22-2009 5 1 411 4-22-2009 1 411
1-24-2014 1 0 2091 1-24-2014 0 2091
2-1-2011 5 1 1036 2-1-2011 1 1036
9-16-2009 5 1 352 9-16-2009 1 352
12-24-2013 1 0 1970 12-24-2013 0 1970
5-29-2013 5 1 1702 5-29-2013 1 1702
6-18-2013 1 0 1688 6-18-2013 0 1688
7-1-2011 2 0 917 7-1-2011 0 917
7-16-2013 1 0 1957 7-16-2013 0 1957
10-4-2013 1 0 1863 10-4-2013 0 1863
1-22-2010 5 1 467 1-22-2010 1 467
3-5-2010 5 1 447 3-5-2010 1 447
11-18-2008 2 0 249 11-18-2008 0 249
5-14-2013 1 0 1652 5-14-2013 0 1652
11-10-2009 2 0 591 11-10-2009 0 591
6-24-2008 8 0 46 6-24-2008 0 46
12-23-2008 5 1 105 12-23-2008 1 105
12-27-2012 2 0 1754 12-27-2012 0 1754
5-5-2010 5 1 771 5-5-2010 1 771
9-9-2009 5 1 359 9-9-2009 1 359
9-25-2012 1 0 1663 9-25-2012 0 1663
6-9-2012 5 1 1496 6-9-2012 1 1496
3-24-2009 5 1 255 3-24-2009 1 255
11-25-2011 2 0 1188 11-25-2011 0 1188
3-3-2009 5 1 104 3-3-2009 1 104
10-1-2010 2 0 693 10-1-2010 0 693
6-12-2012 2 0 1306 6-12-2012 0 1306
7-31-2008 5 1 62 7-31-2008 1 62
3-1-2013 1 0 1550 3-1-2013 0 1550
3-3-2009 8 0 89 3-3-2009 0 89
8-9-2013 1 0 2222 8-9-2013 0 2222
8-27-2013 1 0 2067 8-27-2013 0 2067
12-14-2007 5 1 142 12-14-2007 1 142
6-25-2007 5 1 153 6-25-2007 1 153
10-1-2013 1 0 2429 10-1-2013 0 2429
4-17-2012 2 0 1816 4-17-2012 0 1816
5-10-2013 1 0 2151 5-10-2013 0 2151
2-18-2014 2 0 2413 2-18-2014 0 2413
1-24-2014 1 0 2400 1-24-2014 0 2400
10-1-2013 1 0 2449 10-1-2013 0 2449
2-15-2011 2 0 1474 2-15-2011 0 1474
11-30-2010 2 0 1191 11-30-2010 0 1191
7-31-2008 5 1 313 7-31-2008 1 313
2-21-2014 1 0 2305 2-21-2014 0 2305
3-25-2008 2 0 313 3-25-2008 0 313
8-5-2010 5 1 1023 8-5-2010 1 1023
7-9-2010 2 0 964 7-9-2010 0 964
2-22-2008 5 1 354 2-22-2008 1 354
9-21-2012 2 0 1780 9-21-2012 0 1780
4-12-2013 1 0 2286 4-12-2013 0 2286
8-16-2013 1 0 2390 8-16-2013 0 2390
11-1-2013 1 0 2425 11-1-2013 0 2425
4-13-2007 7 1 39 4-13-2007 1 39
3-22-2013 1 0 2170 3-22-2013 0 2170
12-15-2009 1 0 941 12-15-2009 0 941
3-13-2009 5 1 493 3-13-2009 1 493
2-14-2014 1 0 2562 2-14-2014 0 2562
3-26-2013 1 0 2155 3-26-2013 0 2155
5-6-2011 1 0 1403 5-6-2011 0 1403
12-27-2011 5 1 1602 12-27-2011 1 1602
7-1-2008 2 0 246 7-1-2008 0 246
12-4-2007 2 0 45 12-4-2007 0 45
8-7-2012 1 0 1913 8-7-2012 0 1913
7-18-2008 2 0 249 7-18-2008 0 249
11-25-2011 2 0 1559 11-25-2011 0 1559
3-14-2008 5 1 186 3-14-2008 1 186
12-27-2013 1 0 2226 12-27-2013 0 2226
2-22-2013 1 0 2102 2-22-2013 0 2102
5-12-2013 5 1 1969 5-12-2013 1 1969
3-25-2008 5 1 162 3-25-2008 1 162
7-30-2010 5 1 1211 7-30-2010 1 1211
5-13-2008 2 0 305 5-13-2008 0 305
4-30-2010 5 1 910 4-30-2010 1 910
1-22-2010 5 1 1037 1-22-2010 1 1037
5-25-2010 5 1 897 5-25-2010 1 897
2-21-2014 1 0 2414 2-21-2014 0 2414
1-10-2014 2 0 2538 1-10-2014 1 2538
4-10-2012 1 0 1794 4-10-2012 0 1794
9-8-2007 7 1 29 9-8-2007 1 29
1-24-2014 1 0 2503 1-24-2014 0 2503
8-6-2007 8 0 73 8-6-2007 0 73
11-23-2007 3 1 155 11-23-2007 1 155
6-26-2007 5 1 537 6-26-2007 1 537
6-21-2011 3 1 1938 6-29-2010 1 1581
11-23-2012 1 0 2338 0 -38898
6-25-2013 1 0 2435 0 -39015
9-14-2012 2 0 2099 0 -39067
10-31-2008 2 0 986 0 -38766
3-22-2013 1 0 2447 0 -38908
3-4-2014 1 0 2965 0 -38737
6-30-2006 7 1 27 7-30-2006 1 57
6-1-2007 5 1 335 1-16-2007 1 199
9-8-2006 5 1 22 9-5-2006 1 19
3-27-2007 2 0 214 0 -38954
3-20-2009 1 0 1137 0 -38755
4-30-2010 2 0 1519 0 -38779
12-5-2012 5 1 2417 12-5-2012 1 2417
2-28-2014 1 0 2853 0 -38845
6-27-2006 7 1 23 7-27-2006 1 53
8-16-2013 1 0 2766 0 -38736
7-4-2007 5 1 436 1-11-2007 1 262
7-25-2008 2 0 761 0 -38893
8-9-2013 1 0 2592 0 -38903
7-24-2008 5 1 596 7-24-2008 1 596
11-18-2011 1 0 2123 0 -38742
2-14-2014 1 0 2689 0 -38995
11-20-2007 7 1 375 12-20-2007 1 405
1-13-2009 5 1 988 9-16-2008 1 869
8-5-2010 5 1 1401 3-8-2010 1 1251
9-24-2013 1 0 2811 0 -38730
2-18-2011 5 1 1576 12-30-2010 1 1526
5-18-2012 2 0 2271 0 -38776
3-17-2009 2 0 992 0 -38897
10-3-2006 7 1 68 10-3-2006 1 68
5-1-2008 2 0 588 0 -38981
10-26-2010 1 0 1560 0 -38917
12-17-2010 5 1 1465 4-20-2010 1 1224
3-10-2007 5 1 162 1-6-2007 1 99
4-1-2007 2 1 174 4-1-2007 1 174
9-4-2012 1 0 2092 0 -39064
4-18-2006 5 1 103 3-27-2006 1 81
7-16-2010 2 0 1399 0 -38976
10-22-2006 2 0 89 0 -38923
10-5-2006 7 1 93 10-5-2006 1 93
12-8-2006 5 1 149 12-4-2006 1 145
8-18-2006 5 1 116 9-18-2006 1 147
1-5-2010 5 1 1135 12-29-2009 1 1128
5-4-2007 2 1 307 5-4-2007 1 307
7-2-2007 5 1 342 1-5-2007 1 164
3-5-2008 5 1 573 12-24-2007 1 501
11-12-2007 5 1 436 11-10-2007 1 434
7-22-2008 5 1 648 4-23-2008 1 558
9-1-2009 5 1 1034 1-29-2008 1 453
7-19-2007 5 1 247 9-7-2007 1 297
7-5-2007 2 1 296 7-5-2007 1 296
5-12-2007 5 1 306 5-12-2007 1 306
8-3-2007 2 0 441 0 -38856
6-12-2007 5 1 440 6-12-2007 1 440
2-25-2014 1 0 2784 0 -38911
1-22-2010 1 0 1409 0 -38791
11-2-2010 1 0 1916 0 -38568
1-19-2007 5 1 498 11-14-2006 1 432
10-22-2013 1 0 2847 0 -38722
5-16-2006 5 1 363 3-21-2006 1 307
2-10-2006 2 0 211 0 -38547
8-23-2007 3 1 622 7-23-2007 1 591
7-1-2005 7 1 22 8-1-2005 1 53
7-25-2006 5 1 248 6-8-2006 1 201
11-20-2007 2 0 1034 0 -38372
10-17-2006 5 1 622 9-8-2006 1 583
5-19-2006 5 1 401 5-5-2006 1 387
2-8-2013 1 0 2783 0 -38530
11-11-2011 1 0 2246 0 -38612
1-6-2007 3 1 595 12-11-2006 1 569
12-13-2013 1 0 2971 0 -38650
4-22-2008 2 0 979 0 -38581
1-22-2010 1 0 1543 0 -38657
6-2-2006 5 1 190 5-30-2006 1 187
2-10-2005 8 0 29 0 -38364
4-2-2013 1 0 2715 0 -38651
11-26-2010 1 0 1812 0 -38696
8-19-2005 5 1 186 6-18-2005 1 124
1-25-2011 5 1 1898 1-25-2011 1 1898
8-20-2013 1 0 2789 0 -38717
5-6-2011 5 1 2199 1-20-2009 1 1363
5-16-2005 7 1 9 6-16-2005 1 40
1-7-2006 2 1 105 1-7-2006 1 105
6-10-2005 5 1 64 7-10-2005 1 94
10-8-2005 5 1 8 11-8-2005 1 39
2-14-2012 5 1 2394 6-1-2009 1 1406
1-9-2009 3 1 1395 1-25-2008 1 1045
2-25-2014 1 0 3178 0 -38517
11-18-2005 5 1 125 12-10-2005 1 147
8-1-2008 5 1 1367 8-1-2008 1 1367
2-1-2011 1 0 2536 2-1-2011 0 2536
6-1-2010 1 0 2099 6-1-2010 0 2099
7-1-2005 5 1 252 7-1-2005 1 252
10-9-2009 2 0 1844 10-9-2009 0 1844
3-20-2014 2 0 3411 3-20-2014 1 3411
5-19-2006 5 1 506 5-19-2006 1 506
9-30-2008 2 0 1670 9-30-2008 0 1670
11-8-2005 2 0 621 11-8-2005 0 621
12-13-2013 2 0 3600 12-13-2013 0 3600
1-3-2006 5 1 445 1-3-2006 1 445
8-19-2005 2 1 283 8-19-2005 1 283
11-9-2012 1 0 3152 11-9-2012 0 3152
4-12-2005 5 1 408 4-12-2005 1 408
12-5-2008 1 0 1789 12-5-2008 0 1789
5-10-2005 5 1 418 5-10-2005 1 418
4-19-2005 5 1 377 4-19-2005 1 377
12-21-2005 5 1 383 12-21-2005 1 383
12-12-2008 1 0 1529 12-12-2008 0 1529
8-5-2008 5 1 1403 8-5-2008 1 1403
12-27-2011 2 0 2603 12-27-2011 0 2603
10-11-2013 1 0 3549 10-11-2013 0 3549
6-28-2011 1 0 2600 6-28-2011 0 2600
9-16-2004 5 1 181 9-16-2004 1 181
8-22-2008 5 1 1429 8-22-2008 1 1429
2-22-2005 2 0 144 2-22-2005 0 144
5-24-2005 5 1 346 5-24-2005 1 346
3-24-2005 2 1 134 3-24-2005 1 134
1-14-2005 5 1 289 1-14-2005 1 289
7-18-2005 8 0 248 7-18-2005 0 248
3-21-2014 2 0 64 3-21-2014 0 64
3-4-2014 2 0 27 3-4-2014 0 27
2-25-2014 2 0 20 2-25-2014 0 20
2-26-2014 2 0 26 2-26-2014 0 26
3-4-2014 2 0 26 3-4-2014 0 26
3-7-2014 2 0 144 3-7-2014 0 144
2-25-2014 2 0 356 2-25-2014 0 356
3-7-2014 2 0 123 3-7-2014 0 123
3-4-2014 2 0 187 3-4-2014 0 187
3-7-2014 2 0 78 3-7-2014 0 78
2-25-2014 2 0 412 2-25-2014 0 412
2-7-2014 5 1 153 2-7-2014 1 153
02-06-2013 7 1 2 02-06-2013 1 2
8-18-2013 7 1 57 8-18-2013 1 57
9-24-2013 2 0 228 9-24-2013 0 228
2-25-2014 2 0 340 2-25-2014 0 340
2-28-2014 2 0 280 2-28-2014 0 280
3-7-2014 2 0 268 3-7-2014 0 268
2-21-2014 2 0 227 2-21-2014 0 227
12-6-2013 2 0 217 12-6-2013 0 217
3-4-2014 2 0 80 3-4-2014 0 80
2-21-2014 2 0 185 2-21-2014 0 185
8-9-2013 8 0 29 8-9-2013 0 29
2-21-2014 2 0 213 2-21-2014 0 213
1-23-2014 2 0 0 1-23-2014 0 0
1-31-2014 2 0 155 1-31-2014 0 155
03-10-2013 7 1 17 03-10-2013 1 17
9-24-2013 2 0 100 9-24-2013 0 100
11-19-2013 2 0 293 11-19-2013 0 293
2-25-2014 2 0 361 2-25-2014 0 361
2-28-2014 1 0 352 2-28-2014 0 352
3-4-2014 2 0 183 3-4-2014 0 183
3-1-2013 7 1 10 3-1-2013 1 10
1-17-2014 2 0 232 1-17-2014 0 232
3-21-2014 2 0 235 3-21-2014 0 235
3-4-2014 2 0 204 3-4-2014 0 204
3-22-2013 2 0 34 3-22-2013 0 34
2-18-2014 2 0 321 2-18-2014 0 321
2-28-2014 2 0 398 2-28-2014 0 398
9-30-2013 2 0 19 9-30-2013 0 19
2-28-2014 2 0 392 2-28-2014 0 392
2-21-2014 2 0 326 2-21-2014 0 326
2-28-2014 2 0 321 2-28-2014 0 321
12-28-2013 2 0 29 12-28-2013 0 29
2-14-2014 2 0 215 2-14-2014 0 215
1-14-2014 2 0 368 1-14-2014 0 368
3-12-2013 8 0 25 3-12-2013 0 25
3-7-2014 2 0 225 3-7-2014 0 225
2-28-2014 2 0 335 2-28-2014 0 335
12-20-2012 5 1 3 20-01-2013 1 3
11-26-2012 7 1 0 11-26-2012 1 0
2-25-2014 2 0 20 0
1-14-2014 2 0 15 0
1-11-2013 2 0 3 0
7-28-2012 8 0 0 0
5-10-2013 3 0 4 6-10-2013 1 6
12-20-2013 2 0 14 0
3-7-2014 2 0 16 0
10-4-2013 2 0 10 0
4-16-2013 2 0 4 0
2-28-2014 2 0 20 0
10-23-2012 7 1 1 10-23-2012 1 1
3-7-2014 2 0 16 0
